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Résumé 
Les micelles polyioniques ont émergé comme des systèmes prometteurs de 
relargage de médicaments hydrophiles ioniques. Le but de cette étude était le 
développement des micelles polyioniques à base de dextrane pour la relargage de 
médicaments hydrophiles cationiques utilisant une nouvelle famille de copolymères bloc 
carboxymethyldextran-poly(éthylène glycol) (CMD-PEG). Quatre copolymères CMD-PEG 
ont été préparés dont deux copolymères identiques en termes de longueurs des blocs de 
CMD et de PEG mais différent en termes de densité de charges du bloc CMD; et deux 
autres copolymères dans lesquels les blocs chargés sont les mêmes mais dont les blocs de 
PEG sont différents. Les propriétés d’encapsulation des micelles CMD-PEG ont été 
évaluées avec différentes molécules cationiques: le diminazène (DIM), un médicament 
cationique modèle, le chlorhydrate de minocycline (MH), un analogue semi-synthétique de 
la tétracycline avec des propriétés neuro-protectives prometteuses et différents antibiotiques 
aminoglycosidiques. La cytotoxicité des copolymères CMD-PEG a été évaluée sur 
différentes lignées cellulaires en utilisant le test MTT et le test du Bleu Alamar. La 
formation de micelles des copolymères de CMD-PEG a été caractérisée par différentes 
techniques telles que la spectroscopie RMN 1H, la diffusion de la lumière dynamique 
(DLS) et la titration calorimétrique isotherme (ITC). Le taux de relargage des médicaments 
et l’activité pharmacologique des micelles contenant des médicaments ont aussi été évalués. 
Les copolymères CMD-PEG n'ont induit aucune cytotoxicité dans les hépatocytes humains 
et dans les cellules microgliales murines (N9) après 24 h incubation pour des 
concentrations allant jusqu’à 15 mg/mL. Les interactions électrostatiques entre les 
copolymères de CMD-PEG et les différentes drogues cationiques ont amorcé la formation 
de micelles polyioniques avec un cœur composé du complexe CMD-médicaments 
cationiques et une couronne composée de PEG. Les propriétés des micelles DIM/CMD-
PEG ont été fortement dépendantes du degré de carboxyméthylation du bloc CMD. Les 
micelles de CMD-PEG de degré de carboxyméthylation du bloc CMD  ≥ 60 %, ont 
incorporé jusqu'à 64 % en poids de DIM et ont résisté à la désintégration induite par les sels 
et ceci jusqu'à 400 mM NaCl. Par contre, les micelles de CMD-PEG de degré de 
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carboxyméthylation ~ 30% avaient une plus faible teneur en médicament (~ 40 % en 
poids de DIM) et se désagrégeaient à des concentrations en sel inférieures (∼ 100 mM 
NaCl). Le copolymère de CMD-PEG qui a montré les propriétés micellaires les plus 
satisfaisantes a été sélectionné comme système de livraison potentiel de chlorhydrate de 
minocycline (MH) et d’antibiotiques aminoglycosidiques. Les micelles CMD-PEG 
encapsulantes de MH ou d’aminoglycosides ont une petite taille (< 200 nm de diamètre), 
une forte capacité de chargement (≥ 50% en poids de médicaments) et une plus longue 
période de relargage de médicament. Ces micelles furent stables en solution aqueuse 
pendant un mois; après lyophilisation et en présence d'albumine sérique bovine. De plus, 
les micelles ont protégé MH contre sa dégradation en solutions aqueuses. Les micelles 
encapsulant les drogues ont maintenu les activités pharmacologiques de ces dernières. En 
outre, les micelles MH réduisent l’inflammation induite par les lipopolysaccharides dans les 
cellules microgliales murines (N9). Les micelles aminoglycosides ont été quant à elles 
capable de tuer une culture bactérienne test. Toutefois les micelles aminoglycosides/CMD-
PEG furent instables dans les conditions physiologiques. Les propriétés des micelles ont été 
considérablement améliorées par des modifications hydrophobiques de CMD-PEG. Ainsi, 
les micelles aminoglycosides/dodecyl-CMD-PEG ont montré une taille plus petite et une 
meilleure stabilité aux conditions physiologiques. Les résultats obtenus dans le cadre de 
cette étude montrent que CMD-PEG copolymères sont des systèmes prometteurs de 
relargage de médicaments cationiques. 
 
Mots-clés : Dextrane, Micelles polyioniques, Diminazène, Médicaments hydrophiles, 
Minocycline, Neuro-inflammation, Aminoglycosides, Stabilité des micelles.  
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Abstract 
Polyion complex (PIC) micelles have emerged as promising delivery systems of 
ionic hydrophilic drugs. It was the aim of this study to develop dextran-based PIC micelles 
for the delivery of hydrophilic cationic drugs using a new family of carboxymethyldextran-
block-poly(ethylene glycol) (CMD-PEG) copolymers. Four CMD-PEG copolymers were 
prepared: (i) two copolymers identical in terms of the length of CMD and PEG blocks, but 
different in terms of the charge density of the CMD block; and (ii) two copolymers in 
which the charged block is the same, but the PEG block is of different molecular weight. 
The micellization of CMD-PEG copolymers and drug delivery aspects of the resulting 
micelles were evaluated using different cationic drugs: diminazene (DIM), a model cationic 
drug, minocycline hydrochloride (MH), a semisynthetic tetracycline antibiotic with 
promising neuroprotective properties and different aminoglycoside antibiotics. The 
cytotoxicity of CMD-PEG copolymers was evaluated in different cell lines using MTT and 
Alamar blue assays. CMD-PEG micelles encapsulating different drugs were characterized 
using different techniques, such as 1H NMR spectroscopy, dynamic light scattering (DLS), 
and isothermal titration calorimetry (ITC). The pattern of drug release and pharmacological 
activity of micelles-encapsulated drugs were also evaluated. The CMD-PEG copolymers 
did not induce cytotoxicity in human hepatocytes and murine microglia (N9) in 
concentrations as high as 15 mg/mL after incubation for 24 h. Electrostatic interactions 
between CMD-PEG copolymers and different cationic drugs triggered the formation of PIC 
micelles with a CMD/drug core and a PEG corona. The properties of DIM/CMD-PEG 
micelles were strongly dependent on the degree of carboxymethylation of the CMD block. 
Micelles of CMD-PEG copolymers having degree of carboxymethylation ≥ 60%, 
incorporated up to 64 wt% DIM, resisted salt-induced disintegration in solutions up to 400 
mM NaCl and sustained DIM release under physiological conditions (pH 7.4, 150 mM 
NaCl). In contrast, micelles of CMD-PEG of degree of carboxymethylation ~ 30% had 
lower drug content (~ 40 wt% DIM) and disintegrated at lower salt concentration (∼ 100 
mM NaCl). The CMD-PEG copolymer that showed the most satisfactory micellar 
properties, in terms of high drug loading capacity, sustained drug release and micelles 
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stability was selected as a potential delivery system of minocycline hydrochloride (MH) 
and different aminoglycosides. CMD-PEG micelles encapsulating either MH or 
aminoglycosides had small size (< 200 nm in diameter), high drug loading capacity (≥ 50 
wt% drug) and sustained drug release. These micelles were stable in aqueous solution for 
up to one month, after freeze drying and in the presence of bovine serum albumin. 
Furthermore, the micelles protected MH against degradation in aqueous solutions. 
Micelles-encapsulated drugs maintained their pharmacological activity where MH micelles 
reduced lipopolysaccharides-induced inflammation in murine microglia (N9) cells. And 
aminoglycosides micelles were able to kill a test micro-organism (E. coli X-1 blue strain) in 
culture. Aminoglycosides/CMD-PEG micelles were unstable under physiological 
conditions. Micelle properties were greatly enhanced by hydrophobic modification of 
CMD-PEG. Thus, aminoglycosides/dodecyl-CMD-PEG micelles showed smaller size and 
better stability under physiological conditions. The results obtained in this study show that 
CMD-PEG copolymers are promising delivery systems for cationic hydrophilic drugs.       
 
Keywords : Dextran, Polyion complex micelles, Diminazene, Hydrophilic drugs, 
Minocycline, Neuroinflammation, Aminoglycosides, Micelles stability.  
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1.1. The need for new drug delivery systems 
Potency and therapeutic effects of many drugs are limited or otherwise reduced 
because of their unfavorable physiochemical and/or pharmacokinetics properties. For 
example, instability, limited solubility, accumulation in non-target sites leading to side 
effects and low bioavailability are just a few of the properties that limit therapeutic benefit 
of many drugs.[1] Discovery of new drugs may improve these unfavorable properties. 
However, discovery and development of new drugs are very long processes with enormous 
expenditure. In the United States, the average time to discover, develop and approve a new 
drug is approximately 14.2 years [2, 3] with an average development cost of $ 802 million.[4] 
A large fraction of the rising health care expenses is accounted for by expenses on 
pharmaceuticals, which have grown rapidly over the last two decades.[4] Properly designed 
drug delivery systems can minimize the cost of developing new drugs by optimizing the 
properties of existing drugs. The search for new drug delivery technologies is also fueled 
by pharmaceutical companies aiming at registering off-patent or about to be off-patent 
products. The nano-based drug delivery market is expected to increase from its current 
value at $3.4 billion (about 10% of the total drug delivery market) to about $26 billion by 
2012.[5] The following sections describe the current challenges that face the pharmaceutical 
formulator and can be overcome through the development of new drug delivery systems. 
1.1.1. The solubility challenge 
Poor water solubility of drugs presents a challenge for the development of 
successful drug formulations for either oral or parenteral administration. For orally 
administered drugs, drug aqueous solubility is a key factor that determines its dissolution 
rate in the gastrointestinal (GI) fluids and hence, its oral bioavailability. Only soluble drug 
molecules can be absorbed by the cellular membranes and reach their target after oral 
administration.[6] Moreover, oral administration of poorly water soluble drugs quite often 
leads to low and highly variable bioavailability.  
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Poor aqueous solubility could also result in serious side effects for drugs 
administered by intravenous (IV) injection. Water insoluble drugs form aggregates after IV 
injection leading to blockage of blood vessels and embolism.[7] Drug aggregates could also 
lead to local toxicity at the site of accumulation and/or reduced systemic availability. Other 
problems associated with the administration of poorly water soluble drugs are summarized 
in Figure 1.1.[8]  
  
 
 
 
 
 
 
 
 
Figure 1.1. Different problems associated with the administration of poorly water soluble 
drugs.[8]  
 
A Biopharmaceutics Classification System (BCS) class I drug (high solubility-high 
permeability) is ideal in terms of solubility and bioavailability.[9] Advances in the fields of 
combinatorial chemistry and/or biologically based high-throughput screening have resulted 
in the availability of large number of new drugs. Most of these newly developed drugs 
belong to BCS Class II (low solubility-high permeability) or Class IV (low solubility-low 
permeability).[10] It is estimated that about 40% of newly developed drug candidates lack 
adequate water solubility.[11-13] These insoluble drug candidates are usually rejected by the 
pharmaceutical industry and never enter a formulation development stage.[13] Examples of 
Poor  
bioavailability 
Use of highly acidic or 
basic conditions to  
solubilise the drug 
Use of harsh excipients i.e. organic 
solvents, surfactants 
Lack of dose/response 
proportionality 
Precipitation after dosing 
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in bioavailability 
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water insoluble drugs include anticancer drugs since many of them are bulky polycyclic 
compounds like  paclitaxel, tamoxifen, camptothecin, phenytoin, cyclosporine-A, digoxin, 
nitroglycerin and sulphathiazole.[14] The modified Noyes-Whitney equation (equation 1) 
identifies possible parameters that can be modified to enhance the dissolution rate of water 
insoluble drugs.[15, 16] 
 
          
Where dC/dt is the rate of dissolution, A is the surface area available for dissolution, D is 
the diffusion coefficient of the compound, Cs is the solubility of the drug in the dissolution 
medium, C is the concentration of drug in the medium at time t and h is the thickness of the 
diffusion boundary layer adjacent to the surface of the dissolving particle. The dissolution 
rate can be increased by increasing the surface area available for dissolution (e.g. by 
decreasing the particle size of the drug and/or by optimizing the wetting characteristics of 
the substance surface), by decreasing the boundary layer thickness, by maintaining sink 
conditions for dissolution and, by improving the apparent solubility of the drug under 
physiologically relevant conditions. One strategy to increase drug solubility is to create 
various drug salts, which not only improve drug aqueous solubility but also retain its 
biological activity. Other approaches to improve drug aqueous solubility include the use of 
clinically acceptable organic solvents, mixtures of cosolvents, surfactants or pharmaceutical 
excipients, such as cyclodextrins.[16] However, these approaches often end-up in serious 
side effects.[12, 17] For instance, the water-insoluble anticancer drug paclitaxel (Taxol®) is 
formulated in a 1:1 mixture of Cremophor®-EL and ethanol. Cremophor® EL causes many 
side effects, such as hypersensitivity, nephrotoxicity, neurotoxicity, vasodilatation, difficult 
breathing, lethargy and hypotension.[17, 18]  
1.1.2. Poor oral absorption 
Oral dosage forms are, so far, the most preferred drug formulations by the patient, 
clinician and pharmaceutical manufacturer. In the United States over 80% of drugs 
administered to produce systemic effects are marketed as oral dosage forms (e.g. tablets, 
dt 
dC AD (Cs-C) 
h 
= (1) 
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capsules). From the patient point of view, oral administration is “natural”, easy, safe and 
less painful than injection. For the clinician, oral administration improves the therapeutic 
outcome since the patient has more chances to adhere to the prescribed therapeutic regime. 
Oral drug products are more profitable for the pharmaceutical manufacturer since they 
require less strict conditions during their manufacturing compared to parentral products 
(e.g. sterility etc).  
Successful oral drug therapy is faced by several obstacles. The very first 
prerequisite for successful oral therapy is the adequate drug absorption from its site of 
administration. Factors affecting oral drug absorption can be broadly divided into three 
main categories: (i) physicochemical variables, (ii) physiological variables and (iii) dosage 
form variables.[19] Rate and extent of drug absorption are governed by a complex interplay 
of all these factors. Physicochemical properties that influence oral drug absorption include 
its oil/water partition coefficient (Ko/w), its degree of ionization in biological fluids as 
determined by its pKa and pH of the surroundings and its molecular weight. The drug Ko/w 
is one of the most important physicochemical properties that govern its oral absorption. 
This is not surprising since the cell membrane is lipidic in nature while the surrounding 
fluid into which the drug should dissolve is water. Therefore, for a drug to be adequately 
absorbed it should have enough hydrophilicity to dissolve in the GI fluids and enough 
lipophilicity to cross the cell membrane.  
According to the fluid mosaic model (Figure 1.2), the cell membrane is composed 
of a lipid bilayer in which the lipid portions (long tails) are arranged inside the bilayer 
while the polar portions (round head) point outward. The membrane is crossed by 
transmembrane (or integral) proteins whereas peripheral proteins are attached to the inner 
surface of the membrane. The outer surface has carbohydrates attached to lipids and 
proteins.[19, 20] The cell membrane has small water-filled channels or pores that allow 
absorption of water, ions or small water soluble molecules. The effective radius of these 
pores was estimated to be 7-8.5 Å and 3-3.8 Å in human jejunum and ileum, 
respectively.[21]  
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Figure 1.2. Schematic representation of the fluidic mosaic model of the cell membrane. 
http://lamp.tu-graz.ac.at/~hadley/nanoscience/week4/membrane.jpg 
Passive drug absorption through the cellular membranes can take place by either 
transcellular or paracellular pathways. Transcellular absorption involves passage of the 
drug through the lipophilic cell membrane, therefore it requires adequate lipophilicity of the 
drug (1 < Ko/w < 105). In contrast, paracellular absorption takes place by diffusion through 
space between adjacent cells. The presence of tight junctions between the cells limits the 
absorption through this pathway to water soluble small molecules (Ko/w < 1 and molecular 
weight < 500 g/mol).[22, 23] In order to correlate the physicochemical properties of drugs to 
their absorption, Lipinski et al. developed the so-called “rule of 5”.[24] The rule states that a 
new drug candidate is likely to have poor absorption or membrane permeability if: 
1. It has more than 5 hydrogen bond donors. 
2. It has more than 10 hydrogen bond acceptors. 
3. Its molecular weight is greater than 500 g/mol. 
4. Its Log Ko/w is greater than 5. 
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5. The above rules only apply to compounds that undergo passive membrane 
transport. 
The incredible advances in the areas of biotechnology, molecular biology and 
biochemistry have led to the advent of new classes of therapeutic agents. Peptides, proteins, 
oligonucleotides, DNA and small interfering RNA (siRNA) are examples of these new 
therapeutics that present major challenges to drug delivery scientists. For instance, high 
water solubility and high molecular weight of peptide and protein drugs significantly 
reduce their permeability through the cell membranes.[25, 26] Also DNA and siRNA have 
poor penetration through the cellular membranes due to their high molecular weight and 
strong anionic charges.[27-29] The unique physicochemical properties of these therapeutics 
have motivated drug delivery scientists to develop new delivery systems or explore new 
routes of drug administration. Thus, nasal, pulmonary and transdermal administration are 
some of the less conventional routes of drug administration that are currently being 
explored for the delivery of such new therapeutics.[30-33] 
1.1.3. The stability challenge 
Instability in solution, in vitro or in vivo is one of the hurdles that reduce the 
usefulness of many therapeutic agents. For instance, instability in solution prevents the 
development of liquid dosage forms for antibiotics, such as tetracyclines. Instead, these 
drugs are formulated in solid dosage forms or powders ready for reconstitution at the time 
of use. Indeed, liquid dosage forms are more desirable in many occasions, such as 
ophthalmic use, pediatric patients, geriatric patients and patients with difficulty in 
swallowing.[34, 35] Moreover, liquid dosage forms are the first choice when rapid onset of 
action is required like in analgesia and migraine.[36] Chemical degradation of drugs 
decreases their potency leading to non effective therapy. The picture is further complicated 
by the fact that chemical degradation of drugs often results in the formation of toxic 
degradants with subsequent serious side effects to the patients. For example, 
epianhydrotetracyline and m-aminophenol are toxic degradants of tetracycline and p-
aminosalicyclic acid, respectively.[37] Chemical instability of drugs in solution could result 
from hydrolysis, oxidation, photolysis, racemization or decarboxylation.[37]  
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  Adequate in vivo stability in the gastrointestinal fluids and in the blood is a key 
factor that ensures adequate bioavailability, low clearance and long circulation time. The 
vast majority of peptide and protein drugs are unstable in the GI tract due to enzymatic 
degradation and/or instability in the harsh acidic conditions in the stomach.[38] 
Consequently, these drugs are given by subcutaneous or IV injections. Injections are not 
patient friendly and lead to side effects.  In addition, DNA instability and degradation by 
nucleases in the plasma and in the cytoplasm are challenges that need to be addressed for 
successful gene therapy.[39] For all these reasons, much effort has been continuously 
devoted to the development of drug delivery systems that improve drug stability, both in 
vitro and in vivo.    
1.1.4. Unfavorable pharmacokinetics 
The ultimate goal of drug therapy is to achieve and maintain effective drug 
concentration at its site of action, which is usually located away from the site of 
administration. As soon as a drug appears in the blood stream, it is subjected to distribution 
to various organs and tissues. These organs include the liver and kidney, which metabolizes 
the drug and excretes it from the body, respectively. As a result, drug concentration at the 
site of action decreases over time and repeated dosing becomes necessary. Moreover, the 
drug may be metabolized and/or excreted before reaching its site of action leading to 
therapy failure. Repeated administration usually results in poor compliance and eventually 
poor therapeutic outcome. In this regard, drug delivery systems that release their cargo in a 
sustained, controlled, stimuli-responsive or delayed manner are much appreciated. These 
delivery systems reduce the frequency of administration, enhance drug efficacy by its 
localization at the site of action and reduce the required dose.[40] 
The lack of “targetability” is another inherent undesirable pharmacokinetic property 
of most drugs. Following absorption, drugs are usually distributed non-specifically 
throughout the whole body including healthy tissues. This leads to numerous side effects, 
which are particularly alarming for cytotoxic drugs whose accumulation in healthy tissues 
leads to serious adverse effects and limits the allowable dose.[41] Moreover, the widespread 
distribution into the whole body dilutes the drug and decreases its concentration at the 
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target sites. This increases the required doses, which in turn increases the cost of therapy 
and induces more side effects. Therefore, a delivery system that maximizes drug 
concentration in pathological tissues and minimizes its concentration in healthy tissues can 
enhance the drug therapeutic index, reduce the cost of therapy and improve the overall 
therapeutic outcome. This led to the appearance of the concept of drug targeting, which can 
be defined as selective drug delivery to certain organ, tissue or cell within the body where 
its action is needed.[42] Historically, the 19th century “magic bullet” idea of Paul Ehrlich 
was the first drug targeting proposal. He proposed that if a substance “magic bullet” would 
have a specific affinity for disease-causing microorganisms; it would reach these 
microorganisms and destroy them without affecting healthy tissues. Nowadays drug 
targeting is a well-known drug delivery strategy that is achieved by either passive or active 
mechanisms.[43]     
1.2. Polymeric nanoparticulate drug carriers 
Scientists ever-expanding knowledge of the human body has led to the identification 
and understanding of the mechanisms underlying many challenging diseases. Many of these 
diseases can not be treated by conventional drug delivery systems.[44] This increases the 
demand for new drug delivery systems/technologies, which require multidisciplinary 
collaboration from physical, chemical, biological and engineering scientists.[45] An ideal 
drug delivery system should improve aqueous solubility of insoluble drug, enhance its 
bioavailability, maintain effective drug concentration in the blood over prolonged period of 
time, reduce side effects associated with drug administration, stabilize the drug both in vitro 
and in vivo and deliver the drug, passively or actively to its target.[46] It should also be cost-
effective and acceptable by the patients. To meet all these requirements, the last few 
decades have witnessed considerable interest in the development of new drug delivery 
systems.[44, 47-49] Advances in the fields of polymer chemistry and polymer colloid physico-
chemistry have resulted in the availability of many tailor-made polymers. This development 
changed the conventional role of polymers in drug delivery systems. Polymers were 
typically used for decades as additives or coatings in conventional drug delivery systems 
(e.g. tablets, suspensions, capsules) to solubilise, stabilize or control drug release.[47, 50, 51] 
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New polymers with tunable properties are now major components of many drug delivery 
systems.  
1.3. Advantages of polymeric nanoparticles as drug carriers 
Polymeric nanoparticulate drug carriers hold a promising future due to their superior 
performance relative to other drug carriers. Firstly, polymers can be designed to be 
biocompatible and/or biodegradable, which increases the safety of the resulting 
nanoparticles.[28] Secondly, polymers physicochemical properties (e.g. hydrophilicity/ 
hydrophobicity balance, charge, molecular weight) can be tuned resulting in nanoparticles 
with various adjustable properties (e.g. size, surface charge). Moreover, polymeric 
nanoparticles can be coated with hydrophilic polymers, such as poly(ethylene glycol) 
(PEG), which decreases the adsorption of opsonin proteins in the blood. This  helps 
nanoparticles escape recognition by the mononuclear phagocytic system (MPS) and 
circulate longer in the blood.[52] Polymeric nanoparticles usually have a molecular weight 
above the threshold for glomerular filtration (42-50 kDa for water soluble synthetic 
polymers), which is another factor prolonging their residence time in the blood.[44, 53] 
Surface of polymeric nanoparticles can be decorated with ligands/antibodies to direct them 
to certain target in the body.[54] Some polymeric nanoparticles achieves high drug loading, 
which maximizes drug/excipients ratio. Incorporation of drugs in polymeric matrices 
controls their release, which can be sustained or stimuli responsive.[55] Drug release from 
the so-called smart nanoparticles can be effected under different external stimuli (i.e. 
change in pH, temperature or ionic strength).[56] This allows drug release in certain 
pathological area in the body.[57] Absorption of nanoparticles is better than that of 
microparticles due to their small size.[58] In addition, nanoparticles small size allows them 
to accumulate, passively in solid tumors, infarcts and inflamed tissues through the so-called 
enhanced  permeability and retention effect (EPR).[59] This effect relies on the 
pathophysiological characteristics of solid tumors, which are characterized by 
hypervascularity, incomplete vascular architecture, poorly aligned endothelial cells and 
wide fenestrations.[14, 60] These characteristics make the vasculature of pathological tissues 
more “leaky” than that of healthy tissue. Leaky vasculature together with impaired 
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lymphatic drainage facilitates accumulation of macromolecules and nanoparticles in 
pathological tissues. The EPR effect is applicable to any macromolecule with molecular 
weight greater than 40 kDa. Exploiting the EPR effect, drug concentration in the tumor of 
10-30 times higher than that in the blood was achieved.[61] Moreover, the EPR effect results 
in prolonged drug retention in pathological tissues (e.g. tumor or inflamed tissue) for 
several weeks.  
Despite the great potential of polymer chemistry, the number of synthetic polymers 
suitable for in vivo applications is limited.[62] A candidate polymer should be biodegradable 
and/or biocompatible to be considered for in vivo drug delivery. In case a polymer is not 
biodegradable it should be totally eliminated from the body in a reasonable period of time. 
This allows repeated administration without any risk of uncontrolled accumulation. The 
polymer and its degradation products, if any, must be non toxic and non immunogenic. 
Examples of polymers approved by US-FDA (United States Food and Drug 
Administration) for administration in human beings are poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol) 
(PEG), and poly(methyl methacrylate) (PMMA).[63] 
Polymeric nanoparticles are colloidal drug carriers that vary in diameter between 10 
and 1000 nm. Polymers used in the fabrication of nanoparticles can be categorized, 
according to their source, into natural, synthetic or semisynthetic. Natural polymers are 
generally safer and biocompatible, though the synthetic ones are more appealing due to the 
greater control over their physicochemical properties. Natural polymers that have been used 
in the formulation of nanoparticles for drug delivery applications include proteins (e.g. 
collagen, gelatin and albumin) and polysaccharides (e.g. dextran, chitosan, hyaluronic acid, 
pullulan, cellulose and inulin).[64, 65] Examples of synthetic polymers used in the 
manufacture of nanoparticles include aliphatic polyesters, polyanhydrides, polyorthoesters 
and polycyanoacrylates.[66] Aliphatic polyesters (e.g. PLA, PGA, PLGA and PCL) are, so 
far, the most widely used synthetic polymers in the preparation of drug-loaded 
nanoparticles. One advantage of aliphatic polyesters is their biocompatibility and their 
controlled degradation to biocompatible monomers.[65] Controlled polymer degradation 
results in controlled release of encapsulated drugs. Aliphatic polyesters are degraded by 
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bulk hydrolysis of their ester bonds.[67] Their degradation products (e.g. lactic acid or 
glycolic acid) are removed from the body by normal metabolic pathways.[68] These 
degradation products, however, can create acidic microenvironment, which can degrade 
some acid-labile drugs like protein therapeutics. 
1.4. Classes of polymeric nanoparticles 
Pharmaceutically interesting polymeric nanoparticulate drug carriers include 
nanospheres, nanocapsules, polymeric micelles, dendrimers and polymersomes. Each class 
of these nanocarriers has its own advantages and shortcomings. The type of nanoparticulate 
carrier obtained from a given polymer depends on the polymer physicochemical properties 
and the method used to fabricate the nanoparticles. Based on the nanoparticle type, drugs 
may be encapsulated or dissolved into the nanoparticles core, dispersed in the polymeric 
matrix or adsorbed to the nanoparticles surface (Figure 1.3).  
1.4.1. Nanocapsules 
Polymeric nanocapsules are colloidal drug carriers with a solid polymeric shell 
surrounding a core that is liquid or semisolid at room temperature. The core is used as a 
reservoir space for encapsulation of different drugs (Figure 1.3). Nanocapsules shell is 
usually a single polymeric layer formed during polymerization at the interface between the 
dispersed and continuous phases of the emulsion used in nanocapsules preparation. The 
shell can also be formed by precipitation of a preformed polymer at the surface of emulsion 
droplets. Double coated nanocapsules have been prepared through coating of poly(methyl 
methacrylate) (PMMA) nanocapsules by hydroxypropyl methyl cellulose.[69] Recently, 
nanocapsules having a core of liposomes coated by alternating layers of polycation (poly 
(allylamine hydrochloride)) and polyanion (poly (acrylic acid)) were prepared. This new 
hybrid system combined the advantages of both liposomes and nanocapsules.[70] 
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Traditionally, the nanocapsules core consisted of a lipophilic solvent, usually oil 
into which hydrophobic drugs were dissolved. The oil type affects drug loading capacity: 
high drug solubility in the oil gives high drug loading capacity.[71] Application of 
nanocapsules with an oily core is limited to encapsulation of hydrophobic drugs.[72] To 
overcome this limitation, nanocapsules with aqueous core suitable for encapsulation of 
water soluble drugs have been developed recently.[72, 73] Polymeric nanocapsules have been 
useful in the encapsulation and delivery of hydrophobic drugs (e.g. indomethacin[74], 
methotrexate[75], paclitaxel[76], spironolactone[77]), proteins (e.g. insulin[78], salmon 
calcitonin[79]) and water-soluble therapeutics (e.g. oligonucleotides[72], chlorhexidine 
digluconate[80]).  
1.4.2. Nanospheres 
Contrary to nanocapsules, nanospheres are matrix-type polymeric systems into 
which the drug is dissolved or entrapped in the matrix or adsorbed to the surface (Figure 
1.3). Advantages of nanocapsules over nanospheres include their low polymeric content 
and high loading capacity for hydrophobic drugs.[81] Therefore, they have higher 
drug/polymer ratio. Polymers typically used in the preparation of nanocapsules and 
nanospheres include aliphatic polyester homopolymers, such as PLA, PLGA and PCL and 
poly(alkylcyanoacrylates) (PACA).[82-84] These nanoparticles have found wide spread 
applications in enhancing in vivo performance and delivery of various drugs through 
different routes of administrations (e.g. IV, oral, ocular).[85-88]  
Following parenteral administration, nanoparticles with hydrophobic surfaces are 
coated by a group of plasma proteins, of which opsonin proteins facilitate recognition and 
uptake by the mononuclear phagocytic system (MPS) cells.[89] Uptake of nanoparticles by 
these cells depends greatly on their surface chemistry. It is affected by neither the type of 
the polymer used in nanoparticles preparation nor by their morphology (e.g. nanocapsules 
or nanospheres). This significantly reduces the residence time of nanoparticles in the blood 
and results in nanoparticles accumulation in the liver spleen and bone marrow. For 
instance, bare poly(methyl methacrylate) nanoparticles had a half life in the blood of only 3 
min.[90]Although this phenomenon was found useful in the treatment of liver and spleen 
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diseases, it is undesirable when drug action is needed in other tissues.[91, 92] Thus, 
gentamicin-loaded PLGA nanospheres were designed for the treatment of experimental 
Brucellosis in mice. Following IV injection, gentamicin-loaded PLGA nanospheres 
accumulated preferentially in the liver and spleen, the target organs for Brucella 
melitensis.[93] Adsorption of serum proteins by nanoparticles has also been useful in drug 
targeting to the brain. Thus, doxorubicin-loaded poly(butyl cyanoacrylate) (PBCA) 
nanoparticles coated by 1% polysorbate 80 resulted in drug level in the brain that was 60 
times higher than that of non-coated nanoparticles.[94] Polysorbate coat facilitated 
adsorption of plasma proteins, especially apolipoprotein E (Apo-E), which helped the 
nanoparticles cross the blood brain barrier (BBB).[95]    When it comes to treating diseases 
away from the liver and spleen, nanoparticles that evade the uptake by MPS cells are 
needed. This is usually achieved by coating nanoparticles with hydrophilic polymers. 
Hydrophilic polymers allow nanoparticles to escape recognition by the cells of the immune 
system and stay in the circulation for time long enough to target various pathological 
tissues in the body.[89] Surface modification with PEG or “pegylation” is the most widely 
used approach to prepare long circulating or “stealth” nanoparticles.[96, 97] Thus, 
copolymers, such as PLA-PEG[98], PLA-PEG-PLA[99], PLGA-PEG[100], chitosan-PEG[101] 
and PCL-PEG[102] have been used in the preparation of drug loaded nanocapsules and 
nanospheres.   
1.4.3. Polymersomes 
Polymersomes (polymeric vesicles) are vesicular structures formed by the hydration 
of amphiphilic block copolymers (Figure 1.3).[103] They were first introduced by Kunitake 
et al. in 1981 in an attempt to overcome the inherent disadvantages of liposomes.[104] 
Polymersomes are analogues of liposomes since both are vesicular structures but they have 
different composition of the shell, which consists of amphiphilic copolymers in 
polymersomes and lipids in liposomes. Unlike liposomes which are formed by small 
molecular weight lipids, polymersomes are formed by high molecular weight amphiphilic 
copolymers of different architectures (e.g., diblock, triblock, graft and dendritic polymers). 
This makes polymersomes wall thicker, stronger, tougher and thus, more stable than 
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conventional liposomes.[105] Polymersomes presents a number of advantages for biomedical 
applications: high stability, tunable membrane properties, versatility and ability to 
encapsulate different types of drugs including hydrophilic, hydrophobic or ionized.[105] 
Examples of amphiphilic block copolymers that form polymersomes are poly(butadiene)-
PEG[106], PCL-PEG[107, 108], polystyrene-dextran[109], PLA-PEG[110], poly(propylene 
sulfide)-PEG[111], polyphosphazenes containing PEG and ethyl-p-aminobenzoate side 
groups [112]. For biomedical applications, biodegradable polymers are always preferred. 
Aqueous core of polymersomes acts as a reservoir space for encapsulating water soluble 
drugs whereas the thick polymeric shell can be used to integrate hydrophobic molecules 
(Figure 1.3). This property has been taken advantage of in the preparation of polymersomes 
loaded with cocktail anticancer drugs. Thus, doxorubicin, a hydrophilic anticancer drug was 
encapsulated in the aqueous core while the hydrophobic anticancer drug paclitaxel was 
integrated in the thick polymersomes wall.[113] Polymersome drug cocktail showed a higher 
maximum tolerated dose and reduced tumors growth more effectively and for longer 
durations than free drugs. This shows the potential of polymersomes in mutlti-drug therapy 
and its attractiveness as a carrier for wide range of drugs. 
1.4.4. Dendrimers 
Dendrimers (from the Greek word dendron, meaning tree) are a fairly new class of 
colloidal drug carriers (Figure 1.3). They are globular branched nanostructures with core-
corona architecture. The core is a single atom or a group of atoms having at least two 
identical chemical functionalities. The branches that stem from the core are composed of 
repeating units with at least one junction of branching. Branching results in a series of 
radially concentric layers or generations.[13, 39] Dendrimers possess several features that 
make them attractive nanocarriers for drug delivery applications. Firstly, it is possible to 
fine-tune their properties to suit certain therapeutic needs. Secondly, their surface can be 
engineered with countless functional groups that are used to attach a drug or targeting 
moiety. This together with their small size (10-100 nm in diameter) makes them ideal 
carriers for drug targeting. Thirdly, the cavities or spaces between branches (especially in 
higher generations) are used for encapsulation of different drugs.[114, 115] Despite these 
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numerous advantages, cationic dendrimers, such as polyamidoamine (PAMAM) and 
polypropyleneimine (PPI) are cytotoxic.[116] Dendrimers cytotoxicity can be reduced by 
modifying their surface with hydrophilic polymers, such as PEG. Thus, PEGylated 
PAMAM and PPI dendrimers not only showed less cytotoxicity, haemolytic activity and 
immunogenicity compared to the parent compound but also had higher drug loading, 
stability and longer circulation time in the blood.[116-119] Another strategy to increase the 
PAMAM dendrimers biocompatibility while maintaining their ability to encapsulate siRNA 
involved the synthesis of internally cationic dendrimers with neutral surfaces.[120] 
Dendrimers have been used as delivery vehicles for various hydrophobic drugs to improve 
their aqueous solubility and to enhance their therapeutic efficacy.[121, 122] Furthermore, 
surface functional groups have been used for the loading of various hydrophilic drugs. 
Thus, surface amino groups of dendrimers have been used to encapsulate DNA, 
oligonucleotides or siRNA through electrostatic interactions.[123] Dendrimers/ 
oligonucleotides complexes decreased oligonucleotides degradation by RNase and showed 
improved transfection efficiency.[123, 124] Some dendrimer-based products have been 
approved by the FDA. VivaGel™ (Starpharma) is a vaginal microbicide gel for the 
prevention of sexually transmitted diseases. SuperFect®, developed by Qiagen, is used for 
gene transfection in a broad range of cell lines.[125] 
1.4.5. Micelles of amphiphilic copolymers 
 Polymeric micelles are colloidal drug carriers formed in aqueous media through self 
assembly of amphiphilic copolymers of different architectures (e.g. block, graft, 
random).[126] Polymeric micelles have size in the range of 5-100 nm and a core-corona 
structure (Figure 1.3).[12] Copolymers that form micelles in water have two segments with 
different affinities to water: one is hydrophilic while the other is hydrophobic. When these 
copolymers are dissolved in water, hydrophobic segments tend to aggregate and withdraw 
from the aqueous environment to minimize system free energy. Above certain 
concentration of the amphiphile in water, called the critical association concentration 
(CAC), the copolymer self assemble resulting in the formation of polymeric micelles. The 
driving force of self assembly is entropy gain of the solvent due to removal of hydrophobic 
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segments from the aqueous environment.[127] Self assembly in water of a certain amphiphile 
results in polymersomes or micelles according to the weight fraction of its hydrophilic 
block (f), the molecular weight of the amphiphile and the effective interaction parameter of 
its hydrophobic block with H2O (χ). For block copolymers with a high χ, polymersomes are 
formed when f = 20-40%. Worm-like micelles are formed at 40% < f < 50% whereas 
spherical micelles are obtained for copolymers with f  = 50-70%.[128, 129] 
 Polymeric micelles are interesting nanocarriers for drug delivery applications due to 
their unique segregated core-corona structure that provides them with numerous 
advantages. The micelles lipophilic core offers a microenvironment for the solubilisation of 
hydrophobic drugs. In this regard, polymeric micelles are much more efficient and safer 
than other formulations currently in use. For example, the water-insoluble anesthetic agent 
propofol is formulated as an oil-in-water microemulsion, which is unstable against dilution, 
causes pain on injection and poses risk of hyperlipidemia.[130, 131] To overcome these 
drawbacks, propofol was encapsulated in polymeric micelles of poly(N-vinyl-2-
pyrrolidone)-block-poly(D,L-lactide).[132] Sodium deoxycholate used for the solubilisation 
of amphotericin B is known to be haemolytic, whereas Cremophor®EL used for the 
solubilisation of numerous anticancer drugs has numerous side effects.[133] In addition to 
their well-established safety profiles, polymeric micelles are known to remarkably increase 
the solubility of numerous hydrophobic drugs. Polymeric micelles of PLA-PEG increased 
aqueous solubility of paclitaxel and doxorubicin, two clinically important anticancer drugs, 
by 5000-fold and 12 000-fold, respectively.[134, 135] Encapsulating hydrophobic drugs within 
the micelles core not only improves their solubility but also sustains their release, protects 
them against degradation, modifies their biodistribution, decreases their side effects and 
increases their overall therapeutic efficacy.[136-139] The hydrophilic corona of polymeric 
micelles maintains their water solubility and colloidal stability, reduces their uptake by the 
cells of the immune system and prolongs their circulation time. Micelles corona has also 
been used to attach targeting ligands so that the micelles accumulate selectively in certain 
tissue in the body. Thus, certain cancers have over-expression of peripheral benzodiazepine 
receptor (PBR), which was used to prepare paclitaxel-loaded PBR-targeted micelles. These 
micelles showed a significantly higher toxicity against human glioblastoma cancer cells in 
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vitro.[140] Examples of other receptors that are over-expressed by cancer cells and have been 
used to prepare targeted polymeric micelles are folate and transferrin.[12]   
 Poly(ethylene glycol) is the most commonly used corona-forming segment of 
polymeric micelles, though other hydrophilic polymers, such as poly(N-vinyl-2-
pyrrolidone) have been used.[132, 141] Various polymers have been used as core-forming 
segments of polymeric micelles.[142] Examples of these polymers include aliphatic 
polyesters (e.g., PLA, PCL, PLGA), polyethers (e.g., poly(propylene oxide)) and poly(L 
amino acids).[60] Poly(L amino acids) commonly used as core-forming segments in 
polymeric micelles include poly(aspartic acid) (PAsp), poly(glutamic acid) (PGlu), poly(L 
lysine) (PLL) and poly(histidine) (PHis). Since these amino acids are hydrophilic, they 
should be hydrophobized in order to form the micelles core.[44, 60] Many polymeric 
micelles-based anticancer drug formulations have progressed well beyond 
experimental/conceptual stages where many formulations are now in clinical trials (Table 
1.1).[14]  
Table 1.1. Polymeric micelles-based formulations in clinical trials.[14, 143] 
Trade name Drug Polymer Phase completed Ref. 
NK-911 Doxorubicin PEG-PAsp-DOX Phase I [144] 
SP-1049C Doxorubicin PEG-PPO-PEG Phase I [145] 
PAXCEED® Paclitaxel PEG-PDLLA Phase II [146] 
Genexol®-PM Paclitaxel PEG-PDLLA Phase II [147] 
NK-105 Paclitaxel PEG-PPBA Phase I [148] 
NK-012 SN-38 PEG-P(Glu) Phase I [149] 
 PEG: poly (ethylene glycol); PAsp: poly (aspartic acid); PDLLA: poly(D,L lactide); PPBA: 
poly(4-phenyl-1-butanoate)l-aspartamide; P(Glu): poly(glutamic acid);  SN-38: 7-ethyl-10-
hydroxycamptothecin. 
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1.4.6. Polyion complex (PIC) micelles  
Polyion complex (PIC) micelles were described for the first time in the mid 90’s 
independently by Kataoka and Kabanov groups.[150, 151] Since then PIC micelles found 
applications in various fields including delivery of ionic therapeutics.[152] This special class 
of micelles is formed by electrostatic interactions between an ionic-neutral copolymer of 
different architectures (i.e. block, graft, random) and an oppositely charged species. For 
drug delivery applications, the oppositely charged species is a therapeutic entity (e.g. drug, 
DNA or protein). In aqueous media, PIC micelles have a core-corona structure. The neutral 
water-soluble segment of the polymer forms the corona while the ionic segment-drug 
complex forms the core. Since their introduction, these colloidal carriers have been given 
different nomenclatures by different research groups. Thus, the term PIC micelles has been 
proposed by Kataoka and co-workers[153], Kabanov and co-workers[154] have been using the 
term block ionomer complexes, BIC, while Stuart and co-workers[155] use the term complex 
coacervates core micelles, C3Ms. The term PIC micelles will be used throughout the 
following sections. 
1.4.6.1. Driving force for PIC micelles formation 
Electrostatic interactions between oppositely charged polyelectrolytes (e.g. a pair of 
oppositely charged homopolymers, an ionic polymer and an oppositely charged drug) are 
mainly driven by entropy gain of the system due to release of small molecular weight 
counter ions.[156] Charge neutralization due to these interactions creates hydrophobic 
domains, which leads to precipitation and phase separation in water especially in the 
vicinity of charge stoichiometric compositions (Figure 1.4).[157] Replacing one of the 
interacting polyelectrolytes by an ionic-neutral copolymer endows the system with the 
amphiphilicity required for self assembly and micelle formation.[152] The neutral polymer 
segments that form the PIC micelles corona ensure water solubility of the micelles even 
under charge stoichiometric conditions (Figure 1.4). Moreover, the hydrophilic shell 
stabilizes the micelles against aggregation or phase separation. Depending on the chemical 
nature of the various PIC micelles components, other forces such as metal-ligand 
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coordination, hydrogen bonding, hydrophobic interactions or van der Waals forces may 
assist in PIC formation and stabilization.[158-160]    
 
 
 
 
 
 
 
 
Figure 1.4. Schematic illustration of PIC micelles formation from a pair of oppositely 
charged species.  
1.4.6.2. Advantages of PIC micelles as drug delivery systems 
PIC micelles are unique amid colloidal polymeric drug carriers in that they are used 
exclusively for encapsulation and delivery of ionic drugs. Ionic drugs usually have high 
water solubility, a property that makes their encapsulation into other nanoparticles 
tricky.[161] Moreover, these drugs have low affinity for the hydrophobic core of other 
nanoparticles and tend to diffuse out in the aqueous medium resulting in very low 
encapsulation efficiency.[162, 163] Thus, PLGA nanospheres encapsulated ~ 1 wt% 
gentamicin, a cationic water soluble aminoglycoside antibiotic.[92] A given dose of this drug 
formulation has polymer concentration that is 100 times higher than that of gentamicin. 
This is not desirable from toxicological point of view since it subjects the body to 
chemicals that can be avoided by properly selecting the drug carrier. In this regard, PIC 
micelles have higher drug loading capacity for ionic drugs.[164] In most cases, PIC micelles 
have almost complete drug incorporation since micelle formation relies on electrostatic 
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interactions between the polymer and the oppositely charged drug. For instance, PEG-g-
chitosan formed PIC micelles with all-trans retinoic acid that incorporated more than 80 
wt% drug.[165] The same micelles encapsulated another anionic drug, diammonium 
glycyrrhizinate (DG) with encapsulation efficiency higher than 96%.[166] PIC micelles are 
usually prepared in aqueous media limiting the use of organic solvents. Residuals of 
organic solvents in pharmaceutical preparations should be minimal since they could cause 
several side effects and pose risk to the human health.[167] Moreover, organic solvents may 
inactivate or denaturate delicate biotherapeutics, such as peptides and proteins.[168] 
Fabrication of PIC micelles involves simple mixing in aqueous solvents without the need of 
vigorous processing conditions, such as heat, sonication, or emulsification. This certainly 
avoids any deleterious effects on drugs stability and activity. Similar to micelles of 
amphiphilic copolymers, PIC micelles have excellent colloidal stability, small size and 
narrow size distribution. Corona forming blocks in PIC micelles are usually selected to 
provide the micelles with long circulation properties. Moreover, targeting ligands can be 
attached to the micelles corona to direct them towards certain organ or tissue in the body. 
Thus, Wakebayashi et al., synthesized α-lactosyl-PEG-poly(2-(dimethylamino) ethyl 
methacrylate) (lactose-PEG-PDMAEMA) as gene carriers for selective transfection of 
hepatic cells.[169] Lactosylated PIC micelles showed substantially higher transfection 
efficiency compared to non-lactosylated micelles in HepG2 cells having asialoglycoprotein 
(ASGP) receptors. This higher transfection efficiency was attributed to possible specific 
interaction between ASGP receptors and lactose moieties of the micelles. Having this in 
mind, Yang et al., reported the preparation of lactose-conjugated PEG-g-chitosan PIC 
micelles for liver-targeted delivery of diammonium glycyrrhizinate.[166] Three drug 
formulations were administered IV to rats: drug solution in PBS, micelles of PEG-g-
chitosan and micelles of lactose-PEG-g-chitosan.  Pharmacokinetics analysis showed that 
the micelles modified with lactose had more ability to deliver the drug to the liver.[169] 
1.4.6.3. Preparation methods for PIC micelles 
The most commonly used method for preparation of drug-loaded PIC micelles is 
simple mixing of the drug and polymer aqueous solutions under proper conditions of 
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drug/polymer molar charge ratio, polymer concentration, pH and ionic strength.[170-173] This 
method is not suitable for the encapsulation of water-insoluble ionic drugs. Other methods, 
such as dialysis, solvent evaporation and thin film hydration have been adopted for the 
incorporation of such drugs. Dialysis and solvent evaporation methods typically involve 
dissolving the polymer in water and dissolving water-insoluble drugs in a water miscible 
organic solvent, such as dimethyl sulfoxide (DMSO), dimethyl formamide (DMF) or 
ethanol. The drug and polymer solutions are mixed and the organic solvent is removed by 
dialysis against water or by evaporation under reduced pressure. Gradual removal of the 
organic solvent induces micelles formation and drug encapsulation. These two methods 
have been used for the preparation of all-trans retinoic acid/PEG-g-chitosan PIC 
micelles.[165, 174] Thin film hydration method was used to prepare amphotericin B-loaded 
poly(2-ethyl-2-oxazoline)-b-poly(aspartic acid) (PEOz-b-PAsp) PIC micelles.[175] Polymer 
and drug were dissolved in a suitable volatile organic solvent, such as DMF. A thin film is 
then formed by the evaporation of the organic solvent under reduced pressure followed by 
hydration with aqueous solvent. The free drug was removed by filtration. PIC micelles 
preparation by simple mixing of drug and polymer aqueous solutions is advantageous over 
other methods for scale-up production since it results in high yield and does not involve 
vigorous processing conditions. 
 
1.4.6.4. Classification of copolymers used for PIC micelles formation 
PIC micelles for biomedical applications have been developed using a wide range of 
ionic-neutral copolymers. Based on their architecture, these copolymers can be divided into 
4 main categories (Figure 1.5): 
1. Block copolymers: linear copolymers where the end group of one block is 
covalently linked to the head of another block giving diblock or triblock 
architectures.[157]  
2. Graft copolymers: branched copolymers with a comb-like architecture where 
different branches emanate from one main chain.  
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3. Random copolymers: linear copolymers with the building blocks arranged 
randomly.[176] 
4. Alternating copolymers: linear copolymers with perfectly alternating 
arrangement of their building blocks.  
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Architectures of different copolymers used in the preparation of PIC micelles.  
 
Copolymers used for PIC micelles formation can also be classified according to the 
charge of their ionic segment into two groups: cationic and anionic copolymers.  
1.4.6.4.1. Cationic copolymers 
Polycation-neutral copolymers as the name implies have two segments; one is 
neutral while the other contains ionizable cationic functional groups able to interact 
electrostatically with negatively charged species. The cationic functional groups are 
primary, secondary, tertiary or quaternary amines. Other ionizable cationic groups, such as 
amidine and guanidine are also used.   According to the chemical nature of the polyamine 
segment, these copolymers can be classified into: (i) copolymers based on poly(amino 
acids), (ii) copolymers based on poly(acrylamides), (iii) copolymers based on 
AB-type diblock 
Block copolymers 
ABA-type triblock ABC-type triblock 
graft copolymers 
random copolymers alternating copolymers 
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polyethylenimines, (iv) copolymers based on polysaccharides and (v) copolymers based on 
poly(pyridines). Examples of these different cationic copolymers are given in Table 1.2.  
Table 1.2. Different cationic copolymers used in the preparation of PIC micelles  
Polyamine Examples Ref. 
Poly(amino acids) 
PEG-b-PLL, PLL-b-PEG-b-PLL, PEG-g-PLL, PEG-b-thiol-
PLL, PLL-g-DEX, PEG-b-PLL dendrimer, PLL-g-DEX, 
PLL-g-polysaccharide (dextran, amylase, maltose), PNIPAM-
g-PLL, PEG-b-PDMAPA, PEG-b-PEDA 
[177-182] 
[183-191]
Poly(acrylamides) 
PHPMA-b-PTMAEMA, PHPMA-b-PDMAPMA, PEG-b-
PDEAEMA, random copolymers of 2-(dimethylamino)ethyl 
methacrylate (DMAEMA) with triEGMA or  NVP,PEG-b-
PDMAEMA, PVP-b-PDMAEMA, thiol-PEG-b-PDMAEMA, 
α-lactosyl-PEG-b-PDMAEMA, acetal-PEG-b-PDMAEMA  
[169, 
179, 192-
203] 
Polyethylenimines PEI-g-PCL, PEG-b-PEI, PEG-g-PEI, PNIPAM-g-PEI  [204-210]
Polysaccharides PEG-g-chitosan 
[165, 
166, 168] 
Poly(pyridines) 
PEG-b-PQ4VP, PEG-b-PQ2VP, PEG-b-P4VP,  
PEG-b-P2MVP, PS-b-P2VP-b-PEG 
[155, 
208, 211-
213]  
Poly(spermine) PEG-b-PSPM  [214] 
PLL: poly(L lysine); DEX: dextran; PNIPAM: poly(N-isoproply acrylamide); PDMAPA:  
poly(3-dimethylamino) propyl aspartamide; PEDA: poly(ethylenediamine aspartamide); 
PHPMA: poly-N-(2-hydroxypropyl) methacrylamide; PTMAEMA: 
poly(trimethylammonioethyl methacrylate); PDMAPMA: poly(N-[3-(dimethyl amino) 
propyl]methacrylamide); PDEAEMA: poly(2-(diethylamino) ethyl methacrylate); 
PDMAEMA: poly(2-(N,N-dimethylamino)ethylmethacrylate); triEGMA: ethoxytriethylene 
glycol methacrylate, PVP: poly(N-vinylprrolidone; PEI: polyethylenimine; PQ4VP: 
poly(N-methyl-4-vinylpyridinium sulfate); lyso: lysozyme; PQ2VP: poly(N-methyl-2-vinyl 
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pyridinium iodide); P4VP: poly(4-vinylpyridine); P2MVP: poly(2-methyl vinyl 
pyridinium); PS-b-P2VP-b-PEG: poly(styrene-b-2-vinyl pyridine-b-ethylene glycol). 
1.4.6.4.2. Anionic copolymers 
Anionic functional groups of the polyanion-neutral copolymers commonly used in 
PIC micelles preparation are carboxylate and sulfonate. Analogous to polycations, 
polyanionic copolymers are classified according to the chemical nature of their charged 
segment into: (i) copolymers based on poly(amino acids) (e.g. PEG-b-poly(aspartic acid) 
(PEG-b-PAsp)[150, 159, 160, 170, 215-217], PEG-g-PAsp[218],  poly(2-ethyl-2-oxazoline)-b-
poly(aspartic acid) (PEOz-b-PAsp)[175], poly(2-isopropyl-2-oxazoline)-b-poly(aspartic acid) 
(PiPrOz-PAsp)[219], PEG-b-poly(L-glutamic acid) (PEG-b-PGlu)[158, 220, 221]); (ii) copolymers 
based on polyacrylic acid (PAA) (e.g. PEG-b-poly(methacrylic acid) (PEG-b-PMAA)[222-
225], polystyrene-b-PNIPAM-b-PAA (PS-b-PNIPAM-b-PAA)[226], PNIPAM-b-PAA[227]); 
and (iii) others (poly(N-vinylpyrrolidone)-b-poly(styrene-alter-maleic anhydride) (PVP-b-
PSMA)[164]).  
The vast majority of copolymers used in the formulation of PIC micelles for 
biomedical applications have PEG as their neutral segment. This derives from its biological 
inertness, hydrophilicity, biocompatibility and ability to reduce protein adsorption over the 
micelles surface. Other neutral hydrophilic polymers, such as PVP, PNIPAM, PEOz and 
PiPrOz have also been used as corona forming blocks in PIC micelles. The attractiveness of 
PNIPAM, PEOz and PiPrOz as corona forming blocks relies on their thermo-sensitive 
properties. In aqueous solutions these polymers exhibit reversible thermo-responsive phase 
transition. This property has been exploited to prepare smart drug carriers that release their 
payload in certain pathological tissues with abnormally elevated temperature, such as 
certain types of cancer.[228, 229] 
1.4.6.5. Properties of PIC micelles  
1.4.6.5.1. Particle size and size distribution 
Most PIC micelles designed for biomedical applications are intended for parenteral 
administration. Therefore, particle size and size distribution are two crucial parameters 
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since they affect PIC micelles safety, biodistribution and stability.[230] Although the 
smallest capillaries in the body are 5-10 µm in diameter, the size of nanoparticles intended 
for parenteral administration and any possible aggregates should be far below this size to 
avoid blocking blood vessels and emboli formation.[39] Moreover, in order to attain 
longevity in the blood, nanoparticles diameter should be ≤ 200 nm since the sub-200 nm 
size along with biocompatibility allows nanoparticles to escape recognition by the MPS 
cells.[231, 232]  
Particle size of PIC micelles is dependent on many factors including chemical 
nature of their components, the ratio at which these components are mixed, pH and ionic 
strength of the medium. The molar charge ratios at which the drug and polymer are mixed 
greatly influence size and polydispersity index of the resulting PIC micelles. Micelles size 
is also affected by the order of addition (i.e. drug is added to polymer or vice versa). When 
a drug is added to an oppositely charged polymer in amounts such that the polymer is in 
excess, two species usually exist in solution: drug-polymer complex and free polymer. This 
usually gives micelles with high polydispersity indices where two or more populations exist 
in solution.[233]  Further increase in drug concentration relative to polymer concentration 
neutralizes free polymer chains resulting in monodispersed micelles at charge neutrality.  
For instance, Harada and Kataoka[153] showed that diameter and polydispersity index of 
lysozyme/PEG-b-PAsp micelles were dependent on their mixing ratio, r (the ratio of the 
number of aspartic acid residues in PAsp to the total number of arginine and lysine residues 
in lysozyme).  Micelles diameter remained constant ~ 50 nm in the range of 0.125 ≤ r ≤ 1.0 
and increased almost linearly from ~ 50 to ~ 80 nm when r increased from 1.0 to 4.0. 
Polydispersity index decreased from 0.1 to 0.05 when r increased from 0.125 to 1.0 and 
remained constant thereafter. Constant micelles size at r < 1.0 was attributed to the 
formation of stoichiometric micelles (r = 1.0) where all PEG-b-PAsp in solution 
participated in micelles formation leaving excess lysozyme free in solution. At r > 1.0 
thickness of the micelles shell increased due to the increased number of PEG-b-PAsp 
chains in the micelles, which led to increasing the overall micelles size.  
1.4.6.5.2. Surface charge 
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Nanoparticles surface charge or zeta potential is one of the key factors that 
determine their in vitro stability, biodistribution and in vivo fate.[97] Nanoparticles with 
charged surfaces, either positive or negative have better in vitro colloidal stability since 
electrostatic repulsions reduce particle aggregation.[234, 235] Cell surface is negatively 
charged due to the presence of sulfated proteoglycans.[236]  Thus, positively charged 
nanoparticles have a better chance to interact with the cells than neutral or negatively 
charged ones. Although this improves the cellular uptake of positively charged 
nanoparticles, it typically results in non-specific distribution and uptake by various non-
target tissues. Moreover, positively charged nanoparticles form aggregates with negatively 
charged serum proteins following IV injection. These aggregates cause transient embolism 
in the lung capillaries.[237] Negatively charged liposomes with diameter ~ 200 nm were 
shown to be cleared from the blood at a rate higher than that of neutral ones.[238] For all 
these reasons, PIC micelles for drug delivery applications usually have a neutral PEG 
corona. The PIC micelles surface charge is determined by measuring their ζ potential (see 
below).  
1.4.6.5.3. Effect of pH on PIC micelles formation and stability 
The extent to which solution pH affects PIC micelles formation and stability 
depends on the type of the polyelectrolytes used in the complex formation. Thus, PIC 
micelles formed by a pair of strong polyelectrolytes are not affected by pH change since the 
charge density of these polyelectrolytes is fixed.[152] In contrast, charge density of weak 
polyelectrolytes is strongly affected by pH change. Consequently, there exists a pH range 
for which polyelectrolytes have enough charge density to promote PIC micelles formation 
and stability.  The width of this pH range depends on whether the micelles are formed by 
two weak or one weak and one strong polyelectrolyte. Above or below this pH range, one 
of the polyelectrolytes becomes neutral resulting in micellar disassembly.[239-241] This pH 
responsiveness, although compromises micelles stability, has been taken advantage of in 
the preparation of PIC micelles that release their payload in response to change in pH of the 
surroundings. For instance, PIC micelles of PEG-b-PMMA/PLL dissociated at pH 5.0 
showing their ability to release their cargo in the acidic environment of the endosomes (pH 
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~ 5-6) following endocytosis.[223, 242] Yang et al., reported that the release rate of 
diammonium  glycyrrhizinate (an anionic drug) from its PIC micelles with PEG-g-chitosan 
was faster at higher pH values due to the decrease in chitosan degree of ionization.[166] In 
addition to its influence on PIC micelles electrostatic interactions, pH affects other forces 
that contribute to PIC micelles formation and stability, such as hydrogen bonding. Thus, 
Gohy et al., reported that poly (2-vinylpyridine)-b-poly(ethylene glycol) (P2VP-b-PEG) 
and poly(methacrylic acid)-b-poly(ethylene glycol) (PMAA-b-PEG) did not form PIC 
micelles at low pH values, instead they formed micelles with a core formed by the 
hydrogen bonding between neutral PMAA and PEG chains.[243]  
1.4.6.5.4. Effect of ionic strength on PIC micelles stability 
PIC micelles are strongly sensitive to changes in ionic strength of the medium since 
salts cause charge screening and weakening of electrostatic interactions between oppositely 
charged polyelectrolytes.[168, 244] Therefore, PIC micelles dissociate above certain salt 
concentration called critical ionic strength, Icr. Critical ionic strength is dependent on the 
nature of PIC micelles constituents, their charge density, pKa, pH, mixing ratio, micellar 
concentration and the type of added salt.[225] PIC micelles formed by a combination of 
driving forces, such as electrostatic, hydrophobic and metal coordination are much more 
resistant to increase in salinity than those formed by electrostatic interactions only.[245, 246] 
For biomedical applications, PIC micelles should be stable under physiological conditions 
(NaCl concentration of 0.15 M and pH 7.4). These conditions are challenging for many PIC 
micelles formulations. Thus, Yuan et al., reported that PIC micelles of lysozyme/PEG-b-
PAsp disintegrated after NaCl concentration of 0.05 M at pH 7.4.[241] In addition, 
Nishiyama et al., reported that PIC micelles of cisplatin/PEG-b-PAsp were stable at 
physiological salt concentration and 37 ºC for 10 h, after which the micelles 
disassembled.[247] Accordingly, several strategies have been proposed to improve PIC 
micelles stability under physiological conditions. Two eminent approaches include core-
cross linking and hydrophobic modification of the ionic polymers. Thus, siRNA/PEG-b-
PLL micelles with disulfide cross-linked core were stable against increase in salt 
concentration up to 0.3 M, well above the physiological salt concentration.[173] In addition,  
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lysozyme/PEG-b-PAsp micelles cross linked by glutaraldehyde resisted increase in salinity 
up to 0.2 M.[241] Hydrophobic modification of the ω end of PEG-b-PAsp by different 
hydrophobic groups (e.g. phenyl, naphthyl and pyrenyl) improved the stability of 
lysozyme/PEG-b-PAsp micelles against increase in salinity. However, non of these 
hydrophobized derivatives yielded stable micelles under physiological conditions.[248] 
1.4.6.5.5. Colloidal stability of PIC micelles 
PIC micelles colloidal stability refers to their ability to remain stable in solution 
without macroscopic phase separation. At charge neutrality ratios, electrostatic interactions 
between oppositely charged polyelectrolytes result in phase separation and precipitation. In 
contrast, if a neutral segment is linked to one of the interacting polyelectrolytes, soluble 
colloidal particles (PIC micelles) are formed instead. Therefore, PIC micelles colloidal 
stability is determined by the balance between the tendency of the interacting species to 
phase separate and the tendency of the neutral blocks to stabilize the micelles and keep 
them in solution.[152] Hence, PIC micelles colloidal stability is governed by the factors 
affecting the strength of electrostatic interactions (e.g. pH, ionic strength, charge density) 
and the factors affecting neutral blocks stabilizing effect (e.g. block length, molecular 
architecture, temperature, block length ratio of corona to core forming monomers, 
Ncorona/Ncore). For pharmaceutical applications, PIC micelles should be colloidally stable in 
solution for periods long enough to permit accurate dosing in vitro and delivery of the drug 
to its target in vivo without precipitation or phase separation. Moreover, these micelles 
should maintain their integrity and colloidal stability after freeze drying and reconstitution 
since freeze dried formulations have enhanced shelf life and are easy to handle and 
transfer.[249] PIC micelles of lysozyme/PEG-b-PAsp prepared at charge neutrality showed 
no precipitation even after one month of storage at room temperature.[153] Size of 
heparin/PEG-b-PDEMAEMA PIC micelles was not affected by freeze drying and 
reconstitution.[233]   
1.4.6.5.6. Critical association concentration (CAC) of PIC micelles                                                   
Critical association concentration (CAC) or the concentration below which PIC 
micelles dissociate is one of the factors that determine their in vivo stability due to micelles 
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dilution in the body.[177] CAC of PIC micelles prepared at charge neutrality is usually very 
low and affected by the nature of their constituents, their charge density, Ncorona/Ncore and 
whether there are additional forces that participate in micelles formation (e.g. hydrophobic 
interactions).[250] For instance, CAC of antisense-oligonucleotides/PEG-b-PLL micelles 
was ~ 0.2 mg/mL whereas that of PEG-b-PLL/PEG-b-PAsp micelles was below 0.01 
mg/mL.[177, 251] 
1.4.6.6. Methods used to characterize PIC micelles 
1.4.6.6.1. Dynamic light scattering (DLS) 
DLS has been the method of choice to determine PIC micelles hydrodynamic radius 
(RH). DLS measurements involve determining the time dependence of the light scattered 
from a small region of solution over a certain period of time.[252] In case of coherent and 
monochromatic light, such as the light of a laser beam, it is possible to observe the time-
dependent fluctuations of the scattered intensity. These fluctuations are due to Brownian 
motion of the particles in solution, which makes the distance between them constantly 
changing with time. Scattered light then undergoes either constructive or destructive 
interference by the surrounding particles and within this intensity fluctuation, information is 
obtained about the time scale of particles movement. Scattered light intensity is measured 
with a detector, such as a photomultiplier tube capable of operating in the photon counting 
mode. Analysis of the time dependence of intensity fluctuation gives the diffusion 
coefficient (D). The diffusion coefficient of the particles is used to calculate RH from the 
Stokes Einstein equation (equation 2). RH is the radius of a hypothetical hard sphere having 
the same diffusion coefficient as the particle in question. 
 
  
  
 
 
Where RH is the hydrodynamic radius, k is the Boltzmann’s constant, T is the absolute 
temperature, η is the solvent viscosity and D is the diffusion coefficient.  
__________ RH  (2) 
6πηD 
kT 
=  
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DLS data is analyzed by the cumulant method or inverse Laplace transform (ILT) 
programs, such as CONTIN. RH obtained from the cumulant method of analysis is the 
weighted distribution of all objects present in solution, weighted with their relative 
scattering power. Therefore, cumulant analysis is best suited for solutions having 
monodispersed particles. CONTIN analysis is preferred for heterodisperse or polydispersed 
systems.[152] 
1.4.6.6.2. Static light scattering (SLS) 
In a typical SLS experiment, one measures the intensity of light scattered by a given 
solution as a function of the scattering angle and concentration of the solution. The light 
scattered by a dilute polymer solution can be expressed by equation 3[177]:  
 
 
 
 
Where C is the concentration of the polymer, ∆R(Θ) is the difference between the Rayleigh 
ratio of the solution and that of the solvent, Mw, app is the apparent weight average 
molecular weight of the polymer, q is the magnitude of the scattering vector, Rg is the  
radius of gyration, A2 is the second virial coefficient, and K = (4π2 n2 (dn/dc)2 )/(NA λ4) (N 
is Avogadro’s number and dn/dc is the refractive index increments). The Mw, app of the PIC 
micelles is obtained from Zimm plot of the data. The association number of the micelles is 
obtained by dividing micelles Mw, app by molecular weight of a single polyanion/polycation 
constituting chain, assuming that PIC micelles have composition equal to the mixing 
ratio.[177] SLS measurements have also been used to determine CAC of PIC micelles since 
the scattering intensity is a sensitive function of the weight average molecular weight of the 
micelles.[253] Intensity of light scattered by PIC micelles at a fixed angle (i.e. 90º) has been 
frequently used to monitor micelles stability as a function of solution pH, ionic strength and 
storage under different conditions.[170, 233, 247] 
1.4.6.6.3. ζ potential measurements 
= + (1+ q
2 Rg2/3) (3) __________ __________ 2A2C 
1 ∆R (Θ) 
KC  Mw, app 
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ζ potential of PIC micelles is usually determined via light scattering detection in the 
so-called Zetasizer. ζ potential is calculated from micelles electrophoretic mobility in 
response to an applied external electric field using Smoluchowski equation. ζ potential 
measurements are used to determine PIC micelles surface charge and to confirm the 
formation of PIC micelles with core-corona structure. Thus, neutral ζ potential values 
observed for lysozyme/PEG-b-PAsp micelles were taken as an indirect evidence for the 
formation of PIC micelles with lysozyme/PAsp core coated by neutral PEG corona.[153] 
Furthermore, ζ potential measurements have been used to confirm drug encapsulation into 
PIC micelles. Drug incorporation into the micelles neutralizes both the polymer and drug 
charges, which decreases the absolute value of micelles ζ potential. For instance, the 
encapsulation of all-trans retinoic acid into PEG-g-chitosan PIC micelles resulted in 
decreasing their ζ potential.[165] 
1.4.6.6.4. 1H nuclear magnetic resonance (1H NMR) 
  In the PIC micelles literature, 1H NMR studies have been used to confirm the 
formation of micelles with core-corona structures. This takes advantage of the restricted 
motion of the drug and polymer segments forming the core, which results in significant line 
broadening and/or disappearance of the signals due to corresponding protons. In contrast, 
protons of the polymer segments forming the corona maintain their mobility and thus, 
appear well resolved.[254] Thus, for all-trans retinoic acid (ATRA)/PEG-g-chitosan micelles, 
the specific 1H NMR signals of ATRA and chitosan were not visible in either D2O or 
DMSO. This was in contrast to the signals of PEG, which were visible in both solvents. 
These results confirmed that the PIC micelles have ATRA/chitosan core and a PEG 
corona.[165]  
1.4.6.6.5. Isothermal titration calorimetry (ITC) 
Electrostatic interactions taking place during PIC micelles formation can be 
characterized by isothermal titration calorimetry (ITC) if they are associated with 
generation (exothermic reaction) or absorption (endothermic reaction) of heat. ITC 
monitors heat change due to these interactions and determines thermodynamic parameters 
of the binding. ITC is the only instrument that in a single experiment determines 
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thermodynamic parameters of the binding including binding constant (K), reaction 
stoichiometry (N), enthalpy change (ΔH) and entropy change (ΔS).[255, 256]   
ITC is composed of two cells (reference and sample) and an injection syringe 
(Figure 1.6, left). The reference and sample cells are made of a thermally conducting 
material, surrounded by an adiabatic jacket. A typical ITC experiment involves addition at 
a constant temperature of aliquots of known volume of ligand solution from the syringe 
into the sample cell containing macromolecule solution. Addition of ligand is automated by 
a highly precise syringe stirred at desired speed by a computer-controlled stepper motor. 
Each injection of the syringe solution triggers the binding reaction and, depending on the 
binding affinity and the concentration of reactants in the cell, a certain amount of 
ligand/macromolecule complex is formed. Heat released or absorbed during complex 
formation causes a difference in temperature between the reference and sample cells. 
Consequently, ITC raises or lowers the thermal power (μcal/sec) required to keep a 
constant temperature difference (close to zero) between the sample and the reference cell. 
After each injection, the system reaches equilibrium and the temperature balance is 
restored. The recorded signal shows a typical deflection pattern in the form of a peak (raw 
data). Integrating the area under the peak with respect to time provides the heat change per 
injection (Figure 1.6, right). As the interaction in the cell finishes, the heat signal 
diminishes until only the background heat due to ligand dilution is observed. The heat 
change profile as a function of the ligand/macromolecule molar ratio can be analyzed to 
give thermodynamic parameters of the interaction under investigation. Thermodynamics of 
binding between poly(ethylene glycol)-b-poly(2-(diethylamino)ethyl methacrylate) and 
Plasmid DNA were studied by ITC.[195] 
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Figure 1.6. Diagram of ITC showing cells and syringe (left) and representative ITC data 
(right).  
www.microcalorimetry.com  
 
1.4.6.6.6. Other methods 
In addition to the previously described methods, many other techniques have been 
used to characterize PIC micelles and study their formation, structure, dynamics and 
functions. Thus, gel retardation assays have been used to detect complex formation between 
siRNA and polycations and to qualitatively confirm the absence of free siRNA.[173, 257] 
Fluorescence resonance energy transfer (FRET)[258] and circular dichroism (CD)[216] have 
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been used to study secondary structures of DNA and protein/peptide entrapped in PIC 
micelles. Imaging techniques that have been used to visualize PIC micelles include atomic 
force microscopy (AFM)[233], transmission electron microscopy (TEM)[165], scanning 
electron microscopy (SEM)[259] and cryogenic transmission electro microscopy (cryo-
TEM)[260]. Enthalpy changes associated with the complexation in PIC micelles have been 
studied by differential scanning calorimetry (DSC)[261].  
1.4.6.7. Applications of PIC micelles as drug delivery systems 
1.4.6.7.1. PIC micelles as non-viral gene vectors  
Gene therapy is the delivery of genes to cells and tissues to treat a disease, such as 
hereditary diseases  in which a non-functional mutant gene is replaced by a functional one. 
Gene therapy has a great potential not only in the treatment of hereditary diseases but also 
in the treatment of acquired diseases, such as cancer and infectious diseases. In addition to 
delivery of functional genes, silencing of defective genes can be achieved by the 
conventional antisense technology or more recently by sequence specific gene silencing 
using small interfering RNA (siRNA).[27, 262]  Efficient gene delivery is hindered by many 
obstacles including poor tissue penetration due to large molecular weight and anionic 
nature of the genes, difficulty of targeting genes to the nucleus, instability and rapid in vivo 
elimination and poor transfection efficiency.  
In order to overcome these obstacles either viral or non viral gene vectors are used. 
Although viral vectors have the advantage of high transfection efficiency, their potential 
safety risks, as well as immunogenicity justify the search for alternative non-viral vectors. 
Among different non-viral gene vectors, those based on electrostatic interactions between 
DNA and cationic lipids (i.e. lipoplexes)[263] or DNA and cationic polymers (i.e. 
polyplexes)[264] are the most studied systems. Lipoplexes and polyplexes are not soluble at 
charge stoichiometric ratios due to charge neutralization. Water solubility of lipoplexes and 
polyplexes is preserved by using an excess of the cationic species resulting in numerous 
side effects after in vivo administration.[262] In contrast, PIC micelles, as polyplexes, have 
the ability to condense DNA and maintain their water solubility at stoichiometric ratios, 
thanks to their neutral corona (usually PEG). To be viable gene vectors, PIC micelles 
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should be stable under physiological conditions, their DNA payload should be kept 
encapsulated as long as the micelles are circulating in the blood and it should be released 
once the micelles are inside the target cells.  
The literature shows numerous examples of PIC micelles being used as non-viral 
gene vectors. For instance, PEG-b-poly(amino acids) copolymers (e.g. PEG-b-PLL, PEG-b-
PGlu) have been frequently used for the delivery of DNA, oligonucleotides and siRNA. 
Plasmid DNA (pDNA) encapsulated in PIC micelles of PEG-b-PLL was more resistant to 
degradation by nucleases than free pDNA.[180] Moreover, pDNA was more tolerable to 
physiological conditions when encapsulated in PIC micelles than pDNA encapsulated in 
polyplexes (pDNA/PLL) or lipoplexes (pDNA/lipofectamine).[258] Transfection efficiency 
of pDNA/PEG-b-PLL PIC micelles in cultured 293 cells increased with increasing the 
length of PLL segment or the mixing charge ratio (PLL/pDNA) suggesting that the 
transfection efficiency is related to the degree of pDNA condensation.[265] Following IV 
injection, naked pDNA was cleared from the blood stream within 5 minutes. In contrast, 
pDNA/PEG-b-PLL micelles had a considerably higher blood retention time. Moreover, in 
vivo gene expression was observed for up to 3 days post-injection of the micelles.[266]  
Despite these advantages of PIC micelles as gene vectors, their stability in the blood 
was not enough to permit their clinical application. To address this issue, the core of PEG-
b-PLL micelles entrapping DNA was cross linked by disulfide bonds, which are stable in 
the blood and readily hydrolyzed in the cytoplasm due to the presence of high 
concentrations of glutathione.[267] Interestingly, core-cross linked PIC micelles were stable 
under physiologic conditions and showed 100-fold higher siRNA transfection efficiency 
compared to non cross-linked micelles, which were not stable at physiological ionic 
strength.[173]  
In addition to PIC micelles of PEG-b-poly(amino acids), those based on cationic 
aliphatic polyesters were used as delivery vectors for siRNA. Thus, Xiong et al., evaluated 
a novel family of PEG-b-PCL based copolymers with polyamine side chains on the PCL 
block for siRNA delivery. Polymers studied were PEG-b-PCL with grafted spermine (PEG-
b-P(CL-g-SP)), grafted tetraethylenepentamine (PEG-b-P(CL-g-TP)), or grafted N,N-
dimethyldipropylenetriamine (PEG-b-P(CL-g-DP)).[257] The siRNA formulated in PEG-b-
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P(CL-g-SP) and PEG-b-P(CL-g-TP) micelles demonstrated effective endosomal escape and 
efficient gene silencing. Another PCL-based copolymer for siRNA delivery was a cationic 
triblock copolymer consisting of PEG, PCL and poly(2-aminoethyl ethylene phosphate) 
(PEG-b-PCL-b-PAEEP).[268] Based on MTT assays, these new polymers were not cytotoxic 
even at polymer concentration of 1 mg/mL. PIC micelles of siRNA/PEG-b-PCL-b-PPEEA 
were effectively internalized into HEK293 cells, resulting in significant gene silencing 
activity. These studies demonstrated the promise of PIC micelles as efficient non-viral gene 
vectors. 
1.4.6.7.2. PIC micelles as delivery systems for anticancer drugs 
Cisplatin (cis-dichlorodiammineplatinum(II); CDDP) is an anticancer drug that is 
widely used for the treatment of many malignancies, including testicular, ovarian, bladder, 
head and neck, small-cell, and non-small-cell lung cancers.[269] However, its clinical use is 
limited due to emergence of intrinsic and acquired resistance and severe side effects.[270, 271] 
Moreover, it is cleared from the body by glomerular filtration within 15 min following IV 
injection.[44] PIC micelles of CDDP and PEG-b-poly(amino acids) copolymers have been 
developed in order to increase the drug half life in the blood and to enhance its 
accumulation in solid tumors.  
When aqueous solutions of CDDP and poly(amino acids) are mixed, metal 
complexation between platinum of CDDP and carboxylic acid groups of the poly(amino 
acid) segment of the copolymer trigger formation of PIC micelles. CDDP/PEG-b-PAsp 
micelles sustained drug release for over 50 h in the presence of 150 mM NaCl. Following 
IV injection to Lewis lung carcinoma-bearing mice, micelles showed a 4.6-fold higher 
CDDP accumulation in tumor sites compared to free CDDP. However, in vivo anti-tumor 
activity of micelles-encapsulated drug was similar to that of the free drug.[272] To improve 
micelles stability under physiological conditions and increase their blood circulation time, 
PEG-b-PAsp was replaced by PEG-b-PGlu. PGlu has a more hydrophobic backbone due to 
the presence of one additional CH2 group, which can increase micelles stability. This 
modification resulted in better control over drug release from the micelles under 
physiological conditions. Thus, 50% CDDP was released after 30 h and 90 h from PEG-b-
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PAsp and PEG-b-PGlu micelles, respectively.[158] Furthermore, CDDP/PEG-b-PGlu 
micelles showed longer circulation in the blood, 11% of the injected dose was detected in 
the blood at 24 h post injection, compared to 1.5% in the case of CDDP/PEG-b-PAsp 
micelles at the same time. Tumor accumulation of CDDP/PEG-b-PGlu micelles was 20-
fold higher than that of free CDDP, indicating tumor-selective targeting by the EPR effect. 
Intravenous injection of CDDP/PEG-b-PGlu micelles to tumor bearing mice showed 
complete tumor regression for more than 80% of the treated mice, with only minimal body 
weight loss (within 5% of the initial weight). In contrast, treatment with free CDDP at the 
same dose exhibited tumor regression for only 15% of treated mice and significant body 
weight loss (20% of the initial weight). The CDDP/PEG-b-PGlu micelles are now 
undergoing a phase I/II clinical trial as NC-6004 in the UK.[273, 274] 
Photodynamic therapy (PDT), which involves photosensitizers accumulation in 
solid tumors followed by local photoirradiation of solid tumors with light of a specific 
wavelength, is a promising physical approach of cancer treatment.[275, 276] Following 
photoirradiation, PSs generate reactive oxygen species (ROS), such as singlet oxygen, 
which results in photochemical destruction of tumor tissues. However, PSs readily form 
aggregates, resulting in self quenching and significant reduction in singlet oxygen 
production.[277] Moreover, PDT causes skin hyperphotosensitivity requiring the patient to 
stay in a darkened room away from light for at least 2 weeks. These side effects result from 
lack of tumor selectivity of currently approved PSs, such  as Photofrin® 
(polyhematoporphyrin esters, PHE).[278] To overcome these drawbacks and enhance the 
efficacy of PDT, phthalocyanine (Pc), an anionic photosensitizer dendrimer was 
encapsulated into PIC micelles of PEG-b-PLL.[275] The micelles showed significantly 
higher in vivo PDT efficacy than Photofrin®  in mice bearing human lung adenocarcinoma 
A549 cells. Micelles-treated mice did not show skin phototoxiciy, which was apparently 
observed for Photofrin®-treated mice, under identical conditions. Other anticancer drugs 
that have been successfully encapsulated into PIC micelles are shown in Table 1.3.  
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Table 1.3. Different drugs that have been encapsulated into PIC micelles  
Polymer Drug Application Ref. 
PEG-b-PMAA cisplatin anticancer [224] 
PEG-g-chitosan ATRA anticancer [165] 
PEG-b-PLL dendrimer phthalocyanine PDT [279] 
PEG-b-PLL anionic porphyrin PDT [181] 
PEG-b-PAsp cationic porphyrin PDT [215] 
PS-b-PNIPAM-b-PAA/ 
PEG-b-P4VP 
ibuprofen 
anti-inflammatory, 
analgesic 
[226] 
PEG-b-PAsp vasopressin ADH [160] 
PLL-g-DEX DNA gene therapy [187] 
PEG-b-MAA/PDMAEMA DNA gene therapy [280] 
PAA-b-pluronic-b-PAA doxorubicin anticancer [281] 
PEG-b-PDMAEMA heparin anticoagulant [233] 
PEG-g-chitosan DG anti-inflammatory [166] 
PEG-b-PMAA: PEG-b-poly(methacrylic acid); ATRA: all-trans retinoic acid; PEG-b-PLL: 
PEG-b-poly(L lysine); PDT: Photodynamic therapy; PEG-b-PAsp: PEG-b-poly(aspartic 
acid); PS-b-PNIPAM-b-PAA: poly(styrene)-b-poly(N-isoproply acrylamide)-b-poly(acrylic 
acid); PEG-b-P4VP: PEG-b-poly(4-vinylpyridine); PLL-g-DEX: poly(L lysine)-g-dextran; 
ADH : antidiuretic hormone; PDMAEMA: poly(2-(N,N-dimethylamino) ethyl 
methacrylate); DG: diammonium glycyrrhizinate.  
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1.4.6.7.3. PIC micelles as delivery systems for other drugs 
In addition to their usefulness in gene and cancer therapy, PIC micelles have found 
applications as delivery systems for other drugs (Table 1.3). Thus, the antifungal drug 
amphotericin B (AmB) was encapsulated into PIC micelles of PEOz-b-PAsp to reduce its 
cytotoxicity and enhance its efficacy.[175] Prolonged release of the drug from micelles 
effectively inhibited the growth of Candida albicans even after three days of 
administration. Moreover, AmB-loaded micelles showed lower cytotoxicity, in vitro and 
higher potency than the commercial AmB formulation, Fungizone®.  PIC micelles of poly 
(N-vinylpyrrolidone)-b-poly(styrene-alter-maleic anhydride/chitosan were used as a 
delivery vehicle for coenzyme A (CoA).[164] CoA was released from the micelles in 
response to change in solution pH and ionic strength showing the potential of these 
micelles for drug delivery applications. 
1.5. Nanoparticles based on modified dextran as drug carriers 
From toxicological point of view, biopolymers are ideal for pharmaceutical 
applications since they are biocompatible and biodegradable. Amongst biopolymers, the 
polysaccharides class offers the advantages of structural diversity, functional versatility and 
abundance in nature. According to their charge, polysaccharides can be classified into 
neutral, cationic or anionic. Chitosan (cationic), hyaluronic acid (anionic) and dextran 
(neutral) are the most frequently used biopolymers in the preparation of polysaccharides-
based nanoparticles.  
Dextran (Figure 1.7) is synthesized from sucrose by different bacterial strains. It is 
consisting of α-(1-6) linked D-glucose units with varying degrees of α-(1-3) branching 
depending on the bacteria used in its preparation.[282] The degree of branching may vary 
between 0.5 and 60%. Branching at α-(1-2) and α-(1-4) is also possible.[283] Dextrans 
obtained from Leuconostoc mesenteroids NRRL B-512 are of particular pharmaceutical 
interest.[282] They are characterized by their content of 95% α-1,6-glucopyranosidic 
linkages and 5% 1,3-linkages.  
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Figure 1.7. Chemical structure of dextran showing α(1-6) glycosidic linkages and α(1-3) 
branching.  
 
Dextran is soluble in many solvents including water, mild acidic and alkaline 
conditions [284], dimethyl sulfoxide, formamide, glycerol, and ethylene glycol.[285] Dextran 
is not absorbed orally since its hydrophilicity prevents its transcellular absorption while its 
size prevents its paracellular absorption in the GI tract.[286] It is degraded into low 
molecular weight fractions during passage through the GI tract.[287] Dextran is 
depolymerized by various α-1-glucosidases (dextranases) available in various organs, 
including the liver, kidney, spleen and the lower part of the GI tract.[288] The presence of 
high concentrations of dextranases in the colon allowed the preparation of colon-targeted 
dextran-based drug delivery systems for the local treatment of various colon disorders, such 
as irritable bowel syndrome, colon cancer and ulcerative colitis.[289-292] 
The pharmacokinetics of intravenously administered dextran are dependent on its 
molecular weight. Mehvar et al.[286] studied molecular weight dependence of dextran 
pharmacokinetics in rats by measuring dextran concentrations in serum and urine after IV 
injection of five different molecular weights: 4, 20, 40, 70, and 150 kDa. Dextran of high 
molecular weights (i.e. 40, 70 and 150 kDa) was detectable in the blood for up to 12 h post-
dosing. In contrast, dextran having molecular weights of 4 and 20 kDa was rapidly 
eliminated so that it was undetectable in the blood 1.5 and 3 h post-dosing, respectively. 
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Chang et al.[293] showed that neutral dextran is eliminated in rats by glomerular filtration 
without any tubular secretion or reabsorption. Therefore, renal clearance of dextran is 
reported as a fraction of the glomerular filtration rate.  
Dextran is clinically used as plasma volume expander, peripheral flow promoter and 
antithrombolytic agent for more than 5 decades.[294, 295] Other biomedical applications of 
dextran include its use as a drug carrier system. Thus, dextran hydrogels have been used for 
the delivery of various drugs, such as salmon calcitonin and vitamin E and as scaffolds for 
vascular tissue engineering.[296-298] Dextran has also been used for the preparation of 
macromolecular prodrugs through conjugation with different drugs and proteins either 
directly or through a spacer.[295] Furthermore, dextran-based nanoparticles served as 
delivery vehicles for several hydrophobic and hydrophilic drugs. Native dextran lacks the 
amphiphilicity required to form nanoparticles since it is highly water soluble and neutral. 
Therefore, dextran-based nanoparticles are obtained either by hydrophobic modification of 
dextran or by electrostatic interactions between ionic dextran derivatives and oppositely 
charged drugs. 
1.5.1. Nanoparticles of hydrophobically modified dextran (HM-DEX) 
Hydrophobic modification of dextran facilitates its self assembly into nanoparticles 
and creates microreservoirs suitable for solubilization of hydrophobic drugs. The structural 
features of dextran (Figure 1.7) with numerous hydroxyl groups along its backbone gives 
diversity in the type of bonds that can be used to attach a hydrophobic moiety. Thus, 
different hydrophobic moieties have been linked to dextran by ester, ether, amide and many 
others bonds. Table 1.4 gives examples of the various hydrophobic moieties that have been 
used to modify dextran. 
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Table 1.4. Different hydrophobic compounds used to modify dextran. 
Hydrophobic moiety Resulting polymer  Ref. 
PCL 
 
PCL-g-DEX [299-301] 
PLGA 
 
PLGA-g-DEX [302] 
Polyethyleneglycolalkyl ether 
 
PEG-Cn-g-DEX [303] 
Phenoxy, C6 and C10 alkyl chains  
 
 
 
DEX-Px, DEX-C6x, 
DEX-C10x 
[304] 
Cholic acid  
 
Cholate and 
deoxycholate esters of 
dextran  
[305] 
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Deoxycholic acid  
 
2-methoxypropene 
OCH3
 
Ac-DEX [306] 
PLA 
 
PLA-g-DEX [307] 
Styrene 
 
PS-g-DEX 
PS-b-DEX 
[308, 309] 
IBCA 
 
PIBCA-g-DEX 
PIBCA-b-DEX 
[310] 
MMA 
 
PMMA-b-DEX [311] 
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PLGA: poly(lactic-co-glycolic acid); PCL: poly(ε-caprolactone); PLA: poly(lactic acid); 
IBCA: isobutyl cyanoacrylate; MMA: methyl methacrylate; PS: polystyrene; Ac-DEX: 
acetalated dextran. 
Drug-loaded nanoparticles of HM-DEX have been prepared by different methods 
based on the solubility characteristics of HM-DEX and the drug. For instance, cyclosporin 
A(CsA)-loaded PEG-Cn-g-DEX micelles were prepared by the dialysis method.[303] CsA 
solution in ethanol was mixed with aqueous solution of PEG-Cn-g-DEX followed by 
dialysis against water. Gradual replacement of the organic solvent with water induces 
micelles formation and simultaneous drug incorporation in micelles core. Other examples 
of drug-loaded HM-DEX nanoparticles and their preparation methods are given in Table 
1.5.   
 
Table 1.5.  Methods used for the preparation of drug-loaded HM-DEX nanoparticles 
Polymer Drug Preparation method 
Drug contenta   
(% w/w) 
Ref. 
PLGA-g-DEX amphotericin B dilaysis 4.2 [312] 
PLGA-g-DEX clonazepam dialysis 10.2 [313] 
PLGA-g-DEX amphotericin B dialysis 4.8-18.9 [314] 
PLGA-g-DEX doxorubicin dialysis 5.7-7.5 [302] 
PCL-g-DEX tamoxifen nanoprecipitation  3.8-43.5 [315] 
PCL-g-DEX indomethacin dialysis ND [299] 
PCL-g-DEX coumarin-6 oil/water emulsion ND [316] 
PEG-Cn-g-DEX cyclosporin A dialysis 1.5-4.8 [303] 
Ac-DEX ovalbumin double emulsion  3.7 [306] 
a: Drug content = weight of drug in nanoparticles X 100 / total weight of nanoparticles. 
ND: not determined. 
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Nanoparticles of HM-DEX usually have a core-corona structure with the 
hydrophobic chains forming the core and dextran forming the corona. Nanoparticles core is 
used to solubilise hydrophobic drugs (Table 1.5) whereas the dextran shell reduces protein 
adsorption and uptake by the MPS cells and thus, prolong the nanoparticles circulation in 
the blood. The configuration of dextran chains over nanoparticles surface had a crucial role 
in determining their interaction with biological systems.[317, 318] Thus, PCL-g-DEX 
nanoparticles with dextran chains organized as larger and looser loops adsorbed higher 
amounts of bovine serum albumin compared to nanoparticles having dextran chains 
arranged in dense and compact configuration.[319] Moreover, PMMA nanoparticles with 
dense brush-like dextran shell had significantly higher blood circulation time than uncoated 
PMMA nanoparticles. Uncoated PMMA nanoparticles were eliminated from the blood in 
few minutes whereas DEX-PMMA nanoparticles were slowly eliminated over a period of 
more than 48 h.[90]  
1.5.2. Nanoparticles based on ionic dextran derivatives 
These nanoparticles are formed by electrostatic interactions between ionic dextran 
derivatives, either anionic or cationic and an oppositely charged polymer, protein, drug or 
DNA. Contrary to nanoparticles of HM-DEX where dextran forms the nanoparticles shell, 
nanoparticles of ionic dextran have a core of dextran electrostatically linked to a drug. 
Dextran sulfate (anionic), diethylaminoethyl-dextran (DEAE-DEX) (cationic) and dextran-
spermine (DEX-SPM) (cationic) are the most commonly used ionic dextrans for 
nanoparticles formation (Figure 1.8). Dextran sulfate forms nanoparticles by strong 
electrostatic interactions with positively charged polymers, such as chitosan [259, 320, 321], 
polyethylenimine (PEI) [322, 323], poly(L lysine) (PLL)[324] and polyallylamine.[325] 
Nanoparticles of dextran sulfate/chitosan have been used to encapsulate several drugs, such 
as insulin, amphotericin B and doxorubicin.[321, 326, 327] Cationic dextrans (e.g. DEAE-DEX 
and DEX-SPM) have been used as non-viral gene vectors due to their ability to condense 
DNA.[328, 329] 
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Figure 1.8. Chemical structure of dextran sulfate, DEAE-dextran and DEX-SPM. 
 
1.6. Thesis rationale and research objectives 
1.6.1. Rationale 
Dextran is a well-known biocompatible and biodegradable polysaccharide that has 
been in clinical use for more than 5 decades.[295] Different kinds of dextran-based drug 
carrier systems, such as nanoparticles, microparticles and hydrogels have been prepared 
and evaluated for the delivery of numerous drugs. Among these different carriers, 
O
R
R
O
O
O
1 H
2
3
4
5
6
S
O
O
NaO
Dextran sulfate, R = -OH or –SO4Na 
O
HO
HO
O
O
O
1 H2
3
4
5
6
N
DEAE-dextran 
O
OH
HO
HO
O
O
O
CH2
HO
HN
HN
NH NH2
HOH2C
O
O
OH
HO
HO
O
O
O
CH2
HO
NH
NH
NH NH2
HOH2C
n
DEX-SPM 
49 
 
 
nanoparticles are, on many levels, the most promising ones because of their outstanding 
performance, both in vitro and in vivo. Most of these drug carriers were designed to 
encapsulate hydrophobic drugs. Little work was devoted to the development of dextran-
based nanoparticles for the delivery of ionic water soluble drugs. PIC micelles are formed 
by electrostatic interactions between an ionic drug and oppositely charged copolymer. PIC 
micelles have found several applications in drug delivery due to their unique characteristics 
of straightforward preparation, small size, high drug loading capacity and excellent 
colloidal stability.[153, 164, 177] However, very few PIC micelles were based on 
polysaccharides, such as chitosan and none at all was based on dextran. This, together with 
the success of PEGylated nanoparticles and the favorable properties of dextran prompted us 
to develop dextran-block-PEG copolymers suitable for drug delivery applications. Dextran 
block of these copolymers was functionalized by connecting carboxymethyl groups at 
different degrees of substitution to give a new family of carboxymethyldextran-PEG 
(CMD-PEG) block copolymers.[330] When CMD-PEG copolymers are mixed with cationic 
drugs, PIC micelles are expected to form by electrostatic interactions between CMD 
segment of the copolymer and the cationic drug. These micelles are expected to have a 
CMD/cationic drug core surrounded by a PEG corona. Drug incorporation into the micelles 
core should sustain its release and protect it against degradation in solution. PEG corona of 
the micelles should prevent aggregation in solution and prolong their circulation in the 
blood. It was the overall aim of this project to develop PIC micelles based on CMD-PEG 
block copolymers for the encapsulation of different cationic drugs, such as aminoglycoside 
antibiotics and tetracycline antibiotics.  
Physicochemical properties of PIC micelles, as well as their performance as drug 
delivery systems are affected; to a great extent by the properties of the copolymers used to 
formulate them.[251, 331] Thus, relative block length of the ionic-neutral copolymer segments, 
charge density of the ionic block and the presence of other forces that assist in PIC micelles 
formation (e.g. hydrophobic interactions, metal coordination or hydrogen bonding) have 
been shown to affect PIC micelles properties.[152] To reveal the effect of these parameters 
on the properties of CMD-PEG micelles, we developed four CMD-PEG copolymers: (i) 
two copolymers identical in terms of the length of CMD and PEG blocks, but different in 
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terms of the charge density of the CMD block; and (ii) two copolymers in which the 
charged block is the same, but the PEG block is of different molecular weight. The 
micellization of these four copolymers with a model water soluble cationic drug, 
diminazene diaceturate was studied. The polymer that showed the most satisfactory results 
in terms of various drug delivery aspects, such as high drug loading, controlled drug release 
and micelles stability was chosen for encapsulation of other cationic drugs, such as 
aminoglycoside and tetracycline antibiotics (different properties of the drugs used in this 
thesis are given in appendix D).  
1.6.2. Research objectives 
1. To synthesize and characterize a series of CMD-PEG copolymers of different 
relative block lengths and ionic charge densities.  
2. To study the effect of CMD-PEG relative block length and ionic charge density on 
the properties of PIC micelles formed with a model water soluble cationic drug, 
diminazene diaceturate.  
3. To develop and characterize a CMD-PEG micelle formulation encapsulating 
minocycline hydrochloride, a neuroprotective tetracycline as a potential treatment of 
several diseases, such as stroke, amyotrophic lateral sclerosis and Parkinson’s 
disease.   
4. To develop and characterize CMD-PEG PIC micelles formulations encapsulating 
various aminoglycoside antibiotics, such as neomycin and paromomycin for the 
treatment of bacterial infections caused by gram negative bacteria.  
5. To improve the stability of aminoglycosides/CMD-PEG micelles against increase in 
salinity by hydrophobic modification of the CMD block. 
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2.1. Abstract 
The micellization of a model cationic drug, diminazene diaceturate (DIM) and a 
series of new diblock copolymers, carboxymethyldextran-poly(ethylene glycols) (CMD-
PEG), were evaluated as a function of the ionic charge density or degree of substitution 
(DS) of the carboxymethyldextran block and the molar ratio, [+]/[−], of positive charges 
provided by the drug to negative charges provided by CMD-PEG. Micelles ([+]/[−] = 2) 
incorporated up to 64% (w/w) DIM and ranged in hydrodynamic radius (RH) from 36 to 50 
nm, depending on the molecular weight and DS of CMD-PEG. The critical association 
concentration (CAC) was on the order of 15–50 mg/L for CMD-PEG of DS > 60%, and ca. 
100 mg/L for CMD-PEG of DS ∼ 30%. The micelles were stable upon storage in solution 
for up to 2 months and after freeze-drying in the presence of trehalose. They remained 
intact within the 4 < pH < 11 range and for solutions of pH 5.3, they resisted increases in 
salinity up to ∼0.4 M NaCl in the case of CMD-PEG of high DS. However, micelles of 
DIM and a CMD-PEG of low DS (30%) disintegrated in solutions containing more than 0.1 
M NaCl, setting a minimum value to the DS of copolymers useful in in vivo applications. 
Sustained in vitro DIM release was observed for micelles of CMD-PEG of high DS ([+]/[−] 
= 2). 
2.2. Author Keywords 
Polyion complex micelles; Dextran; Electrostatic interactions; Polyelectrolytes; 
Diminazene diaceturate; Hydrophilic drug 
2.3. Introduction 
Polysaccharides are ubiquitous components of traditional pharmaceutical 
formulations where they act as coatings or suspending agents, tablet binders and extended-
release matrix formers.[1, 2] They are also known to possess self-assembling qualities and to 
undergo stimuli-responsive transformations, such as heat- or salt-triggered gelation. More 
recently, polysaccharide-based nanostructures have emerged as promising materials for 
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biological and medical applications.[3] Micellar systems based on dextran[4], cellulose 
ethers[5], poly(ethylene glycol)(PEG)-grafted chitosans[6], hyaluronan-block-poly(2-ethyl-2-
oxazoline)[7] or pullulans, have been shown effective nanocarriers for various drugs and 
proteins. [6-9] In most cases polysaccharide nanoparticles were designed for the delivery of 
hydrophobic drugs. Fewer studies have been devoted to polysaccharide-based nanoparticles 
for the delivery of highly water soluble drugs. To address this issue, we developed a 
straightforward synthesis of carboxymethyldextran-block-poly(ethylene glycol)s (CMD-
PEG, Figure 2.1).[10] The CMD-PEG copolymers were designed specifically as substrates of 
tunable charge density, able to form polyion complex (PIC) micelles upon interaction with 
an oppositely charged drug. The charge density of the ionic segment cannot be adjusted 
readily in the case of diblock copolymers used in most PIC-micelle-based drug delivery 
systems, in which the ionic fragment is usually a poly(amino acid) bearing a charge on each 
repeat unit. Since the number of charged groups linked to the ionic segment determines the 
loading efficiency and drug release characteristics of PIC micelles, the control of charge 
density adds a new dimension in the design of drug-loaded PIC micelles which we set 
about to explore. 
We compare the properties of PIC micelles formed by four CDM-PEG copolymers: 
(i) two copolymers identical in terms of the length of each block, but different in terms of 
the charge density of the CMD block and (ii) two copolymers in which the charged block is 
the same, but the neutral block is of different molecular weight. This strategy enabled us to 
determine the optimal charge density required to form stable micelles with high drug 
loading efficiency, small size, and suitable drug release profiles of diminazene 
diaceturate(DIM), a dicationic molecule used as model drug. DIM is effective in the 
treatment of trypanosomiasis in animals.[11] It has been used previously to demonstrate the 
formation of PIC micelles with poly(aspartic acid)-block-poly(ethylene glycol)[12] and 
poly(ethylene oxide)-block-poly(L-glutamate).[13]   
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Figure 2.1. Idealized  chemical structure of carboxymethyldextran-block-poly(ethylene 
glycol) (CMD-PEG); n represents the number of ethylene glycol units, m is the number of 
glucopyranose rings of the polysaccharide block, and x represents the fraction of glucose 
units of the dextran chain that bear a carboxymethyl group. The polysaccharide segment 
consists of a random distribution of glucopyranose units and carboxymethyl glucopyranose 
units. 
 
We characterize the micelles formed between diminazene and the four CMD-PEG 
copolymers and assess the effect of charge density on the physico-chemical properties of 
the micelles, on their stability as a function of salinity, pH, and storage time, and on the 
drug release kinetics. In order to determine the level of drug loading as a function of charge 
density, we used static and dynamic light scattering which, together with 1H NMR 
spectroscopy, allow one to characterize drug-loaded micelles and to detect drug molecules 
dissolved in the aqueous medium (free drug). 
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2.4. Materials and methods 
2.4.1. Materials 
Trizma®hydrochloride (Tris–HCl), diminazene diaceturate (≥ 90% pure, as stated by 
the supplier), d(+) trehalose dihydrate, Amberlite® IR-120 and all other chemicals were 
purchased from Sigma–Aldrich Chemicals (St. Louis, MO, USA). The drug (m.p. = 215–
217 ºC) was used without further purification. The purity of DIM was estimated to be ≥ 
96% on the basis of the 1H NMR spectrum of DIM in D2O. Dextran-PEG (DEX-PEG) 
samples were synthesized as described previously.[10] Dialysis tubing (SpectraPore, 
MWCO: 1000 or 3500 g/mol) was purchased from Fisher Scientific (Rancho Dominguez, 
CA, USA). All solvents were reagent grade and used as received.  
2.4.2. Synthesis of carboxymethyldextran-block-poly(ethylene glycols) 
(CMD-PEG) 
CMD-PEG samples of high charge density were obtained according to the protocol 
previously reported.[10] The method is described briefly below and the amounts of reagents 
and solvents employed in each synthesis are given in Table 2.1. Sodium hydroxide was 
added to a solution of DEX-PEG in an isopropanol–water mixture (85:15 v:v) kept at room 
temperature. The reaction mixture was heated to 60 ºC and kept at this temperature for 30 
min. Monochloroacetic acid was added portion-wise to the mixture while stirring. The 
reaction mixture was kept at 60 ºC for 90 min. It was cooled to room temperature, 
transferred in a dialysis bag and dialyzed against water for 24 h. The purified copolymers 
were isolated by lyophilization and characterized by 1H NMR (D2O, 400 MHz) δ/ppm: 5.07 
(anomeric proton on glucopyranose bearing a carboxymethyl group at C2), 4.89 (anomeric 
proton on glucopyranose unsubstituted at C2), 4.15–4.08 (–CH2COONa), 3.97–3.36 (CMD 
C-2 to C-6 glucopyranosyl protons), 3.61 (PEG, –CH2CH2O–), 3.29 (–OCH3). It was found 
advantageous to carry out the carboxymethylation of DEX40-PEG140 copolymer on the 
crude mixture of DEX40-PEG140/PEG-NH2 (Table 2.2) since the separation of this 
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copolymer resulted in low yield (~30 %) due to the partial solubility of DEX40-PEG140 in 
hot ethanol. 
To prepare samples of low degree of carboxymethylation, such as 30-CMD68-
PEG64, the carboxymethylation was achieved by adding monochloroacetic acid to a stirred 
solution of DEX68-PEG64 in aqueous NaOH kept in an ice/water bath, followed by 
treatment at 60 ºC for 1 h. The resulting polymer was purified as described above.1H NMR 
(D2O, 400 MHz) δ/ppm: 5.07 (anomeric proton on glucopyranose bearing a carboxymethyl 
group at C2), 4.88 (anomeric proton on glucopyranose unsubstituted at C2), 4.15–4.08       
(–CH2COONa), 3.95–3.36 (CMD C-2 to C-6 glucopyranosyl protons), 3.61 (PEG,–
CH2CH2O–), 3.29 (–OCH3). 
 
Table 2.1. Experimental conditions for the carboxymethylation of DEX-PEG copolymers 
Polymer 
DEXn-PEGm  
NaOH 
(mmol)
MCAa 
(mmol) 
Isopropanol / 
Water (mL) g       mmol Glu
b 
85-CMD40-PEG140 c 2.20d - 16.51 8.80 9.95 / 1.75 
80-CMD40-PEG64 0.50 2.19 10.68 5.69 6.43 / 1.17 
60-CMD68-PEG64 0.27 1.6 7.50 4.00 4.53 / 0.80 
30-CMD68-PEG64 0.50 3.0 24.00 14.0 0.00 / 4.00 
a MCA: monochloroacetic acid. 
b Glu: glucopyranosyl.  
c : The prefix denotes the degree of  carboxymethylation of the dextran block. 
d: Mixture of DEX40-PEG140 and unreacted PEG-NH2.   
2.4.3. Methods 
2.4.3.1. General methods 
1H NMR spectra were recorded for solutions in D2O (25 ºC) using a Bruker AV-400 
90 
 
 
 
MHz spectrometer operating at 400 MHz. Chemical shifts are given relative to external 
tetramethylsilane (TMS = 0 ppm). Gel permeation chromatography (GPC) measurements 
were carried out using a GPC system with an Agilent 1100 isocratic pump, a Dawn EOS 
multiangle laser light scattering detector (Wyatt Technology Corp., Santa Barbara, USA) 
and an Optilab DSP interferometric refractometer (Wyatt Technology Corp.) using PL-
aquagel-OH 40 (8 μm) and PL-aquagel-OH 30 (8 μm) columns (Polymer Laboratories, 
Amherst, MA, USA) eluted with a pH 7.02 buffer composed of 0.2 M NaNO3, 0.01 M 
NaH2PO4, 0.08 mM NaN3 at a flow rate of 0.5 mL/min. Solutions for analysis had a 
polymer concentration of 10.0 mg/mL and the injection volume was set at 100 μL. For 
dn/dc measurements, solutions of each polymer of concentration ranging from 0.2 to 1.0 
mg/mL were prepared in the same buffer. UV–vis absorption spectra were recorded with an 
Agilent 8452A photodiode array spectrometer. Zeta-potential measurements were carried 
out with a Malvern ZetaSizer Nanoseries ZS (Malvern Instruments, Worcestershire, UK). 
Lyophilizations were performed with a Virtis (Gardiner, NY, USA) Sentry Benchtop (3L) 
freeze-dryer. Melting point was measured with a Büchi 535 capillary melting point 
apparatus (Büchi, Switzerland). 
2.4.3.2. Light scattering 
Static (SLS) and dynamic (DLS) light scattering experiments were performed on a 
CGS-3 goniometer (ALV GmbH) equipped with an ALV/LSE-5003 multiple-τ digital 
correlator (ALV GmbH), a He-Ne laser (λ = 632.8 nm), and a C25P circulating water bath 
(Thermo Haake). The SLS data were analyzed according to the Zimm method.[14] The 
refractive index increment (dn/dc) values of the CMD-PEG samples (Table 2.2) and of 
diminazene diaceturate (0.2543 mL/g) in Tris–HCl buffer, pH 5.3 were measured using an 
Optilab DSP interferometric refractometer (Wyatt Technology Corp.). The dn/dc value of 
the micelles was calculated from Eq. (1).[15, 16]  
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

−
− (1) 
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Where (dn/dc)CMD-PEG  and (dn/dc)drug are the refractive index increments  of CMD-PEG 
and diminazene diaceturate, respectively, and  WCMD-PEG and Wdrug are the weight fractions 
of  CMD-PEG and diminazene diaceturate, respectively. A cumulant analysis was applied 
to obtain the diffusion coefficient (D) of the micelles in solution. The hydrodynamic radius 
(RH) of the micelles was obtained using the Stokes-Einstein Eq. (2),  
           
Hs
B
R6
TkD
πη
=                                                                   (2) 
Where ηs is the viscosity of the solvent, kB is the Boltzmann constant, and T is the absolute 
temperature. The constrained regularized CONTIN method was used to obtain the particle 
size distribution.[17] The data presented are the mean of six measurements ± S.D.  Solutions 
for analysis were filtered through a 0.45 μm Millex Millipore PVDF membrane prior to 
measurements. 
Table 2.2. Molecular properties of the CMD-PEG samples prepared 
Polymer dn/dca (mL/mg) Mwb (g mol-1) Mnb (g mol-1) DSc
85-CMD40-PEG140d 0.1416 14,800 10,800 0.86 ± 0.09 
80-CMD40-PEG64 0.1434 12,200 10,200 0.76 ± 0.08  
60-CMD68-PEG64 0.1376 16,800 13,400 0.62 ± 0.06 
30-CMD68-PEG64 0.1392 15,900 12,000 0.31 ± 0.03 
a: Values recorded for polymer solutions in 25 mM Tris–HCl pH 5.3, 25 ºC.  
b: From GPC measurements in aqueous NaNO3 (0.2 M)/NaH2PO4 (0.01 M)/NaN3 (0.8 
mM); pH 7.02.  
c: Degree of substitution: mol fraction of glucopyranose units carrying a –CH2–COONa 
group; determined by potentiometric titration.  
d: In this nomenclature, the prefix denotes the degree of carboxymethylation of the dextran 
block; the subscripts designate the average number of glucopyranosyl and –CH2–CH2–O– 
repeat units of the CMD and PEG segments, respectively. 
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2.4.3.3. Preparation and characterization of the micelles 
2.4.3.3.1. General method 
Stock solutions of the diblock copolymers (1.0 g/L) and diminazene diaceturate (4.0 
g/L) were prepared in Tris–HCl buffer (25 mM, pH 5.3). Specified volumes of the 
diminazene diaceturate solution were added dropwise to a magnetically stirred polymer 
solution over a 10-min period to obtain solutions with a [+]/[−] ratio ranging from 0.2 to 
5.0. For simplicity reasons the [+]/[−] ratio was calculated assuming a drug purity of 100%. 
The uncertainty of the ratio is estimated to be ∼0.08 knowing that the purity of the drug is 
≥96%. The volume of each sample was adjusted to 5.0 mL by addition of the same buffer. 
The final CMD-PEG concentration was 0.2 g/L in all samples. 
2.4.3.3.2. pH studies 
A micellar solution (CMD-PEG: 0.2 g/L; [+]/[−] = 2.0) was prepared in 25 mM 
Tris-HCl buffer, pH 5.3. Aliquots of this solution were treated either with 1.0 N NaOH or 
with 1.0 N HCl to obtain solutions ranging in pH from 11 to 2. After each pH adjustment, 
the sample was stirred for 5 min prior to measurement. The hydrodynamic radius, 
polydispersity index and scattered light intensity of an aliquot of the sample were 
determined by DLS. A control experiment was carried out with CMD-PEG solutions (0.2 
g/L) treated in the same pH range. The mean ± S.D. of six measurements was determined. 
2.4.3.3.3. Ionic strength studies 
Micellar solutions (CMD-PEG: 0.2 g/L; [+]/[−] = 2.0) were prepared in a 25 mM 
Tris–HCl buffer of pH 5.3. Aliquots of a NaCl stock solution (2.5 M) in the same buffer 
were added to the micellar solutions in volumes such that [NaCl] in the sample ranged from 
50 to 600 mM. The mixture was stirred for 5 min and the volume of each sample was 
adjusted to 5.0 mL with Tris–HCl buffer, pH 5.3. The hydrodynamic radius, polydispersity 
index and scattered light intensity of an aliquot of each sample were determined by DLS 
measurements. The mean ± S.D. of six measurements was determined. 
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2.4.3.3.4. Critical association concentration 
Micellar solutions were prepared using the general procedure described above, with 
a polymer concentration of 0.2 g/L and [+]/[−] = 2. The micellar solutions were serially 
diluted with Tris–HCl (25 mM, pH 5.3) and the intensity of light scattered by the solutions 
was determined by DLS at a scattering angle of 90º. Six consecutive scattered light 
intensity measurements were performed. Their average value is reported. Normalized 
intensities, IC/I0.2 where IC is the intensity of the light scattered by a solution of 
concentration c and I0.2 is the intensity of the light scattered by a solution of polymer 
concentration 0.2 g/L were plotted against polymer concentration. The CAC was 
determined from the plot, following methods reported previously.[18]  
2.4.3.3.5. Zeta-potential 
The ζ-potential of polymer micelles (CMD-PEG concentration: 0.2 g/L) of various 
[+]/[−] molar ratios, prepared in Tris–HCl buffer (25 mM, pH 5.3) following the general 
procedure described above, was measured for solutions kept at 25 ºC. Each sample was 
measured four times and the mean ± S.D. is presented. The ζ-potential of the particles was 
calculated from the electrophoretic mobility values using Smoluchowski equation. 
2.4.3.3.6. Stability of micellar solutions upon storage 
The RH and size distribution of polymer micelles (CMD-PEG concentration: 0.2 
g/L), [+]/[−] = 2), prepared in Tris–HCl buffer (25 mM, pH 5.3) following the general 
procedure described above, were measured by DLS as described above at various time 
intervals up to 60 days. Solutions were kept at 25 ºC between measurements.  
2.4.3.3.7. 1H NMR spectra of DIM/CMD-PEG mixtures 
Specified volumes of a DIM stock solution in D2O (10 g/L) were added dropwise to 
a magnetically stirred solution of CMD-PEG in D2O over a period of 10 min in amounts 
necessary to prepare mixed solutions of CMD-PEG (3.0 g/L) with [+]/[−] ranging from 0.2 
to 10.0. 1H NMR spectra of the mixed solutions were recorded as described above. 
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2.4.3.3.8. Lyophilization/redissolution of DIM/CMD-PEG micelles 
Micellar solutions of DIM/85-CMD40-PEG140 (10 mL, polymer concentration: 0.2 
g/L; [+]/[−] = 2.0) in a Tris–HCl buffer (25 mM, pH 5.3) or in aqueous trehalose (5%, w/v) 
were frozen by placing the glass vials containing the samples in a dry ice/acetone mixture 
(temperature: −78 ºC). After 30 min the vials were placed in the freeze-dryer and 
lyophilized for 48 h. The resulting powder was rehydrated with deionized water (10 mL) to 
reach a polymer concentration of 0.2 g/L. The resulting mixture was stirred at room 
temperature for 10 min and analyzed by DLS.  
2.4.3.3.9. Diminazene release studies 
The release of diminazene diaceturate from micelles (3.0 mL, [DIM] = 1.2 g/L, 
[+]/[−] = 2) in a Tris–HCl buffered saline (25 mM, pH 5.3, 0 mM NaCl or 25 mM, pH 7.4, 
150 mM NaCl) was evaluated by the dialysis bag method at 37 ºC against the buffer (200 
mL) used to prepare the micelles and using a dialysis membrane of MWCO = 3500 
g/mol).[19, 20] The concentration of diminazene in the dialyzate was determined from the 
absorbance at 370 nm using a calibration curve. A control experiment to determine 
diminazene diffusion through the membrane in the absence of the polymer was carried out 
using a solution of diminazene (1.2 g/L, 3 mL) in the same Tris–HCl buffer. The 
concentration of diminazene released from the micelles is expressed as the cumulative 
percentage of the total drug available and plotted as a function of dialysis time. 
2.5. Results and discussion 
2.5.1. Synthesis of carboxymethyldextran-block-poly(ethylene glycol)s 
The ionic diblock copolymers CMD-PEG were obtained by reaction of 
monochloroacetic acid (MCA) with DEX-PEG in the presence of sodium hydroxide.[10] 
Reaction conditions were adjusted in order to obtain copolymers of desired degree of 
substitution (DS), defined as the molar fraction of glucopyranose rings bearing a –
CH2COO− group. To obtain a high substitution level (DS > 0.50), solutions of DEX-PEG 
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in a 85/15 (v/v) isopropanol/water mixture were treated with aqueous NaOH (9.0 M) at 60 
ºC.[21] To achieve moderate carboxymethylation yields (DS ≤ 0.30), MCA was added to a 
solution of DEX-PEG in aqueous NaOH cooled to ∼0 ºC, with subsequent treatment at 60 
ºC for 1 h.[22] All CMD-PEG samples were isolated as their sodium salts. The successful 
incorporation of carboxylate groups onto the dextran block was ascertained by analysis of 
the 1H NMR spectrum of the CMD-PEG samples, which exhibits two doublets (δ 4.89 and 
5.07 ppm) ascribed to the resonance of the anomeric protons, a series of signals between δ 
4.08 and 4.15 ppm, due to the methylene protons α to the carboxylate group, and two 
signals characteristic of the PEG block: a singlet at δ 3.28 ppm due to the methoxy end 
group of the PEG block and a broad signal at δ 3.60 ppm due to the –CH2–CH2–O– 
groups.[10] The average molar mass of the CMD-PEG diblock copolymers measured by gel 
permeation chromatography are listed in Table 2.2, together with the degree of substitution 
(DS) of the polymers determined by potentiometric titration carried out following the 
procedure reported previously.[10]  
2.5.2. Preparation and size of diminazene/CMD-PEG micelles 
Simple mixing of diminazene diaceturate (pKa = 11)[23] and CMD-PEG in a Tris–
HCl buffer (25 mM) of pH 5.3 should trigger the formation of micellar complexes via 
electrostatic interactions, since both DIM and CMD-PEG are fully ionized at this solution 
pH. These conditions were used throughout, unless specified otherwise. Evidence for the 
formation of nanoparticles was provided by dynamic light scattering (DLS) measurements, 
exemplified in Figure 2.2 (top) which presents the size distribution recorded for a solution 
of diminazene/60-CMD68-PEG64 of charge ratio [+]/[−] = 2.0, where [+]/[−] is the ratio of 
the molar concentration of positive charges provided by the drug to that of the negative 
charges provided by the polymer. The changes in the particles hydrodynamic radius (RH) 
and polydispersity index (PDI) as a function of the ratio [+]/[−] are shown in Figure 2.2 
(bottom) for the same drug/CMD-PEG system. Particles of RH ∼50 nm with a PDI of ∼0.5 
were detected in mixed solutions containing a large excess of polymer ([+]/[−] < 0.2) 
signaling the formation of loose polymer/drug aggregates as a result of the competition 
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between drug/polymer attractive forces and repulsive forces between the negative charges 
on the CMD segments. The hydrodynamic radius and polydispersity index of the scattering 
objects reached minimum values, ∼20 nm and 0.05, respectively, in mixed solutions of 
[+]/[−]∼1, i.e., when charge neutralization is achieved. Further increase in drug 
concentration, with respect to polymer concentration, resulted in a gradual increase in the 
size of the nanoparticles until [+]/[−]∼2, implying further incorporation of diminazene 
within the micellar core, as observed also by 1H NMR spectroscopy (see below). No 
changes in RH or PDI took place upon further addition of drug, signifying that micelles with 
[+]/[−]∼2 are unable to incorporate additional drug molecules. The RH and PDI values 
recorded for all DIM/CMD-PEG systems are listed in Table 2.3 for solutions containing 0.2 
g/L of polymer and drug in amounts such that [+]/[−] = 2.0. The hydrodynamic size of 
DIM/85-CMD40-PEG140 micelles is slightly larger than that of DIM/80-CMD40-PEG64. This 
difference in size can be attributed to the difference in the length of the PEG segment of the 
two copolymers (140 EG units or Mn (PEG) ∼ 6200 g/mol vs. 40 EG units or Mn (PEG) ∼ 
2800 g/mol). Diminazene/CMD-PEG micelles of low polydispersity index, such as those 
represented in Figure 2.2 for systems of [+]/[−] > 1 were prepared by dropwise addition of 
a drug solution to a magnetically stirred polymer solution. This method consistently led to 
micelles of identical size for a given [+]/[−] ratio. However, when the drug solution was 
added in one shot to the polymer solution, the resulting micelles were significantly more 
polydisperse in size (PDI > 0.1). These PDI values are similar to those reported by 
Govender et al. in the case of DIM/poly(aspartic acid)-block-PEG systems which were 
prepared by a “one-shot” mixing.[12] In order to ascertain reproducibility of the micellar 
properties, throughout this study diminazene/CMD-PEG nanoparticles were prepared via 
the dropwise addition of the drug solution to the polymer solution. 
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Figure 2.2. (top):  Distribution of the hydrodynamic radius (RH) of micelles in a solution of 
DIM/60-CMD68-PEG64 ([+]/[-] = 2; polymer concentration: 0.2 g/L; solvent: Tris-HCl 
buffer, 25 mM, pH 5.3; temperature: 25 oC; θ: 90 oC); (bottom): plots of the changes of RH 
() and the polydispersity index (PDI, ) as a function of [+]/[-] in mixtures of DIM and 
60-CMD68-PEG64; polymer concentration: 0.2 g/L; temperature: 25 oC; θ: 90 oC. 
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Table 2.3. Characteristics of DIM/CMD-PEG micelles ([+]/[−] = 2)a in a Tris–HCl buffer 
(25 mM, pH 5.3) for four different diblock copolymers 
Polymer RH (nm)b PDIb 
CAC 
(g/L) 
Mw,app 
(X 10-6 
g/mol) 
NDIM Nagg 
% 
DIMc 
85-CMD40-PEG140 48.7 ± 0.6 0.05 ± 0.03 0.048 8.25 12300 363 64.3 
80-CMD40-PEG64 43.5 ± 0.7 0.01 ± 0.01 0.032 7.21 10400 348 62.0 
60-CMD68-PEG64 36.9 ± 0.5 0.02 ± 0.01 0.014 4.99 7300 174 60.1 
30-CMD68-PEG64 49.7 ± 0.6 0.10 ± 0.02 0.095 3.89 3700 178 41.4 
a: [+]/[−]: ratio of the molar concentration of positive charges provided by the drug to that 
of negative charges provided by the polymer. 
b: Mean of six measurements ± S.D. 
c: % DIM loading = weight of drug/(weight of micelles)×100. 
 
In the case of DIM/30-CMD68-PEG64, micelles of uniform size distribution were 
obtained only for [+]/[−] > 1.6. The micelles were larger than DIM/60-CMD68-PEG64 
micelles of identical [+]/[−] ratio (Table 2.3). The backbone of the two copolymers (30-
CMD68-PEG64 and 60-CMD68-PEG64) is the same, but 30-CMD68-PEG64 contains about 
half as many charges as 60-CMD68-PEG64. Consequently, the level of drug incorporation in 
30-CMD68-PEG64 micelles is lower, for identical [+]/[−], compared to the situation in 
DIM/60-CMD68-PEG64.With fewer drug molecules bound to the CMD segments, the 
micellar core remains more hydrated leading to the formation of larger micelles.  
The apparent molecular weight (Mw, app) of DIM/CMD-PEG nanoparticles ([+]/[−] = 
2) was obtained by a Zimm plot analysis of static light scattering measurements. From this 
value, and knowing the weight average molecular weight of individual chains determined 
by GPC (Table 2.2), it is possible to estimate (1) the aggregation number (Nagg) of the 
micelles, defined here as the number of CMD-PEG chains associated in each micelle and 
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(2) the number (NDIM) of drug molecules incorporated in a micelle. In this calculation, it is 
assumed that there is no free drug in the mixed solutions and that each carboxylate 
substituent of the CMD block is bound to one diminazene molecule. Values of Mw, app, NDIM 
and Nagg calculated for micelles formed by CMD-PEG samples of different block lengths 
and degrees of substitution are listed in Table 2.3. The Nagg value depends primarily on the 
length of the CMD block: it is the same for the two copolymers, 30-CMD68-PEG64 and 60- 
CMD68-PEG64, which differ greatly in DS but are of identical length. The Nagg and NDIM of 
micelles formed by two polymers with similar DS and CMD block length, but different 
PEG segments (85-CMD40-PEG140 and 80-CMD40-PEG64) are similar, implying that the 
PEG segments play a passive role in directing the micellar composition, which is driven 
primarily by the CMD block. Control experiments using isothermal titration calorimetry 
confirmed the absence of interactions between PEG and DIM (Supporting information). 
2.5.3. Determination of the [+]/[−] ratios corresponding to the onset of 
micellization and to the maximum drug loading capacity by 1H 
NMR spectroscopy 
Incorporation of drug molecules in the core of polymeric micelles restricts the 
motion of the protons linked to the drug as well as that of the polymer fragments directly 
bound to the drug. This loss of mobility is reflected by a significant line broadening and/or 
disappearance of the 1H NMR signals due to the corresponding protons. We used this 
inherent property of solution NMR spectroscopy to detect the [+]/[−] ratio for which the 
drug is effectively entrapped into micelles (onset of micellization) as well as the [+]/[−] 
value for which the maximum loading capacity of a PIC micelle is attained. The method 
also allows one to ascertain the absence of free drug in a PIC-micelle formulation. It is 
described in detail, since it is applicable readily to other drug/diblock copolymer systems.  
The 1H NMR spectrum of diminazene diaceturate in D2O at room temperature 
(Figure 2.3, bottom) presents signals at δ 7.5 and 7.7 ppm, attributed to the aromatic 
protons, Hc and Hd, respectively[24], as well as singlets at δ 1.92 and 3.63 ppm assigned, 
respectively, to the methyl (Ha) and methylene (Hb) protons of the aceturate counterions. 
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Also shown in Figure 2.3 are the 1H NMR spectra of drug/60-CMD68-PEG64 solutions of 
different [+]/[−] ratios. Turning our attention first to the signals of these spectra 
corresponding to the drug, we note that (1) the signals at δ 1.92 and 3.63 ppm due to the 
drug counterion (aceturate) are sharp and well resolved in all spectra, indicating that the 
aceturates remain in solution, preserving their freedom of motion; (2) the signals in the 
aromatic region (δ 7.5 and 7.7 ppm) due to the protons of the drug are strongly affected by 
the presence of the polymer. They appear weak and broadened in the spectrum of the 
mixture with [+]/[−] = 0.2. Moreover, in the spectrum of this system, the signal attributed to 
the resonance of the protons Hd undergoes a significant upfield shift, implying a change in 
the local environment of these protons upon binding to the polymer linked carboxylates. 
Both signals in the aromatic region vanish in spectra of mixed solutions of [+]/[−] = 1.0–
2.0. They reappear in spectra of mixtures with [+]/[−] > 2.0, signaling the presence of free 
drug in the micellar solution, as seen in Figure 2.3 (right) where we present spectra of 
mixed systems with [+]/[−] = 4 and  10. 
In the 1H NMR spectra of mixed systems, one notices also changes in the signals 
due to the resonance of protons linked to the polymer. Thus, signals at δ 4.08–4.15, 4.89 
and 5.07 ppm ascribed to protons of the CMD block decrease in intensity with increasing 
[+]/[−]. They are still detectable in mixed solutions of [+]/[−] = 0.8, but disappear for 
mixed systems of [+]/[−] > 1, signaling severe loss of mobility of the CMD block under 
these conditions (Figure 2.3). In contrast, the signals due to the PEG protons (–CH2–CH2–
O–, δ 3.61 ppm) remain unaffected by changes in [+]/[−], an indication that the PEG chains 
preserve their mobility within the corona of the PIC micelles. As noted earlier, signals due 
to the DIM protons are visible in spectra of mixed systems with [+]/[−] > 2, yet the signals 
due to the CMD protons remain undetectable up to [+]/[−] = 10, the highest ratio tested. 
Thus the PIC micelles preserve their integrity even in the presence of a large excess of free 
drug.  
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Figure 2.3. 1H NMR spectra recorded for diminazene diaceturate (DIM, lower spectra) and 
solutions of DIM and 60-CMD68-PEG64 of 0 < [+]/[-] < 2 (left) and [+]/[-] = 4, 10 (right); 
polymer concentration: 3.0 g/L, solvent: D2O; temperature : 25 oC.  
 
Taken together, the results of 1H NMR experiments suggest the formation of 
micelles with some ordered structure, presumably a core-corona system, where PEG 
segments form a highly hydrated corona surrounding a core composed of diminazene 
electrostatically bound to CMD segments. Remembering that each drug molecule possesses 
two cationic centres, the 1H NMR data may be taken as an indication that micelles formed 
upon charge neutralization ([+]/[−]∼1), in which each drug molecule interacts with two 
polymer-bound carboxylates, are able to incorporate additional drug molecules, until only 
one of the two binding sites of the drug is involved in the complexation. This conclusion 
can be drawn from the combined facts that (i) signals ascribed to protons of the CMD block 
gradually decrease in intensity in spectra of mixed solutions of 0 < [+]/[−] < 1 and (ii) in 
the same mixed systems, signals of protons linked to the drug cannot be detected, whereas 
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signals due to the drug protons reappear in mixtures of [+]/[−] > 2, a ratio corresponding to 
maximum drug loading in micelles of this copolymer. For this ratio, the weight percent 
loading of drug in the micelle ranges from ∼40 to ∼65 wt% depending on the type of 
CMD-PEG (Table 2.3). An identical spectroscopic analysis was performed also to monitor 
the interactions between DIM and the copolymer 30-CMD68-PEG64, which has a lower DS 
than 60-CMD68-PEG64, but has the same molar mass. The DIM/30-CMD68-PEG64 mixed 
system followed the same trends as those depicted in Figure 2.3, except that the signals due 
the drug aromatic protons and the CMD protons remained detectable as long as [+]/[−] < 
1.6, confirming the observation from DLS experiments (see above) that micelles of this 
copolymer only form in solutions of [+]/[−] > 1.6. In the case of the samples 85-CMD40-
PEG140 and 80-CMD40-PEG64, the 1H NMR experiments revealed trends similar to those 
exhibited by the DIM/60-CMD68-PEG64 system. The results of the 1H NMR study go 
beyond mere structural information. They indicate that for in vivo applications it is crucial 
to use drug-loaded micelles of 1 ≤[+]/[−]≤ 2 in order to ascertain the absence of free drug, 
which is easily accessible to the external harsh conditions, such as those found in the GIT. 
2.5.4. Critical association concentration of diminazene/CMD-PEG 
micelles 
The minimal polymer concentration for which PIC micelles can be detected for a 
given [+]/[−] ratio, or critical association concentration (CAC), is an important parameter 
controlling the in vivo stability of a drug delivery system subjected to extensive dilution 
upon administration.[25] The CAC value of diminazene/CMD-PEG micelles depends on the 
chemical composition of the ionic diblock copolymer and on the level of drug loading 
within the micelle. It was determined for micelles formed in Tris–HCl buffer, pH 5.3 by 
each of the four diblock copolymers in the presence of diminazene in amounts such that 
[+]/[−] = 2.0. Micellar solutions ranging from 5 x 10−3 g/L to 0.2 g/L were prepared by 
dilution of a stock micellar solution (CMD-PEG: 0.2 g/L). The intensity of the light 
scattered by each solution was measured. The CAC values (Table 2.3) were taken as the 
concentration corresponding to the onset of the increase in scattered light intensity, 
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determined graphically from plots of IC/I0.2 vs. CMD-PEG concentration, where IC is the 
intensity of light scattered by a solution of CMD-PEG of concentration c and I0.2 is the 
intensity of light scattered by a solution of CMD-PEG concentration = 0.2 g/L, as shown in 
Figure 2.4. The CAC value of all micelles is very low, (<0.1 g/L of polymer) vouching for 
the stability of the micelles against dilution. The lowest value was recorded for micelles 
formed by the copolymer of longest CMD block and highest DS (60-CMD68-PEG64), 
presumably as a consequence of their high drug loading capacity. The length of the PEG 
block has only a minor influence on the CAC value of the micelles, as seen by comparing 
the values determined for 85-CMD40-PEG140 and 80-CMD40-PEG64 (Table 2.3). Similar 
trends have been reported in previous studies of other micelles.[26]  
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Plots of the changes as a function of polymer concentration of the ratio (IC/I0.2) 
of the intensity of light scattered by a solution of DIM and 60-CMD68-PEG64 () or 30-
CMD68-PEG64 () of concentration c to that of a solution of DIM and polymer of 
concentration 0.2 g/L; solvent: Tris-HCl buffer, 25 mM, pH 5.3; the arrows indicate the 
critical association concentration.  
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2.5.5. Effect of salt (NaCl) on micelle formation and stability 
Low molecular weight salts screen the charges of the ionic diblock copolymer, such 
that above a given salt concentration the micellar assemblies fall apart.[27, 28] For in vivo 
applications it is crucial to ascertain that a specific drug/diblock copolymer system can 
resist the salinity of the biological milieu. Therefore we evaluated by light scattering 
measurements the salt concentration beyond which diminazene/CMD-PEG micelles do not 
form, using aqueous DIM/CMD-PEG solutions containing from 0 to 0.6 M [NaCl]. Figure 
2.5, bottom, illustrates the dependence on salt concentration of the micellar RH and the 
scattered light intensity in the case of the DIM/85-CMD40-PEG140 system (polymer 
concentration: 0.2 g/L; [+]/[−] = 2.0). The profile can be divided into three domains: (i) for 
0 < [NaCl] ≤ 0.2 M, both RH and the scattered light intensity (ISc) increase; (ii) for 0.2 < 
[NaCl] ≤ 0.4 M, RH increases whereas ISc sharply decreases; and (iii) for [NaCl] > 0.4 M, 
RH decreases while the scattering intensity remains weak and constant. The micelles of 
diminazene and 80-CMD40-PEG64 as well as the copolymer of lower DS (60-CMD68-
PEG64) respond to changes in salinity according to the same three-zone pattern.  
The increase of RH and ISc in region I may be attributed to an overall increase in 
micellar size as a result of partial salt-induced dehydration of the PEG corona, which 
facilitates merging of micelles upon collision and promotes the formation of large micelles. 
In this region, the salinity is too low to disrupt the drug/CMD-PEG ionic interactions within 
the core of the micelle. Micelles begin to show signs of disintegration for [NaCl] ~ 0.3 M 
as detected by a decrease in scattered light intensity. This salt concentration corresponds to 
the beginning of region II. The disintegration of the micelles occurs gradually by 
progressive loosening of the core interactions and expansion of the micelle size. The 
breadth of region II is narrow, however, and in solutions of [NaCl] > 0.4 M the solution 
contains primarily isolated drug molecules and polymer chains, with possibly loose 
drug/polymer associates. Thus, all CMD-PEG micelles in which the DS of the CMD block 
was 60% or higher are able to resist salt-induced disintegration up to 0.4 M, a value 
significantly higher than the physiological salt concentration (0.15 M).  
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Figure 2.5. Plots of the changes of RH of micelles () and the intensity of scattered light (I, 
) as a function of NaCl concentration in mixtures of DIM and 30-CMD68-PEG64 (top) or 
85-CMD40-PEG140 (bottom) in Tris–HCl buffer, 25 mM, pH5.3; polymer concentration: 0.2 
g/L; [+]/[−] = 2; temperature: 25 ºC; θ: 90º; the hatched area corresponds to region II (see 
text). 
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neutralization ([+]/[−] = 2). For this system, a plot of ISc vs. [NaCl] (Figure 2.5, top) reveals 
that region I is limited to 0 < [NaCl] < 0.05 M and region II spans from 0.05 to 0.15 M. 
Solutions of higher [NaCl] exhibit low scattered light intensity ascribed to the presence of 
loosely bound objects with RH ~ 60 nm. This observation leads us to conclude that the drug 
loading must be above a threshold value for charge neutralized PIC micelles to remain 
stable under physiological conditions. In the micelles studied here, this value is reached for 
diminazene/60-CMD68-PEG64 ([+]/[−] = 2.0) micelles, but not for diminazene/30-CMD68-
PEG64 ([+]/[−] = 2.0). This result sets the lowest limit for the charge density of diblock 
copolymers useful in PIC-type drug delivery systems. 
2.5.6. Zeta-potential studies 
The interactions of nanoparticles with cells and cellular components are governed, 
at least in part, by their surface charge. The zeta (ζ) potential of DIM/85-CMD40-PEG140 
micelles in Tris–HCl (25 mM, pH 5.3) ranged from ∼ −7.6 mV for [+]/[−] = 0.6 to ∼ −3.4 
mV for [+]/[−] = 2, as expected since their charge is determined by that of the corona 
(PEG). 
2.5.7. Effect of solution pH on the stability of diminazene/CMD-PEG 
micelles 
Since the formation of polyion micelles relies on electrostatic interactions between 
oppositely charged drug and copolymer, there may exist pH conditions for which one of the 
interacting components will be neutral, triggering the disruption of the micellar core. In the 
case of the micelles described here, these conditions are attained when pH < 4 
(neutralization of CMD-PEG) or pH > 11 (neutralization of diminazene). The pH 
dependence of the RH of micelles and of the intensity of the light scattered by the solutions 
was monitored by DLS measurements which indicated that diminazene/85-CMD40-PEG140 
micelles (polymer concentration: 0.2 g/L; [+]/[−] = 2, Figure 2.6) were of constant size (RH 
∼50 nm) and scattering intensity for 4 < pH< 11. Solutions brought to pH < 4.0 rapidly lost 
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their ability to scatter light, presumably as a consequence of the near complete destruction 
of the micellar assemblies. In the high pH region (pH > 11), similar changes in the 
scattering characteristics of the samples took place, although the decrease in scattering 
intensity was not as severe. Similar DLS measurements carried out with polymer solutions 
(0.2 g/L) in the absence of drug gave no evidence of polymer self-assembly. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Plots of the changes of RH of micelles () and of the intensity of scattered light 
(I, ) as a function of solution pH in mixtures of DIM and 85-CMD40-PEG140 in 25 mM 
Tris–HCl; polymer concentration: 0.2 g/L; [+]/[−] = 2; temperature: 25 ºC; θ: 90º. 
 
Interestingly, the pH-window of micellar stability reported in the case of 
DIM/poly(aspartic acid)-PEG micelles[12] does not extend beyond 7.2 while in our study we 
ascertained that micellar systems formed by all CMD-PEG copolymers exhibit the same 
behavior as diminazene/85-CMD40-PEG140, independently on the charge density of the 
copolymer and of drug loading. The pH sensitivity of these PIC micelles, however, can be 
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environment of endosomes (pH∼5–6) or lysosomes (pH ∼ 4–5) following cellular uptake 
of the PIC micelles.[29] Nonetheless, the pH window of micellar stability (4–11) prohibits 
the use of DIM/CMD-PEG micelles in oral formulations, unless care is taken to avoid 
premature drug release in the stomach, such as application of an appropriate enteric 
coating.[30] 
2.5.8. Storage stability of diminazene/CMD-PEG micelles 
We assessed the stability of diminazene/CMD-PEG micelles ([+]/[−] = 2.0) in Tris–
HCl buffer, pH 5.3 at room temperature by following the evolution of their RH over a 
period of 2 months. In the case of diminazene/80-CMD40-PEG140, for instance, the micelle 
RH increased slightly (from 48.5 to 60.1 nm) over the course of the first week and remained 
constant upon further storage. Tests carried out with micelles of diminazene/CMD-PEG of 
different composition yielded similar trends, confirming the stability of the micelles. A 
slight increase in size over the first few days after micelle preparation was noticed in all 
cases. Initial experiments carried out on micellar formulations in Tris–HCl buffer (pH 5.3, 
[+]/[−] = 2.0) indicated that redissolution of the lyophilized micelles was incomplete, even 
after treatment in a sonicator bath. Moreover, the size and size distribution of the micelles 
were significantly larger, compared to those of the micelles prior to freeze-drying, with an 
RH approximately twice that of the original value and a PDI > 0.10. However, micellar 
solutions complemented with 5% (w/v) of the cryoprotectant trehalose readily dissolved in 
water after freeze drying, yielding diminazene/CMD-PEG micelles of size slightly larger 
than the original micelles. Thus, diminazene/85-CMD40-PEG140 micelles had RH values of 
50 and 75 nm, respectively, before and after freeze-drying/redissolution. The tendency of 
nanoparticulate formulations to agglomerate upon freeze-drying has been observed 
previously. Addition of cryoprotectants or cross linking of the micellar core are effective 
means to prevent agglomeration.[31-33] 
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2.5.9. Drug release studies 
The release of diminazene diaceturate from DIM/CMD-PEG micelles ([+]/[−] = 2.0) 
was monitored in vitro by the dialysis bag method using micelles formed between the drug 
and 85-CMD40-PEG140, which were shown to be stable under physiological conditions, as 
well as micelles formed with 30-CMD68-PEG64 known to disintegrate under these 
conditions. The profile recorded under physiological conditions of pH and ionic strength 
([NaCl] = 0.15 M, Tris–HCl buffer 25 mM, pH 7.4) (Figure 2.7) reveals complete drug 
release after ∼8 h. Nonetheless this profile differs significantly from that recorded for a 
drug solution used as control, especially in the initial part of the release experiment, 
implying that micelles sustain the drug release over 8 h. In salt-free conditions 
diminazene/85-CMD40-PEG140 micelles retained ∼ 40% of the drug after 24 h (50% after 8 
h, Figure 2.7), while diminazene/30-CMD68-PEG64 nanoparticles released ∼ 72% drug after 
8 h. These release profiles differ from observations of Prompruk et al. who noted that 
DIM/poly(aspartic acid)-PEG micelles undergo immediate DIM release upon dialysis.[19] 
We suggest that the enhanced stability of DIM/CMD-PEG micelles, compared to 
DIM/poly(aspartic acid)-PEG micelles, may be due to the formation of hydrogen bonds 
between the drug and the CMD block which possesses a large number of hydroxyl groups 
able to interact with the drug. This synergistic effect of weak bonds is akin to the stabilizing 
effect of drug/polymer hydrophobic interactions taking place in DIM/poly(aspartic acid-
stat-phenylalanine), which exhibits sustained drug release[19] or between poly(L-aspartic 
acid)-PEG in its free acid form and [Arg8]-vasopressin.[34] In our case, however, the 
enhanced stability is an inherent property of the charged copolymers. 
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Figure 2.7. Release of DIM evaluated by the dialysis bag method from (■) DIM alone in 
Tris–HCl 25 mM,  [NaCl] = 150 mM, pH 7.4; (▼) DIM/85-CMD40-PEG140 micelles, 
[+]/[−] = 2, in 25 mM Tris–HCl, [NaCl] = 150 mM, pH 7.4; (▲) DIM/85-CMD40-PEG140 
micelles, [+]/[−] = 2, in 25 mM Tris–HCl [NaCl] = 0 mM, pH 5.3, and (□) DIM/30-
CMD68-PEG64 at [+]/[−] = 2, in Tris–HCl, 25 mM [NaCl] = 0 mM, pH 5.3. 
2.6. Conclusion 
Four different CMD-PEG block copolymers have been tested for their ability to 
form PIC micelles with a cationic water soluble drug. The micelles formed were of small 
size (36–50 nm) and unimodal size distribution (PDI < 0.1). Properties of the micelles, such 
as their stability under different salt concentrations and drug release patterns depend 
primarily on the degree of substitution of the CMD block, which was readily adjusted by 
the synthesis protocol. Stable micelles with sustained drug release are formed if the DS of 
the CMD block exceeds a threshold value (∼40%). 1H NMR spectroscopy was used to 
determine the [+]/[−] molar ratio for which complete drug incorporation in the micelle core 
is achieved and the maximum drug loading attained. Further studies are aimed at widening 
the scope of drug/CMD-PEG micelles by assessing the characteristics of micelles formed 
by CMD-PEG and other cationic therapeutic agents, proteins and peptides. The in vivo 
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properties of drug/CMD-PEG micelles will be monitored next, since preliminary studies 
indicate that CMD-PEG samples present no toxicity towards several cell lines (Maysinger 
et al., unpublished data). 
2.7. Appendix A. Supplementary data 
Supplementary data associated with this article can be found, in the online version, 
at doi:10.1016/j.ijpharm.2007.12.029. 
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Appendix A. Supporting information (SI.2) 
 
Isothermal titration calorimetry (ITC) 
ITC Measurements were carried out with a VP-ITC instrument (from Microcal Inc) 
operated at 298 K. Samples of DIM and PEG 5000 were prepared in 25 mM Tris-HCl 
buffer adjusted to pH 5.3 ± 0.05. Prior to measurements all the solutions were degassed 
under vacuum for about 10 min to eliminate any air bubbles. The drug solution (3 g/L, 5.8 
mM) was placed in a 300 µL continuously stirred (300-rpm) syringe and added to a 1.43 
mL sample of PEG 5000 solution (0.092 g/L, 0.018 mM). The titration was performed by 
consecutive injections (10 µL) of the drug solution into the PEG solution. Heats of dilution 
were determined in blank titrations by injecting aliquots (10 µL) of the drug solution (3 
g/L, 5.8 mM) into the same buffer solution (1.43 mL). A total of 28 aliquots were injected 
into the sample cell in intervals of 325 S. The calorimetric data were analyzed and 
converted to enthalpy change using Microcal ORIGIN 7.0.  
PEG 5000 in its (-OH) form was chosen to be identical as the one in the block 
copolymers used in the study. Other experimental conditions, such as the drug and PEG 
concentrations were the same like those used in micelles preparation. Under the 
experimental conditions used, no interaction was detected between DIM and PEG since the 
ITC profiles of injecting DIM into PEG solution were not different from those of injecting 
DIM into the buffer (the blank) (Figure SI.2.1).  
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Figure SI.2.1. ITC profiles for titration 
of DIM into PEG solution in Tris-HCl 
buffer. A and B upper panel: raw 
power data, lower panel: integrated 
heats of interaction. A: titration of 
DIM into PEG, B: titration of DIM into 
the buffer, C: total energy exchanged 
as a function of the DIM/PEG molar 
ratio for titration of DIM into PEG and 
DIM into the buffer (blank).
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3.1. Abstract 
Minocycline hydrochloride (MH), a semisynthetic tetracycline antibiotic with 
promising neuroprotective properties, was encapsulated into polyion complex (PIC) 
micelles of carboxymethyldextran-block-PEG (CMD-PEG) as a potential new formulation 
of MH for the treatment of neuroinflammatory diseases. PIC micelles were prepared by 
mixing solutions of a Ca2+/MH chelate and CMD-PEG copolymer in a Tris-HCl buffer. 
Light scattering and 1H NMR studies confirmed that Ca2+/MH/CMD-PEG core-corona 
micelles form at charge neutrality having a hydrodynamic radius ~ 100 nm and  
incorporating ~ 50 wt-% MH. MH entrapment in the micelles core sustained its release for 
up to 24 h under physiological conditions. The micelles protected the drug against 
degradation in aqueous solutions at room temperature and at 37 ºC in the presence of fetal 
bovine serum. The micelles were stable in aqueous solution for up to one month, after 
freeze drying and in the presence of fetal bovine serum and bovine serum albumin. CMD-
PEG copolymers did not induce cytotoxicity in human hepatocytes and murine microglia 
(N9) in concentrations as high as 15 mg/mL after incubation for 24 h. MH micelles were 
able to reduce the inflammation in murine microglia (N9) activated by lipopolysaccharides. 
These results strongly suggest that MH PIC micelles can be useful in the treatment of 
neuroinflammatory disorders.  
3.2. Author Keywords 
Dextran, drug delivery systems, calcium complexes, minocycline, 
neuroinflammation, polyion complex micelles.  
3.3. Introduction 
There is increasing evidence from studies in cell cultures, in animal models, and 
clinical trials that some antibiotics might have beneficial anti-inflammatory effects in the 
central nervous system.[1, 2]  For example, the tetracycline antibiotic minocycline exerts 
antioxidant and anti-inflammatory effects in hyperactivated microglia in animal models of 
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stroke, inhibiting their activation and proliferation.[1, 3-5] Microglia comprise approximately 
12% of cells in the brain and predominate in the gray matter.[6] They typically exist in their 
surveyance state characterized by a ramified morphology and monitor the brain 
environment. Microglia are readily activated by a variety of stimuli, including pathogens 
producing pro-inflammatory cytokines and particulate matter (e.g. axonal debris). The 
microglial protective and destructive role depends on the degree of their activation and 
therefore agents which can modulate the activation process are clinically useful to shift the 
balance in favor of microglial protective state.[7]  Minocycline seems to be one such agent 
which has been explored as a monotherapy or in drug combinations. However, its poor 
stability and the numerous side effects related to the large doses required present serious 
limitations in terms of clinical applications. 
Minocycline is routinely administered orally for the treatment of infectious and 
inflammatory diseases, such as acne vulgaris, rheumatoid arthritis, and some sexually 
transmitted diseases, in doses on the order of 3 mg kg-1 day-1. [8]  It was shown to induce 
neurorestoration in various animal models when applied intraperitoneally in doses of up to 
200 mg kg-1 several times a day.[9, 10]      
Oral formulations for the treatment of bacterial infections contain minocycline 
hydrochloride (MH, Figure 3.1), which is an ionic compound very soluble in water.[11, 12]  
MH is well absorbed when administered orally. However, due to its numerous side effects 
it is recommended to administer it intravenously (IV).[10] It was noted, however, that after 
IV administration of MH, the levels of the drug in the brain were significantly lower than 
its concentration in the plasma, possibly as a consequence of the short MH lifetime in the 
bloodstream.[10]  MH is notoriously unstable in aqueous solution, especially in acidic or 
alkaline media where it undergoes epimerization at C4.[11, 13, 14]  The resulting epi-MH is 
much less potent than MH and is prone to further degradation upon exposure to oxidants or 
to light.[15]    
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Figure 3.1. Chemical structures of minocycline hydrochloride (left panel) and CMD-PEG 
block copolymer (right panel).  
The poor stability of MH in biological environment and serious side effects require 
new approaches for its administration in clinics. Thus, several research groups have 
developed and evaluated new means of MH delivery.  For instance, Hu et al. have 
demonstrated that MH entrapped within PEGylated liposomes retained its activity and the 
effectiveness of IV injection of MH PEGylated liposomes every five days was comparable 
to that of daily intraperitoneal injection of MH alone.[16]  Core-shell nanoparticles with an 
inner core serving as nanocontainer for the drug and a shell providing both colloidal 
stability in aqueous media and stealth properties in the bloodstream were also assessed as 
delivery vehicles for MH. Thus, Liang et al. have prepared a micellar formulation of MH 
by entrapping it into octadecyl quaternized carboxymethyl chitosan nanoparticles.[17]  The 
MH-loaded nanoparticles were ~ 290 nm in size and contained up to 22 wt% MH. In vitro 
studies indicated that the drug could be released from the particles, but no further data on 
the effectiveness of the formulation were presented so far. Another promising approach 
consists in converting minocycline into alkanoyl-10-O-minocycline, a hydrophobic 
derivative of minocycline known to retain the antioxidant, anti-inflammatory, and antibiotic 
activities of minocycline.  In aqueous media, alkanoyl-10-O-minocyclines self-assemble 
into nanoparticles expected to partition favorably in the blood-brain barrier and to possess 
enhanced stability, compared to minocycline.[9]  The encouraging results reported on the 
use of nanoparticles for the IV administration of MH prompted us to assess formulations of 
MH using polyion complex (PIC) micelles which also belong to the class of core-shell 
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nanoparticles.[18-20] The solid core of PIC micelles contains an ionic drug neutralized by the 
ionic segment of an oppositely-charged hydrophilic diblock copolymer.[19, 21] The shell of 
PIC micelles is formed by the second segment of the diblock copolymer, usually a PEG 
chain selected in view of its hydrophilic, non toxic properties and its outstanding stealth 
characteristics in vivo.[22, 23] PIC micelles have found clinical applications in cancer 
chemotherapy and in gene delivery.[24-26] The usefulness of PIC micelles in drug delivery 
derives from their small size (~ 100 nm), high drug loading, ease of fabrication and 
handling, thermodynamic stability, and design flexibility. Since MH is an amphoteric 
molecule with an isoelectric point of 6.4, it does not interact strongly with polyelectrolytes 
under physiological conditions.[11]  Consequently, MH is not suitable, per se, for 
incorporation into PIC micelles. It is important to recall here that, like all tetracycline 
antibiotics, MH is a metal-binding antibacterial agent, known to form complexes with 
divalent or trivalent cations by chelation of the C11-C12-C1 carbonyl functionalities.[27-29]  
Previous studies have shown that, in combination with the plasma protein-bound fraction of 
MH, the calcium -bound fraction represents more than 99% of MH concentration in the 
plasma.[30] Depending on the metal salt to drug relative concentrations, MH can form 1:1 or 
2:1 metal ion: drug chelates with calcium or magnesium ions.  The 1:1 chelated form of 
MH is neutral under physiological conditions (pH 7.4), whereas the 2:1 metal ion: MH 
chelate is cationic, since the pKas of MH are 5 and 9.5 for the C7 and C4 amino groups, 
respectively.[31] This cationic form of MH should be able to undergo electrostatic 
interactions with polyanions and form PIC micelles with an appropriate hydrophilic anionic 
diblock copolymer. To test this hypothesis, we selected carboxymethyldextran-block-
poly(ethylene glycol) (CMD-PEG, Figure 3.1), a diblock copolymer that consists of a 
neutral polyethylene glycol block linked to an anionic carboxymethyldextran block in 
which approximately 85 % of the glucose units bear carboxylate groups.[32] This copolymer 
is known to be non-toxic and to form PIC micelles, 30-50 nm in radius, with cationic water 
soluble drugs, such as diminazene diaceturate, presenting high drug loading, sustained drug 
release and excellent stability.[33] The Ca2+/MH/CMD-PEG micelles are not intended for 
oral administration since calcium is known to reduce the absorption of MH by 27%.[34] 
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The objectives of the studies reported here were to prepare CMD-PEG based PIC 
micelles loaded with the 2:1 Ca2+/MH chelate and to assess their anti-inflammatory activity 
in activated microglia cells. 1H NMR spectroscopy was used to detect the formation of 
core-shell micelles in mixed solutions of CMD-PEG and 2:1 Ca2+/MH.  The size of the 
micelles and their stability under various conditions were assessed by dynamic light 
scattering (DLS) measurements.  Since MH in aqueous media is prone to rapid degradation, 
we assessed the stability upon storage in ambient conditions and at 37 oC of MH entrapped 
into PIC micelles. The viability of human hepatocytes and murine microglia (N9) treated 
with CMD-PEG was assessed using several biochemical assays. The release of the drug 
from the micelles was determined and nitric oxide release was tested in the presence and 
absence of ternary Ca2+/MH/CMD-PEG micelles in N9 microglia cells activated by 
lipopolysaccharides. The results of this study give strong indications that ternary 
Ca2+/MH/CMD-PEG micellar formulations can act as effective delivery systems for MH to 
attenuate the excessive microglia activation commonly observed in several 
neurodegenerative disorders.  
3.4. Experimental part 
3.4.1. Materials 
Water was deionized using a Millipore MilliQ system.  Minocycline hydrochloride, 
trizma®hydrochloride, amberlite® IR-120, lipopolysaccharides, bovine serum albumin 
(BSA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were 
purchased from Sigma Aldrich, St. Louis, MO. Dialysis membranes (Spectra/por, MWCO: 
6-8 KDa, unless otherwise indicated) were purchased from Fisher Scientific (Rancho 
Dominguez, CA). The block copolymer CMD-PEG (Figure 3.1) was synthesized starting 
with dextran (Mn 6,000 g/mol) and α-amino-ω-methoxy-poly(ethylene glycol) (Mn 5,000 
g/mol), as described previously.[32] The degree of carboxymethylation of the dextran block, 
defined as the number of glucopyranose units having carboxymethyl groups per 100 
glucopyranose units, was 85 %. The average number of glucopyranosyl and of –CH2-CH2-
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O- repeat units of the CMD and PEG segments, were 40 and 140, respectively. Penicillin, 
streptomycin and Griess Reagent (1% sulphanilamide, 0.1% N-(1-naphthyl)-
ethylenediamine dihydrochloride, 5% phosphoric acid) and fetal bovine serum were 
purchased from Invitrogen (Carlsbad, CA). Human hepatocytes and murine microglia (N9) 
cell lines were from ATCC. An alamar blue (7-hydroxy-3H-phenoxazin-3-one-10-oxide 
sodium salt) stock solution was purchased from Trek Diagnostic Systems, (Cleveland, 
Ohio).  
3.4.2. Preparation of MH-loaded CMD-PEG micelles 
Stock solutions of CaCl2 (1.27 mg/mL, 8.63 mM), MH (2.33 mg/mL, 4.71 mM) and 
CMD-PEG (0.5 mg/mL, 1.74 mM -COONa) were prepared in Tris-HCl buffer (10 mM, pH 
7.4). The solution pH was adjusted to 7.4 using 0.1 M NaOH if necessary. Specified 
volumes of the CaCl2 solution were added to the MH solution to attain a Ca2+/ligand molar 
ratio of 2/1. The CaCl2/MH solution was magnetically stirred for 10 min and added over a 
10-min period to a magnetically stirred CMD-PEG solution, in amounts such that the [+]/[-
] ratio ranged from 0.5 to 2.0, where [+]/[-] is the ratio of the molar concentrations of 
positive charges provided by the Ca2+/drug complex to the negative charges provided by 
the polymer. In solutions of pH 7.4, the Ca2+/MH complex has one positively charged 
group (C4 dimethylammonium, Figure 3.1) while all the carboxylate groups of CMD-PEG 
are negatively charged (weak polyacid of pKa ~ 4.5). The CMD-PEG concentration was 0.2 
mg/mL in all samples.  Samples were stirred overnight before measurements. 
3.4.3. Characterization 
1H NMR spectra were recorded on a Bruker AV-400 MHz spectrometer operating at 
400 MHz. Chemical shifts are given relative to external tetramethylsilane (TMS = 0 ppm).  
Samples for analysis were prepared by adding aliquots of a CaCl2 solution (20.4 mg/mL, 
D2O, pH 7.4) to a MH solution in D2O (9.3 mg/mL, pH 7.4) such that the Ca2+/drug molar 
ratio was 2:1. The resulting solutions were stirred for 10 min.  They were added to a stirred 
solution of CMD-PEG in D2O (pH 7.4,) in amounts such that the [+]/[-] ratio ranged from 
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0.25:1 to 1.5:1. The final polymer concentration was 2.0 mg/mL in all the samples. Control 
solutions of MH, Ca2+/MH, and MH/CMD-PEG in D2O were prepared keeping the same 
concentrations as the metal Ca2+/ MH/CMD-PEG solutions. All samples were stirred for 
1.0 h before measurements.  
Dynamic light scattering (DLS) measurements were performed on a CGS-3 
goniometer (ALV GmbH) equipped with an ALV/LSE-5003 multiple-τ digital correlator 
(ALV GmbH), a He-Ne laser (λ = 632.8 nm), and a C25P circulating water bath (Thermo 
Haake). The scattered light was measured at a scattering angle of 90°. A cumulant analysis 
was applied to obtain the diffusion coefficient (D) of the micelles in solution. The 
hydrodynamic radius (RH) of the micelles was obtained using the Stokes-Einstein equation. 
The constrained regularized CONTIN method was used to obtain the particle size 
distribution. Samples were filtered through a 0.45 µm Millex Millipore PVDF membrane 
prior to measurements. The data presented are the mean of six measurements ± S.D.  
HPLC analysis of MH was performed on an Agilent Technologies HP 1100 
chromatography system equipped with a quaternary pump, a UV-visible diode array 
detector, a column thermostat and a HP Vectra computer equipped with the HP-
Chemstation software. The assay was carried out at 25 ºC using a 250 x 4.6 mm column 
filled with 5 µm-reversed phase C18 Hypersil® BDS (Thermo, Bellefonte, PA) eluted at a 
flow rate of 1.5 mL/min with a phosphate buffer (25 mM, pH 3.0)-methanol-acetonitrile, 
85:10:5 v/v/v/ mixture.[12] The injection volume was 40 µL and the run time was 30 min. 
MH, monitored by its absorbance at 255 nm, had a retention time ~16 min. A calibration 
curve (r2 ≥ 0.999) of MH was prepared using standard solutions ranging in concentration 
from 20 to 80 µg/mL prepared immediately prior to the assay.  
3.4.4. Stability studies 
To test the stability of MH-micelles in serum, Ca2+/MH/CMD-PEG micelles (CMD-
PEG: 0.2 mg/mL, [+]/[-] = 1.0, [Ca2+]/[MH] = 2:1) in Tris-HCl buffer (10 mM, pH 7.4) 
were prepared as described above. One set of solutions was supplemented with BSA (0, 5, 
10, 20, 30 and 40 mg/mL). Another set of samples was supplemented by 5 % fetal bovine 
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serum (FBS). Samples without serum were kept at room temperature for up to 30 days.  
Serum and BSA-containing solutions were incubated at 37 ºC for 24 h. Samples were 
analyzed by DLS at various time intervals to determine the RH and polydispersity index of 
the micelles. 
The chemical stability upon storage of MH was tested using micelles (CMD-PEG: 
0.1 mg/mL, [Ca2+]/[MH] = 2, [+]/[-] = 1.0) prepared, as described above, with stock 
solutions of MH (1 mg/mL), CMD-PEG (0.53 mg/mL), CaCl2 (0.54 mg/mL), in 10 mM 
Tris-HCl buffer, pH 7.4. The samples were kept at room temperature or at 37 ± 0.5 ºC 
without protection against light. Samples containing 5 % fetal bovine serum were prepared 
as well and kept at 37 ºC. At different time intervals, aliquots of the solutions were 
analyzed by HPLC. The data presented are the mean of three measurements ± S.D. 
To assess the micelle integrity upon freeze-drying, Ca2+/MH/CMD-PEG micellar 
solutions (3 mL, polymer concentration: 0.1 mg/mL; [+]/[-] = 1.0, [Ca2+]/[MH] = 2) in a 
Tris-HCl buffer (10 mM, pH 7.4) were frozen in a dry ice/acetone bath.  They were 
lyophilized for 48 h.  The resulting powder was rehydrated with deionized water (3 mL) to 
reach a polymer concentration of 0.1 mg/mL. The resulting micellar solution was 
magnetically stirred for 10 min and the RH and polydispersity index of an aliquot were 
determined by DLS. 
3.4.5. Drug release studies  
Identical measurements were performed with solutions (3.0 mL) in Tris-HCl buffer 
(10 mM, pH 7.4, [NaCl] = 0 or 150 mM) of MH, CaCl2/MH, and Ca2+/MH/CMD-PEG 
micelles obtained as described above with a 2:1 Ca2+/drug ratio, a 1:1 [+]/[-] ratio and 
[MH] = 0.75 mg/mL. The solutions were introduced in a dialysis tube (MWCO = 6-8 kDa).  
They were dialyzed against 150 mL of the same buffer at 37 °C. At predetermined time 
intervals, 3 mL aliquots were taken from the release medium and replaced by 3 mL of fresh 
buffer. The concentration of the drug was determined from the absorbance at 246 nm of the 
release medium samples and using a calibration curve. The cumulative percent of drug 
released was plotted as a function of dialysis time. 
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3.4.6. Cell survival and nitrite release determinations 
Human hepatocytes were cultured in Human Hepatocyte Cell Culture Complete 
Media. Murine microglia (N9) cells were cultured in IMDM media containing 5% fetal 
bovine serum and 1% penicillin-streptomycin. Cells were maintained at 37˚C (5% CO2) in 
a humidified atmosphere. For the Alamar blue assay, human hepatocytes and N9 cells were 
seeded in black, clear bottom 96-well plates (Corning) at a density of 5x104cells/cm2 and 
1x104 cells/cm2, respectively. For the MTT assay and nitrite measurement,  hepatocytes and 
N9 cells were seeded in 24-well plates (Sarstedt, Montreal, QC, Canada) at a density of 
5x104 cells/cm2 and 2x105 cells/cm2, respectively. 
Cells were given fresh media (IMDM, 5% FBS, 1% penicillin-streptomycin for N9 
cells; Human Hepatocyte Complete Media for hepatocytes) 24 h after seeding. They were 
treated with free MH (50 μg/ml), the Ca2+/MH complex (dose equivalent to 50 μg/ml MH), 
Ca2+/MH/CMD-PEG micelles (dose equivalent to 50 μg/ml MH), or CMD-PEG (0.1 – 15 
mg/ml) with or without concomitant addition of lipopolysaccharides (LPS; 10 μg/ml) for 
24 hours (37˚C, 5% CO2, humidified atmosphere).  
The alamar blue stock solution was diluted with fresh cell culture media to 10% v/v 
ratio. After cell treatment, media from each well were aspirated and 250 μL of the Alamar 
blue-media mixture were added to each well and incubated with the cells for 1 h at 37˚C 
(5% CO2, humidified atmosphere). The intensity of fluorescence at 590 nm of the reduced 
resazurin (excitation wavelength: 544 nm) was measured from the well bottom using a 
spectrofluorometer (FLUOstar OPTIMA). The percent viability was expressed as the 
fluorescence counts from treated samples over the untreated control. The colorimetric MTT 
assay was performed to assess the viability of N9 cells. One hour before the end of the 
treatment, MTT (12 μM, dissolved in sterile PBS) was added to the cells.  Following a 1-h 
incubation at 37°C, media were removed, cells were lyzed, and formazan was dissolved 
with dimethyl sulfoxide. The absorbance of the recovered formazan was measured at 595 
nm using a Benchmark microplate reader (Bio-Rad, Mississauga, ON, Canada). All 
measurements were done in triplicates in three or more independent experiments.  Nitrite 
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(NO2¯) release from N9 cells was measured using the Griess Reagent (1% sulphanilamide, 
0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride, 5% phosphoric acid). After 
treatment, 50 μL of the supernatant from each well were mixed with 50 μL of Griess 
reagent in a clear bottom 96-well plate, and incubated at room temperature for 15 min. 
Absorbance at 548 nm of each sample was measured in triplicates using the microplate 
reader.   
3.5. Results and Discussion 
3.5.1. Preparation, characterization, and stability of ternary 
Ca2+/MH/CMD-PEG nanoparticles 
At the onset of the study, it was important to confirm that the 2:1 Ca2+/MH chelates 
interact electrostatically with the carboxylate groups of CMD-PEG to form core-shell 
nanoparticles and that competing electrostatic interactions between Ca2+ and the polymer 
carboxylates do not disrupt the Ca2+/drug chelation. 1H NMR spectroscopy, DLS, and 
isothermal titration calorimetry (ITC) measurements were performed to address these 
issues.  The 1H NMR assay employed  takes advantage of the fact that signals due to the 
resonance of low mobility protons broaden, and often cannot be detected at all, under 
conditions used to measure 1H NMR spectra of soluble polymers.[35] Thus, entrapment of 
the drug within the core of a micelle can be monitored readily by changes in the intensity 
and shape of 1H NMR signals, as exemplified in Figure 3.2 which presents 1H NMR spectra 
of solutions in D2O (pH 7.4) of MH, with spectral assignments taken from literature 
data[36],  of the 2:1 Ca2+/MH chelate,  of CMD-PEG, and of a mixture of CMD-PEG and the 
2:1 Ca2+/MH chelate.  The composition of this mixture was such that the molar ratio, [+]/[-
], of positive charges provided by the 2:1 Ca2+/MH chelate to the negative charges provided 
by the diblock copolymer is equal to 1 (charge neutralization).  Turning our attention first 
to the 1H NMR spectrum of the chelate (Figure 3.2B),  we note that upon binding of MH to 
Ca2+ the quartet due to the aromatic protons H8 and H9 decreases in intensity and new 
signals appear further downfield. The signal at 3.69 ppm due to H4 is also affected 
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significantly. These spectral shifts reflect conformational changes of MH upon chelation of 
C11-C12-C1 carbonyl functionalities by the cations.[27] The 1H NMR spectrum of CMD-PEG 
(Figure 3.2C) presents signals at δ 4.08-4.15, 4.89, and 5.07 ppm, ascribed to protons of the 
CMD block, and a broad strong singlet centered at δ 3.61 ppm due to the PEG methylene 
protons (-CH2-CH2-O-).[33]  The 1H NMR spectrum of a mixed solution of the diblock 
copolymer and the drug chelate in amounts corresponding to charge neutralization (Figure 
3.2D) is remarkably featureless: signals in the aromatic region due to the protons of 
chelated MH are undetectable. In the high field spectral range, one can observe a weak and 
broad signal (δ ~ 2.7 – 3.0 ppm) that can be ascribed to MH protons with restricted motion 
and (ii) a strong singlet at δ 3.61 ppm due to the PEG methylene protons.  Signals due to 
the protons of the CMD block are undetectable. The preservation of the PEG signals, 
together with the disappearance of signals due to the drug chelate and to the CMD block, 
are diagnostic in indentifying the formation of nanoparticles with a CMD/drug chelate  
rigid core and a shell made up of flexible hydrated PEG chains.  Figure 3.2E presents the 
1H NMR spectrum of a mixture of MH and CMD-PEG of drug and polymer concentrations 
identical to those of the ternary Ca2+/MH/CMD-PEG system analyzed in Figure 3.2D. The 
signals of the drug and of the polymer are sharp and well resolved, confirming that, at pH 
7.4, the drug does not interact with the polymer in the absence of Ca2+ ions.   
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Figure 3.2. 1H NMR spectra of MH (A), Ca2+/MH, ([Ca2+]/[MH] = 2.0) (B), CMD-PEG  
(C), Ca2+/MH/CMD-PEG (CMD-PEG concentration = 2.0 mg/mL, [+]/[-] =1.0, 
[Ca2+]/[MH] = 2.0) (D) and MH/CMD-PEG ([+]/[-] =1.0) (E) in D2O, room temperature, 
pH 7.4 and representative illustrations of the species examined. 
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1H NMR spectra of Ca2+/MH/CMD-PEG mixtures of [+]/[-] > 1.0 (i.e., [+]/[-] = 
1.25 and 1.5) were recorded as well (Figure SI.3.1, supporting information). They present 
signals characteristic of the metal ion/MH complex in addition to signals due to the 
micelles, confirming that maximum drug loading is achieved at charge neutrality (i.e., 
[+]/[-] = 1.0). The actual drug loading of the micelles at charge neutrality is identical to the 
theoretical drug loading, or ~ 50 wt-% of the micelles, since no signals of the free drug 
were detectable in the 1H NMR spectrum of the micelles at charge neutrality (Figure 3.2D). 
This drug loading capacity is significantly higher than the capacity of other nanoparticulate 
carriers, such as liposomes[37] and poly(lactide-co glycolide) (PLGA) nanoparticles[38], 
which usually have low encapsulation efficiencies for water soluble ionic drugs. High 
loading of drug delivery systems is highly desirable from the toxicological point of view, as 
it enhances the drug/excipients ratio and avoids overloading the body with unwanted 
chemicals. 
To confirm the formation of nanoparticles upon mixing the 2:1 Ca2+/MH chelate 
and CMD-PEG, we analyzed by DLS a series of solutions in which the polymer 
concentration was kept constant (0.2 mg/mL) while the 2:1 Ca2+/MH chelate concentration 
was increased such that the charge ratio in the mixture covered the 0 < [+]/[-] ≤ 2 range.  
Mixed solutions of [+]/[-] < 0.5 did not scatter light.  In mixed solutions with a [+]/[-] ratio 
of 0.5, micellar objects were detected. They had a hydrodynamic radius (RH) of ~ 100 nm 
and a polydispersity index (PDI) of ~ 0.2 (Figure 3.3A).  In solutions of this composition, 
only part of the copolymer carboxylate groups is neutralized by the Ca2+/MH chelate. The 
repulsion between residual carboxylates prevents the formation of tight micelles.  The RH 
value of the micelles decreases to ~ 80 nm as the [+]/[-] ratio reaches 0.75, a consequence 
of the progressive neutralization of the carboxylate groups by added Ca2+/MH chelate.  For 
[+]/[-] > 0.75, the micelle size gradually increases, indicating that additional metal ion/drug 
complex is incorporated within the micelle core.  The micelle RH reaches ~ 105 nm in 
solutions of [+]/[-] = 1.0. For this composition, which will be used in further studies, the 
amount of MH incorporated in the micelles accounts for ~ 50 wt-% of the total micelles 
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weight.  The polydispersity index (PDI) of the micelle population was ~ 0.1 for [+]/[-] > 
0.75, indicating the formation of monodispersed nanoparticles.  
The Ca2+/MH/CMD-PEG micelles ([+]/[-] = 1.0, pH = 7.4) exhibited remarkable 
stability upon storage at room temperature for periods of 1 month, or longer.  Their size and 
polydispersity index remained constant and no aggregation was detected.  Moreover, 
micellar solutions of Ca2+/MH/CMD-PEG were readily reconstituted after freeze drying by 
simple solubilization in water of the lyophilized powder, even in the absence of 
cryoprotectants.  Upon re-dissolution, the micelles recovered their size (RH ~ 100 nm) and 
colloidal stability. The micelles stability upon freeze drying and reconstitution is an 
important criterion for a pharmaceutically viable formulation, since the shelf life of a drug 
formulation in the powder form tends to be much longer than in solution. Also powders are 
easier to handle, store and transfer. 
Control experiments were carried out to confirm that addition of Ca2+ to a solution 
of either CMD-PEG or MH does not trigger the formation of nanoparticles.  The intensity 
of light scattered at an angle of 90° was determined as a function of added Ca2+ for 
solutions of increasing [Ca2+] in the ternary Ca2+/MH/CMD-PEG system and in the binary 
systems Ca2+/ CMD-PEG and Ca2+/MH  (Figure 3.3B).  For the ternary system, the 
scattered light intensity underwent a sharp increase for [Ca2+] > 0.15 mg/mL ([+]/[-] = 
0.75), an indication of the presence of micelles which, given their size, scatter light 
extensively. The intensity of scattered light for mixtures of either Ca2+/CMD-PEG or 
Ca2+/MH mixtures was weak, independently of [Ca2+]. These results, together with the 1H 
NMR results, confirm that PIC micelles incorporating MH only form in the presence of 
both the polymer and Ca2+.  The association constants of Ca2+/MH and Ca2+/CMD-PEG, 
8.9 ± 0.7 x104 M-1 and 1.17 ± 0.03 x 104 M-1, respectively, determined by isothermal 
titration calorimetry (ITC), indicate that the affinity of Ca2+ ions for MH is ~ 8 times higher 
than that for CMD-PEG (Supporting information). Therefore, in tertiary mixtures of 
Ca2+/MH/CMD-PEG, Ca2+ ions preferentially bind to MH.  
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Figure 3.3. A:  Hydrodynamic radius (RH, ♦) of Ca2+/MH/CMD-PEG micelles as a 
function of the [+]/[-] ratio; solvent: Tris-HCl buffer (10 mM, pH 7.4; CMD-PEG 
concentration: 0.2 mg/mL, [Ca2+]/[MH] = 2).  
B: Scattered light intensity as a function of calcium chloride concentration from solutions 
of Ca2+/MH/CMD-PEG micelles (■), Ca2+/MH (▲) and Ca2+/CMD-PEG (○); solvent: Tris-
HCl buffer (10 mM, pH 7.4), CMD-PEG concentration: 0.2 mg/mL. 
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3.5.2. Stability and release of MH entrapped in Ca2+/MH/CMD-PEG 
nanoparticles ([+]/[-] = 1.0, pH 7.4)  
Minocycline hydrochloride is known to degrade rapidly in aqueous solutions 
exposed to ambient light and temperature. A number of studies have shown that chelation 
of MH with Ca2+ significantly enhances the stability of the drug in solution.[12, 29]   It was 
important to confirm that the stabilizing effect of Ca2+ was preserved upon binding of the 
chelate to CMD-PEG and subsequent micellization.  We set about to determine the 
changes, as a function of storage time, of the MH concentration in solutions of ternary 
Ca2+/MH/CMD-PEG micelles ([+]/[-] = 1.0, pH = 7.4) and to compare it to [MH] in 
solutions of the drug alone, MH/CMD-PEG mixtures and the 2:1 Ca2+/MH chelate stored 
under the same conditions.  We used a standard HPLC assay for the quantitative analysis of 
MH.[12] Representative chromatograms for samples stored at room temperature are depicted 
in Figure 3.4. From the chromatograms of the solution of MH alone recorded after various 
storage periods (Figures 3.4A), one can conclude that after ~ 2 weeks, nearly all the drug 
has degraded into several faster eluting derivatives, as reported previously.[12] The same 
behavior was observed for the MH/CMD-PEG mixture (Figure 3.4B), confirming the NMR 
and DLS results that the polymer does not interact with MH in the absence of metal ions.  
Chromatograms recorded for the Ca2+/MH chelate solution (Figures 3.4C) display a 
band corresponding to MH, as the main component, even after 3 weeks of storage.  
Chromatograms of solutions stored for 2 weeks or more present in addition a weak slower 
eluting band, attributed to the MH C4 epimer based on previous studies.[12, 39] 
Chromatograms corresponding to solutions of Ca2+/MH/CMD-PEG micelles ([+]/[-] = 1.0) 
are presented in Figure 3.4D.  Their features are similar to those of the chromatograms 
recorded for the Ca2+/MH chelate solutions, confirming that the enhanced stability provided 
to the drug by Ca2+ is not affected upon incorporation of the chelate in polymer micelles.  
We note that the intensity of the band ascribed to the elution of the MH C4 epimer is 
slightly weaker in the chromatograms recorded for micellar solutions, compared to 
solutions of the Ca2+/MH chelate. This observation gives some indication that the MH 
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epimerization at C4 is somewhat slower when the Ca/MH chelate is entrapped within 
micelles, possibly as a consequence of CMD-PEG/MH chelate electrostatic interactions 
that may take place within the micellar core.  The concentrations of MH in solutions of MH 
alone, of Ca2+ chelated MH, and the micellar formulation are listed in Table 3.1 for various 
times during a 3-month period of storage at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Chromatograms recorded upon storage at room temperature for up to 3 weeks 
of MH in Tris-HCl buffer (10 mM, pH 7.4) (A), MH/CMD-PEG (B), Ca2+/MH 
([Ca2+]/[MH] = 2.0) (C), Ca2+/MH/CMD-PEG ([+]/ [-] = 1.0, [Ca2+]/[MH] = 2.0) (D), 
[CMD-PEG] = 0.1 mg/mL. For elution conditions: see experimental section. 
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Table 3.1. Residual amount of MH upon storage at room temperature of various 
formulations of the drug in Tris-HCl buffer of pH 7.4.a 
Time (days) MHb MH/CMD-PEGc Ca2+/MHd Ca2+/MH/CMD-PEGd,e 
0 99.7 ± 1.9 100.5 ± 0.6 102 ± 0.5 98.4 ± 1.2 
1 99.3 ± 1.4 101.1± 0.2 98 ± 1.2 98.9 ± 1.3 
7 73.6 ± 0.4 72.6 ± 0.6 92.5 ± 0.6 98.3 ± 0.8 
14 7.8 ± 0.6 7.6 ± 0.5 90.6 ± 1.4 96.3 ± 0.7 
21   84.2 ± 0.9 90.9 ± 1.2 
28   80.9 ± 1.1 86.3 ± 1.3 
35   75.1 ± 0.9 81.5 ± 0.9 
42   72.0 ± 0.1 77.3 ± 1.8 
56   64.6 ± 1.4 73.4 ± 2.3 
96   48.4 ± 3.0 68.2 ± 0.6 
a: amounts are expressed in percent of the initial MH concentration. 
b:  solution of MH (0.3 mg/ mL). 
c: concentrations of MH and CMD-PEG are the same as those in Ca2+/MH/CMD-PEG 
micelles. 
d: [Ca2+]/[MH] = 2.0. 
e: [+]/[-] = 1.0. 
 
The drug stability at 37 °C was lower than at room temperature.  Nonetheless, the 
CMD-PEG copolymer still acts as a protective environment for the metal ion/drug 
complex. The concentrations of MH in solutions of MH alone, of Ca2+ chelated MH, and 
the micellar formulation are listed in Table 3.2 for various times of storage at 37 oC. Next, 
in an attempt to simulate the environment of the drug upon injection in vivo, we assessed 
the stability of MH in formulations incubated at 37oC in the presence of serum proteins. 
Addition of serum greatly enhances the stability of uncomplexed MH.  Similar effects were 
reported previously in the case of drugs, such as curcumin and attributed to the formation of 
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protein/drug complexes.[40] MH is known for its affinity to interact with serum proteins.[41]  
The micellar constructs maintained their protective effects even in the presence of serum 
proteins: after a 7-day incubation at 37 oC with serum, ~ 75 % of the drug was intact when 
complexed within Ca2+/MH/CMD-PEG micelles, whereas only ~ 30 % of the drug was still 
present in a sample of free drug treated in the same conditions (Table 3.2). 
 
 
Table 3.2. Residual amount of MH upon storage at 37 ºC of various formulations of the 
drug in Tris-HCl buffer of pH 7.4 and in the same buffer containing 5% fetal bovine 
serum.a 
Time 
(days) 
MHb Ca2+/MHc Ca2+/MH/CMD-PEGc,d 
No serum 5% serum No serum 5% serum No serum 5% serum 
0 102.3±1.3 97.1±1.3 98.9±1.6 98.3±1.4 98.1±1.3 96.6±0.5 
1 96.8±0.7 95.0±0.7 92.9±0.9 92.6±1.5 90.5±0.8 89.5±1.7 
7 3.5±0.0 31.5±0.8 64.9±2.4 76.4±0.6 66.6±1.0 74.0±2.9 
16 - 20.6±0.0 59.0±3.7 65.5±1.7 67.9±5.7 69.7±2.4 
22 -  56.6±1.6 60.7±0.5 66.6±0.5 66.6±0.3 
29 -  47.6±1.0 61.5±0.7 60.4±0.7 63.3±0.6 
a: amounts are expressed in percent of the initial MH concentration. 
b:  solution of MH (0.3 mg/ mL). 
c: [Ca2+]/[MH] = 2.0. 
d: [+]/[-] = 1.0. 
 
We conducted also in vitro drug release studies in order to assess the suitability of 
the micelles to act as drug delivery systems. The release of MH from Ca2+/MH/CMD-PEG 
micelles was evaluated by the dialysis bag method, coupled with quantitative analysis of 
the drug using its UV absorbance at 246 nm (Figure 3.5).[42] The micelles released ~ 50% 
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and 75 % drug after 8 h and 24 h, respectively. The drug release from the micelles was 
slightly faster under physiological salt concentrations (150 mM NaCl), which may be 
attributed to the weakening of the electrostatic interactions between Ca2+/MH and CMD-
PEG upon addition of salt.[19, 33] Control experiments carried out with a solution of the 
Ca2+/MH chelate revealed that drug release from this solution was significantly faster than 
from a Ca2+/MH/CMD-PEG micellar solution (Figure 3.5).  After 8 h, ~ 88 % of the drug 
was released in the case of Ca2+/MH solution, whereas for micellar solutions only 50 % 
drug was released after the same time. The sustained MH release from the micelles is 
expected to reduce the frequency of its administration, which results in fewer side effects 
and better patient compliance.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Release profiles  for MH kept at 37 ºC in Tris-HCl buffer (10 mM, pH 7.4) in 
the case of Ca2+/MH  (●), Ca2+/MH/CMD-PEG [NaCl] = 0  (■) and Ca2+/MH/CMD-PEG 
[NaCl] = 150 mM (▼). [+]/[-]  for micelles = 1.0 and [Ca2+]/[MH] = 2.0. 
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serum.  Although the interactions of the micelles with serum are the most relevant to the 
situation in vivo, BSA, which is the most abundant protein is serum, is often used as a 
model since its size and conformation are known precisely.[43] The intensity fraction 
distribution of the RH of Ca2+/MH/CMD-PEG micellar solutions ([CMD-PEG]: 0.2 mg/mL, 
[+]/[-] =1.0) and various amounts of BSA, from 0 to 40 mg/mL, are presented in Figure 
3.6A. The RH of BSA under the measurement conditions (5 mg/mL, pH 7.4) was 4.2 ± 0.1 
nm, in agreement with reported values (Figure 3.6A, top trace).[43, 44]  The RH value of 
Ca2+/MH/CMD-PEG micelles in the absence of BSA was 84 ± 2 nm (Figure 3.6A, bottom 
trace).  The presence of a signal ~ 4 nm in all BSA/micelle mixed systems, together with a 
signal ~ 90 nm indicates that the micelle integrity is preserved in the presence of BSA. The 
micellar size distribution in solutions of highest BSA concentration is slightly broader than 
in solutions devoid of BSA, possibly as a consequence of some level of BSA adsorption 
onto the micelles.  BSA, which is negatively charged under physiological conditions (pH 
7.4) could act as competing polyelectrolyte for PIC micelles and polyelectrolyte 
complexes.[19, 45] The  stability of Ca2+/MH/CMD-PEG micelles in the presence of BSA 
concentration as high as 100 times the polymer concentration is probably a consequence of 
the limited access of negatively charged BSA to the positively charged Ca2+/MH chelate 
due to its entrapment in the micelles  core.   
DLS analysis of Ca2+/MH/CMD-PEG micelles incubated for 24 h at 37 °C with 5%  
fetal bovine serum  also revealed the presence of two size populations (Figure 3.6B): (i) 
small objects of RH ~ 7 nm, identified as serum proteins by comparison with the serum DLS 
data (Figure 3.6B, top trace) and (ii) larger objects of RH, identical, within experimental 
uncertainty, to the RH of micelles incubated under the same conditions, but in the absence 
of serum (Figure 3.6B, bottom trace).  These observations confirm that the micelles 
withstand the serum environment and that protein adsorption onto micelles occurs to a 
limited extent, if at all.[46] 
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Figure 3.6. A: Normalized size distributions of Ca2+/MH/CMD-PEG micelles upon 
incubation at 37 °C for 15 h with various amounts of BSA.  Also shown are the size 
distributions recorded for micelles alone (bottom trace) and BSA alone (5 mg/mL) (top 
trace); [+]/[-]  for micelles = 1.0 and [Ca2+]/[MH] = 2.0.   
B: Normalized size distribution of Ca2+/MH/CMD-PEG micelles upon incubation at 37 °C 
for 24 h with 5 % serum; also shown are the size distributions of micelles alone after 
incubation for 24 h at 37 °C (bottom trace) and of 5 % serum alone (top trace); [+]/[-]  for 
micelles = 1.0 and [Ca+2]/[MH] = 2.0. 
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3.5.3. Cytotoxicity and anti-inflammatory effects of Ca2+/MH/CMD-PEG 
micelles 
The cytotoxic effect of CMD-PEG on the viability of human hepatocytes and 
murine microglia was evaluated by the MTT and Alamar Blue assays and confirmed by cell 
counting.  Hepatocytes were selected since the liver represents the main organ in which 
biotransformation of drugs and foreign substances takes place, while the inflamed microglia 
are the main targets of the drug in the central nervous system.[47] Cell viability did not 
change significantly after a 24 h-incubation with CMD-PEG up to a concentration of 15 
mg/mL (Figure SI.3.2, supporting information). The concentrations of CMD-PEG assessed 
were within the theoretical concentration range needed to achieve clinically relevant 
minocycline concentrations. It is anticipated that the PEG corona will prolong the micelles 
circulation in blood and reduce their uptake in the liver, as demonstrated previously with 
other PEGylated micelles.[48]  
The usefulness of micelle-entrapped MH  for attenuation of microglia activity  was 
tested in N9 microglia cells treated with lipopolysaccharides, (LPS), which are known 
inducers of microglia activation leading to the release of cytokines and nitric oxide.[49] 
Minocycline can inhibit the LPS-induced microglia activation and, in turn, reduce the 
amount of nitric oxide (NO) released.[50, 51] In the murine microglia (N9) model, a LPS dose 
of 10 μg/mL induced significant release of NO after 24 h (3.8 ± 0.1 a.u. compared to the 
untreated control (Figure 3.7)). The cells were subjected to concomitant treatments with 10 
μg/mL LPS and 50 μg/mL MH in three formulations: MH, Ca2+/MH, and Ca2+/MH/CMD-
PEG micelles or with 10 μg/mL LPS and 10 mg/mL CMD-PEG, in the absence of MH.  As 
expected, MH alone greatly reduced the NO release (0.3 ± 0.01 a.u.). A similar effect was 
induced by Ca2+/MH/CMD-PEG micelles and by Ca2+/MH chelate at concentrations 
equivalent to 50 μg/mL (Figure 3.7). This result confirms that MH is released from the 
micelles in a pharmacologically active form and that the presence of the polymer or of 
CaCl2 does not affect the drug activity. Unexpectedly, a control measurement that involved 
concomitant administration of LPS and CMD-PEG revealed that the polymer itself reduced 
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NO release by ~ 60%, compared to NO release level of the control measurement in the 
absence of CMD-PEG. If such an effect could be obtained in animal models and eventually 
in humans it could be of a significant relevance for improvement of minocycline 
effectiveness in an additive or even synergistic manner. We are currently pursuing these 
studies to assess if this polymer indeed does not only serve as a drug carrier but can also 
enhance beneficial anti-inflammatory effect of minocycline and other anti-inflammatory 
agents.  The exact mechanism of this polymer-induced reduction in NO release is not clear 
and requires further investigations.  .  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Amount of NO released in N9 microglia cells treated with MH alone, Ca2+/MH 
complex, Ca2+/MH/CMD-PEG micelles or CMD-PEG, all in the presence or absence of 10 
μg/ml of lipopolysaccharide under normal cell culture conditions. Cells were treated for 24 
h after which nitrite content in the media was measured using the Griess Reagent. All 
measurements were done in triplicates in three independent experiments. ** p<0.01, *** 
p<0.001 
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3.6. Conclusions 
Complexation of the minocycline calcium chelate into CMD-PEG PIC micelles 
leads to a significant drug stabilization upon storage and in the presence of serum under 
physiological conditions.  A similar approach may be suitable for other antibiotics and 
therapeutic agents whose stability can be increased in this manner.  Preliminary in vitro 
results indicate that while encapsulating MH into Ca2+/MH/CMD-PEG micelles has its own 
merit in stabilizing the drug, controlling its release, and reducing protein adsorption, neither 
CaCl2 nor the polymer negatively affect the anti-inflammatory activity of the drug.  These 
observations need to be strengthened by in vivo investigations aimed at assessing if such 
formulations permit administration of MH in smaller but still effective doses which could 
significantly reduce the extent and severity of its undesirable side effects.  
3.7. Appendix B. Supplementary data 
Supporting information for this article is available at the bottom of the article’s 
abstract page which can be accessed from the journal’s homepage at http://www.mbs-
journal.de. 
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Appendix B. Supporting information (SI.3) 
 
Isothermal titration calorimetry (ITC) studies 
ITC Measurements were carried out with a Microcal VP-ITC instrument (Microcal 
Inc., Northampton, MA). The experiments were carried out in 10 mM Tris-HCL pH 7.4.  
Prior to measurements all the solutions were degassed under vacuum for about 10 min to 
eliminate any air bubbles. In a typical experiment, 10 µL aliquots of CaCl2 solution (3.75 
mM) were injected from a 300 µL continuously stirred (300-rpm) syringe into a 1.43 mL 
sample of MH solution (0.25 mM). In another set of experiments, CaCl2 solution (7.5 mM) 
was injected into a 1.43 mL sample of CMD-PEG copolymer solution (1 mM 
carboxylates). Heats of dilution and mixing were determined in control experiments by 
injecting aliquots (10 µL) of CaCl2 solution into the buffer (1.43 mL). A total of 28 aliquots 
were injected into the sample cell in intervals of 300 s. The calorimetric data were analyzed 
and converted to enthalpy change using Microcal ORIGIN 7.0. The enthalpy change for 
each injection was calculated by integrating the area under the peaks of the recorded time 
and then corrected with control experiments. The binding parameters (N, K, ∆H, ∆S) were 
determined by fitting the data using the fitting models available in Microcal ORIGIN 7.0 
software.  
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Figure SI.3.1. 1H NMR spectra of Ca2+/MH/CMD-PEG micelles prepared in D2O at  [+]/[-] 
of 1.25 (A) and 1.5 (B).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure SI.3.2. Cytotoxicity of CMD-PEG block polymer in human hepatocytes and murine 
microglia after treatment for 24 h with different polymer concentrations under normal cell 
culture conditions. Cell viability was assessed using the MTT and Alamar blue assays. All 
measurements were done in triplicates in three or more independent experiments.
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4.1. Abstract 
The aim of this study was to develop and characterize carboxymethyldextran-b-PEG 
(CMD-PEG) micelles as delivery systems for aminoglycoside antibiotics. Calorimetric 
studies showed that electrostatic interactions between different aminoglycosides and CMD-
PEG were associated with proton uptake by the drugs from the buffers. The number of 
protons uptaken was temperature and pH dependent. CMD-PEG micelles incorporated up 
to 50 wt% drug and had a drug/CMD-PEG core and a PEG corona. Micelles incorporating 
neomycin were smaller in size and more resistant to salt-induced disintegration than those 
of paromomycin. However, both neomycin and paromomycin micelles were unstable under 
physiological conditions (pH 7.4, [NaCl] = 150 mM). Hydrophobically modified CMD-
PEG (dodecyl-CMD-PEG) and guanidylated paromomycin were prepared to increase 
micelles stability under physiological conditions. Guanidylated paromomycin formed 
smaller and more stable micelles than paromomycin, though the micelles were unstable 
under physiological conditions. In contrast, micelles of neomycin/dodecyl-CMD-PEG 
resisted salt-induced disintegration for up to 200 mM NaCl, well above the physiological 
salt concentration. Different aminoglycosides were released from the micelles in a 
pharmacologically active form as indicated by their ability to kill a test micro-organism in 
culture. These results warrant in vivo evaluation of the optimal aminoglycoside/CMD-PEG 
micelle formulations.  
4.2. Author Keywords 
Aminoglycosides; Polyion complex micelles; Dextran; Isothermal titration 
calorimetry; Hydrophobic modification; Micelles stability. 
4.3. Introduction 
Aminoglycosides are a group of structurally diverse polyamines that have been 
frequently used in the treatment of serious infections caused by aerobic gram negative 
bacilli, such as pneumonia, urinary tract infections and peritonitis.[1, 2] The antibacterial 
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activity of aminoglycosides results from their interaction with prokaryotic ribosomal RNA 
(rRNA).[3] Aminoglycosides therapy is associated with a host of side effects due to drug 
accumulation in healthy non-target tissues. Nephrotoxicity and ototoxicity are the most 
common side effects of aminoglycosides and they are usually dose-limiting factors. 
Nephrotoxicity of aminoglycosides results from the accumulation in the kidney of a 
relatively high percentage (~ 10%) of the intravenously administered dose.[4] Moreover, 
aminoglycosides are administered parenterally or locally, rather than orally due to their 
poor absorption in the gastro-intestinal tract as a consequence of their highly polar cationic 
nature.[2, 5] 
In view of the clinical importance of aminoglycosides, much effort has been 
directed towards their encapsulation into different drug delivery systems to modify their 
biodistribution, limit their toxicity and increase their oral bioavailability. Drug delivery 
systems tested include liposomes[6-8], polymeric nanoparticles[9], solid lipid nanoparticles[10] 
and polyelectrolyte multilayers.[11] Liposome-encapsulated aminoglycosides showed 
enhanced activity against resistant strains of Pseudomonas aeruginosa due to enhanced 
entry into the bacterial cell. Transmission electron microscope (TEM) confirmed that 
liposomes interact intimately with the outer membrane of Pseudomonas  aeruginosa, 
leading to membrane deformation.[7] Each of the nanocarriers tested so far, suffer from 
several drawbacks. Liposomes, for example, have limited stability in the presence of blood 
lipoproteins, low encapsulation efficiency, osmotic fragility and are unstable upon 
storage.[9, 12, 13] Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have limited drug 
loading efficiency (e.g. ~ 1 wt% for gentamicin). Gentamicin microspheres, although 
effective in reducing splenic infections in mice, triggered pulmonary embolism due to 
particles aggregation.[14]  
Polyion complex (PIC) micelles form by electrostatic interactions between an ionic 
dihydrophilic copolymer and an oppositely charged compound, such as drug, protein or 
nucleic acid.[15-18] PIC micelles present a number of advantages for biomedical applications, 
including ease of fabrication, excellent colloidal stability in aqueous media, high drug 
loading capacity, small size and narrow size distribution. They are thermodynamically 
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stable and resist disintegration upon dilution as long as their concentration exceeds the 
critical association concentration (CAC), which usually is very low. PIC micelles usually 
have a poly(ethylene glycol) (PEG) corona, which prolongs their circulation time in the 
blood allowing them to accumulate passively in tissues of leaky vasculature, such as tumors 
and inflamed tissues.[19] Carboxymethyldextran-b-PEG (CMD-PEG) copolymers are a new 
family of dextran-based anionic copolymers known to be non-toxic and to form PIC 
micelles with a number of cationic drugs.[20, 21] CMD-PEG PIC micelles had small size, 
high drug loading capacity and were stable upon freeze drying and in presence of serum 
proteins. The shortcomings of the drug carriers used, so far to deliver aminoglycosides and 
the favorable properties of CMD-PEG micelles motivated us to exploit them for 
aminoglycosides encapsulation and delivery.   
The objectives of this study were to formulate and characterize PIC micelles of 
CMD-PEG and two aminoglycoside antibiotics: neomycin sulfate and paromomycin sulfate 
(Figure 4.1). Neomycin and paromomycin are examples of 4, 5-disubstituted 2-
deoxystreptamine aminoglycosides. Their structures differ by the 6´ substituent: 6´ 
hydroxyl group in paromomycin is replaced by an amino group in neomycin. Neomycin 
and paromomycin are positively charged at pH 7.4 making them suitable for PIC micelles 
formation with polyanions, such as CMD-PEG. The thermodynamics of the interaction 
between either neomycin or paromomycin and CMD-PEG were studied by isothermal 
titration calorimetry (ITC). Factors affecting the formation and stability of 
aminoglycosides/CMD-PEG micelles, as well as optimal conditions for their preparation 
were characterized by 1H NMR spectroscopy and dynamic light scattering (DLS). Drug 
release from the micelles, as well as the ability of the released drugs to kill a test micro-
organism in culture was also investigated. 
One of the limitations of PIC micelles is their sensitivity to changes in ionic strength 
of the medium. Thus, small molecular weight salts screen the charges of oppositely charged 
species in the micelles core leading to micellar disassembly after certain salt 
concentration.[22] Herein we proposed two approaches for CMD-PEG micelles stabilization 
against increase in salinity: (i) hydrophobic modification of CMD-PEG copolymers by 
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grafting dodecyl chains at different grafting densities and (ii) guanidylation of 
paromomycin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Chemical structures of neomycin, paromomycin (top) and CMD-PEG block 
copolymer (bottom).  
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4.4. Materials and methods 
4.4.1. Materials 
Trizma® hydrochloride (Tris-HCl), sodium cacodylate, HEPES, Tricine, 
Amberlite® IR-120, neomycin sulfate, paromomycin sulfate and all other chemicals were 
purchased from Sigma-Aldrich Chemicals (St. Louis, MO). Dextran was purchased from 
Fluka Chemical Co. (Buchs, Switzerland) and its number average molecular weight was 
determined to be 6400 g/mol by gel permeation chromatography. Dialysis tubing 
(SpectraPore, MWCO: 1,000 or 6,000-8,000 g/mol) was purchased from Fisher Scientific 
(Rancho Dominguez, CA). All solvents were reagent grade and used as received. The block 
copolymer CMD-PEG (Figure 4.1) was synthesized starting with dextran (Mn 6,000 g/mol) 
and α-amino-ω-methoxy-poly(ethylene glycol) (Mn 5,000 g/mol), as described 
previously.[23] The degree of carboxymethylation of the dextran block, defined as the 
number of glucopyranose units having carboxymethyl groups per 100 glucopyranose units, 
was 85%. The average number of glucopyranosyl and of –CH2-CH2-O- repeat units of the 
CMD and PEG segments, were 40 and 140, respectively. Detailed procedures for synthesis 
of guanidylated paromomycin are given as supplementary data (Figure SI.4.1).  
4.4.2. Methods 
4.4.2.1. General methods 
1H NMR spectra were recorded for solutions in D2O (25 ºC) using a Bruker AV-400 
MHz spectrometer operating at 400 MHz. Chemical shifts are given relative to external 
tetramethylsilane (TMS = 0 ppm). Lyophilization was performed with a Virtis (Gardiner, 
NY) Sentry Benchtop (3L) freeze-dryer. UV–vis absorption spectra were recorded with an 
Agilent 8452A photodiode array spectrometer. Steady-state fluorescence spectra were 
recorded using a Varian Cary Eclipse fluorescence spectrophotometer.  
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4.4.2.2. Synthesis and characterization of hydrophobically modified CMD-PEG [24] 
 CMD-PEG (288 mg, 0.97 mmol carboxylate) was dissolved in deionized water (120 
mL) and the pH was adjusted to 4.0 using 1.0 N HCl. N-Ethoxycarbonyl-2-ethoxy-1,2-
dihydroquinoline (EEDQ) (216 mg, 0.87 mmol) was dissolved in absolute ethanol (120 
mL) and the resulting solution was added gradually to CMD-PEG. The apparent pH of the 
water/ethanol mixture was adjusted to 4.0 and kept at this value for 30 min. Subsequently, 
dodecylamine (162 mg, 0.87 mmol) was added and the pH was increased to 9.0 by 1.0 N 
NaOH and the reaction mixture was stirred for 1.0 h at this pH. The ethanol was removed 
under reduced pressure at 50 °C and the product was recovered by freeze drying. The 
resulting dodecyl-CMD-PEG was purified by soxhlet extraction with hexane for 24 h to 
remove the unreacted dodecylamine and EEDQ. Dodecyl-CMD-PEG was converted to its 
free acid form by treatment with a cation exchange resin (Amberlite® IR 120). It was 
characterized by 1H NMR spectroscopy of its solution in DMSO-d6. The grafting density 
(defined as the number of dodecyl chains per 100 glycopyranose units) was determined 
from the 1H NMR spectrum in DMSO-d6  as the ratio between the area of the signal due to 
terminal methyl protons of the dodecyl chain (0.85 ppm) and the integral due to dextran 
anomeric protons (4.66 ppm) (Figure 4.2). 
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Figure 4.2. 1H NMR spectra of CMD-PEG block copolymer (top spectrum) and dodecyl38-
CMD-PEG copolymer (bottom spectrum) recorded in DMSO-d6 at room temperature. 
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Two water-soluble dodecyl-CMD-PEG copolymers were obtained by amide bond 
formation between dodecylamine and CMD-PEG carboxylate groups: dodecyl18-CMD-
PEG and dodecyl38-CMD-PEG where 18 and 38 are the grafting densities of the dodecyl 
chains. FTIR spectrum of dodecyl38-CMD-PEG copolymers (Figure SI.4.2) show bands at 
1546 cm-1 and 1644 cm-1, attributed to the amide II and amide I vibration bands, 
respectively. Critical association concentration (CAC) was ~ 100 μg/mL for both 
dodecyl18-CMD-PEG and doecyl38-CMD-PEG (Figure SI.4.3, supporting information). 
4.4.2.3. Isothermal titration calorimetry (ITC) 
ITC Measurements were carried out with a Microcal VP-ITC instrument (Microcal 
Inc., Northampton, MA). The experiments were carried out at pH 7.0 and 8.0. The buffer 
solutions used at pH 7.0 were 10 mM phosphate, 10 mM HEPES, 10 mM sodium 
cacodylate and 10 mM Tris-HCl while at pH 8.0 the buffers used were 10 mM phosphate, 
10 mM HEPES, 10 mM Tricine and 10 mM Tris-HCl. Sufficient NaCl was added to each 
buffer solution to bring the total [Na+] to 50 mM. The experiments at pH 7.0 were carried 
out at 25 ºC and 37 °C while those at pH 8.0 were carried out at 25 ºC. The heat capacity 
change (∆Cp) associated with the binding of either neomycin sulfate or paromomycin 
sulfate to CMD-PEG was determined in sodium cacodylate buffer (10 mM, pH 7.0) by 
performing additional experiments at 20 ºC and 45 ºC. Solutions of neomycin sulfate, 
paromomycin sulfate and CMD-PEG were prepared in the buffers and their pH values were 
adjusted as required. Prior to measurements all the solutions were degassed under vacuum 
for about 10 min to eliminate any air bubbles. In a typical experiment, 10 µL aliquots of 
neomycin sulfate solution (6.0 g/L, 6.6 mM, 39.6 mM amine) or paromomycin sulfate 
solution (5.65 g/L, 7.92 mM, 39.6 mM amine) were injected from a 300 µL continuously 
stirred (300-rpm) syringe into a 1.43 mL sample of CMD-PEG solution (0.75 g/L, 2.61 mM 
carboxylate). Heats of dilution and mixing were determined in control experiments by 
injecting aliquots (10 µL) of each drug solution into the same buffer (1.43 mL). A total of 
28 aliquots were injected into the sample cell in intervals of 300 s. The calorimetric data 
were analyzed and converted to enthalpy change using Microcal ORIGIN 7.0. The enthalpy 
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change for each injection was calculated by integrating the area under the peaks of the 
recorded time and then corrected with control experiments. The binding parameters (N, K, 
∆H, ∆S) were determined by fitting the data using the fitting models available in Microcal 
ORIGIN 7.0 software.  
4.4.2.4. 1H NMR spectra of aminoglycosides/CMD-PEG mixtures 
 Specified volumes of aminoglycosides stock solutions in D2O were added dropwise 
to a magnetically stirred solution of CMD-PEG in D2O over a period of 10 min in amounts 
such that [amine]/[carboxylate] ranged from 1.0 to 5.0. The [amine]/[carboxylate] is the 
ratio of the molar concentrations of amino groups provided by the drugs to that of 
carboxylate groups provided by the polymer. The effect of salt on different neomycin 
micelles was studied by preparing the micelles in D2O at pH 7.4 and [NaCl] = 150 mM 
(polymer concentration: 2.0 g/L; [amine]/[carboxylate] = 2.5). 
4.4.2.5. Light scattering studies 
Dynamic light scattering experiments (DLS) were performed on a CGS-3 
goniometer (ALV GmbH) equipped with an ALV/LSE-5003 multiple-τ digital correlator 
(ALV GmbH), a He-Ne laser (λ = 632.8 nm), and a C25P circulating water bath (Thermo 
Haake). A cumulant analysis was applied to obtain the diffusion coefficient (D) of the 
micelles in solution. The hydrodynamic radius (RH) of the micelles was obtained using the 
Stokes-Einstein equation (1),  
 
Hs
B
R6
TkD
πη
=                                                                      (1)  
where ŋs is the viscosity of the solvent, kB is the Boltzmann constant, and T is the absolute 
temperature. The constrained regularized CONTIN method was used to obtain the particle 
size distribution. The data presented are the mean of six measurements ± S.D.  Solutions for 
analysis were filtered through a 0.45 μm Millex Millipore PVDF membrane prior to 
measurements. 
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4.4.2.6. Preparation and characterization aminoglycosides/CMD-PEG micelles 
4.4.2.6.1. General method 
Stock solutions of CMD-PEG or dodecyl-CMD-PEG (1.0 g/L) and aminoglycosides 
(4.96 and 5.27 g/L for paromomycin sulfate and neomycin sulfate, respectively) were 
prepared in phosphate buffer (10 mM, pH 7.0). Specified volumes of the drugs solutions 
were added dropwise to a magnetically stirred polymer solution over a 10-min period to 
obtain solutions with [amine]/[carboxylate] ratio ranging from 1.0 to 5.0. The volume of 
each sample was adjusted to 2.5 mL by the same buffer. CMD-PEG concentration was 0.2 
g/L in all samples. Hydrodynamic radius (RH), polydispersity index (PDI) and intensity of 
scattered light of an aliquot of the samples were determined by DLS. 
4.4.2.6.2. pH studies  
 A micellar solution (polymer concentration: 0.2 g/L; [amine]/[carboxylate] = 2.5) 
was prepared in phosphate buffer (10 mM, pH 7.0) following the general procedures 
described above. Aliquots of this solution were treated with either 1.0 N NaOH or 1.0 N 
HCl to obtain solutions with pH values ranging from 9.0 to 2.0. After each pH adjustment, 
the sample was magnetically stirred for 5 min before measurements. Solutions of polymers 
alone (in absence of drugs) were treated in the same way described above and used as 
controls. RH, PDI and intensity of scattered light were determined by DLS. The mean ± 
S.D. of six measurements were determined.  
4.4.2.6.3. Effect of salt (NaCl) on micelles formation and stability 
Micellar solutions (polymer concentration: 0.5 g/L; [amine]/[carboxylate] = 2.5) 
were prepared in 10 mM phosphate buffer (10 mM, pH 7.0). Aliquots of a NaCl stock 
solution (2.5 M) in the same buffer were added to the micellar solutions in volumes such 
that [NaCl] in the sample ranged from 10 to 400 mM. The mixture was stirred for 5 min 
and the volume of each sample was adjusted to 2.5 mL with the same buffer. pH of 
solutions having [NaCl] = 150 mM  was increased to 7.4 by the addition of 1.0 M NaOH, 
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followed by overnight stirring. RH, PDI and intensity of scattered light were determined by 
DLS. The mean ± S.D. of six measurements were determined. 
4.4.2.7. Effect of freeze-drying on micelles integrity 
Micellar solutions (polymer concentration: 0.2 g/L; [amine]/[carboxylate] = 2.5) in 
a phosphate buffer (10 mM, pH 7.0) were frozen by placing the glass vials containing the 
samples in a dry ice/acetone mixture (temperature: -78 ºC).  After 30 min the vials were 
placed in the freeze-dryer and lyophilized for 48 h.  The resulting powder was rehydrated 
with deionized water to reach a polymer concentration of 0.2 g/L. The resulting mixture 
was stirred at room temperature for 10 min and analyzed by DLS.  
4.4.2.8. Effect of dilution on micelles integrity 
 Micellar solutions were prepared as described above in phosphate buffer (10 mM, 
pH 7.0) with a polymer concentration of 0.5 g/L and [amine]/[carboxylate] = 2.5. The 
micelles were serially diluted to different polymer concentration using the same buffer and 
hydrodynamic radius and intensity of light scattered of aliquots were determined by DLS. 
The relative scattered light intensity (intensity of scattered light at certain polymer 
concentration/intensity at polymer concentration of 0.5 g/L) was plotted against polymer 
concentration. Critical association concentration (CAC) was determined from the plot 
following methods reported previously.[20]  
4.4.2.9. Drug release studies 
 The release of neomycin from micelles was evaluated by the dialysis bag method at 
37 ºC. The micellar solution (3.0 mL, neomycin: 2.0 g/L, [amine]/[carboxylate] = 2.5) was 
introduced into a dialysis membrane of MWCO = 6.0-8.0 kDa and dialyzed against 25 mL 
of 10 mM phosphate buffer containing either 0 mM NaCl (pH 7.0 or 7.4) or 150 mM NaCl 
(pH 7.0 or 7.4). A control experiment to determine the drug diffusion through the dialysis 
membrane was carried out in the absence of the polymer. At predetermined time intervals, 
5 mL aliquots were taken from the release medium and replaced by equal volumes of fresh 
buffer. Neomycin concentration in the release samples was determined using the 
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derivatizing agent o-phthaldialdehyde following reported procedures.[25] Briefly, 1 mL of 
each sample was mixed with 1 mL of o-phthaldialdehyde solution in isopropanol (1 
mg/mL). Next, 1.5 mL isopropanol was added to prevent precipitation of neomycin/o-
phthaldialdehyde complex and the volume of each sample was completed to 5.0 mL by 
borate buffer (50 mM, pH 9.0). The samples were allowed to stand for 1 h at room 
temperature. Subsequently, neomycin concentration was determined using a UV–visible 
spectrophotometer at the wavelength corresponding to maximum absorbance of 
neomycin/o-phthaldialdehyde complex (λmax = 335 nm). A calibration curve of neomycin 
was prepared before each determination.   
4.4.2.10. Minimal inhibitory concentration (MIC) determination 
 Micelles of aminoglycosides/CMD-PEG were prepared in deionized water at drug 
concentration of 0.3 g/L and [amine]/[carboxylate] = 2.5. Micellar solutions were diluted 
using sterile Luria-Bertani media (LB) in a 96 wells plate to get drug concentrations of 
0.25, 0.50, 0.75, 1.00, 2.00, 4.00, 8.00, 16.0 and 32.0 µg/ mL. E. coli X-1 blue strain was 
grown at 37 °C in 2 mL sterile LB to mid log phase (until absorbance at 595 nm reaches 
0.6) and this suspension was shaken for homogeneity before adding 1 μL in each well. 
Blank samples were prepared without E. coli X-1 blue strain. After shaking the plate at 37 
°C for 5 h, the absorbance at 595 nm of each well was monitored. The lowest concentration 
at which the absorbance at 595 nm was the same as the blank samples was considered to be 
the MIC. MIC determination was done in triplicate in all cases. 
4.5. Results and discussion  
4.5.1. Isothermal titration calorimetry (ITC) studies 
PIC micelles formation relies on electrostatic interactions between an ionic 
copolymer and an oppositely charged drug.[26-28] In vitro and in vivo performance of PIC 
micelles depends to a large extent on the strength of these electrostatic interactions.[29] This 
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necessitates a thorough characterization of these interactions and understanding the factors 
affecting them.  
4.5.1.1. Buffer and pH dependence of aminoglycosides and CMD-PEG interactions 
We used ITC to study the binding of neomycin sulfate and paromomycin sulfate to 
CMD-PEG at 25 and 37 ºC in four buffers with different ionization enthalpies (∆Hion) at pH 
7.0 and 8.0. Figure 4.3 shows the corrected integrated heats for the titration of neomycin 
(panels A, B and E) and paromomycin (panels C, D and F) into CMD-PEG in four different 
buffers at pH 7.0 (panels A, C, E and F) and 8.0 (panels B and D). The integrated heats of 
the interaction were corrected by subtracting the corresponding dilution heats resulting 
from injecting identical amounts of drugs into buffers. The thermodynamic parameters 
resulting from the data fit are presented in Table 4.1, 4.2 and 4.3. By inspecting Figure 4.3 
and Table 4.1, 4.2 and 4.3, one notices that at pH 7.0 and 8.0 at either 25 ºC or 37 ºC, the 
binding of neomycin and paromomycin to CMD-PEG was exothermic in the following 
buffers: cacodylate, HEPES, Tricine and phosphate and endothermic in Tris-HCl. The 
observed enthalpy change (∆Hobs) was buffer dependent and its magnitude at pH 7.0 
followed the following order: cacodylate > phosphate > HEPES > Tris-HCl whereas at pH 
8.0 the order was: phosphate > HEPES > Tricine > Tris-HCl.  This signifies that the 
observed enthalpy change (∆Hobs) was not intrinsic to the binding of neomycin and 
paromomycin to CMD-PEG but it also contains contribution from the buffer ionization. 
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Figure 4.3. Corrected integrated injection heats plotted as a function of the 
[amine]/[carboxylate] ratio for the titration of either neomycin sulfate (A, B, E) or 
paromomycin sulphate (C, D, F) into CMD-PEG copolymer in different buffers at pH 7.0 
(A, C, E, F) or 8.0 (B, D) at 25 °C (A, B, C, D) or 37 °C (E, F). 
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Table 4.1. Thermodynamic parameters for the binding of neomycin sulfate to CMD-PEG at pH 7.0 and 8.0, at 25 °C and a Na+ 
concentration of 50 mM.   
pH 7.0 pH 8.0 
Binding 
parameter 
Cacodylatea Phosphatea HEPESa Tris-HCla Phosphateb HEPESb Tricineb Tris-HClb 
N 3 3 3 3 0.3± 0.02 0.52± 0.02 0.63±0.02 0.46± 0.009 
K  (X103)(M-1) 6.02 ± 1.6 0.89 ± 0.57 59.9± 98 2.69±0.59 6.64± 2.4 2.49±0.34 2.59 ±0.3 1.54±0.06 
∆Hobs (kcal/mol) -2.51±0.09 -1.25± 0.25 -0.77± 0.03 0.61 ±0.01 -2.45 ± 0.30 -1.81±0.10 -0.92±0.03 0.52±0.01 
T∆Sobs (kcal/mol) 2.63 2.77 5.75 5.30 2.75 2.81 3.72 4.88 
∆G (kcal/mol) -5.15 -4.02 -6.52 -4.69 -5.2 -4.62 -4.64 -4.36 
 
a: Data was fitted using a model for three sequential binding sites. 
b: Data was fitted using a model for single set of binding sites. 
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Table 4.2. Thermodynamic parameters for the binding of paromomycin sulfate to CMD-PEG at pH 7.0 and 8.0, at 25 °C and a Na+ 
concentration of 50 mM.  
pH 7.0 pH 8.0 
Binding parameter Cacodylatea Phosphatea HEPESa Tris-HClb Phosphateb HEPESb Tricineb Tris-HClb 
N 3 3 3 0.72±0.00 0.55± 0.02 0.40± 0.02 0.58±0.02 0.53± 0.04 
K  (X103) (M-1) 14.1±4.2  1.83± 0.09 2.63±0.58 2.69±0.05 1.3±0.12 0.82 ±0.04 0.89±0.04 1.25 ±0.19 
∆Hobs (kcal/mol) -1.53±0.01 -1.20±0.01 -0.66±0.02 0.53±0.00 -3.04±0.18 -2.06±0.12 -0.73±0.03 0.33 ±0.03 
T∆Sobs (kcal/mol) 4.11 2.97 3.65 5.21 1.2 1.91 3.27 4.55 
∆G (kcal/mol) -5.64 -4.17 -4.31 -4.68 -4.24 -3.97 -4.00 -4.22 
 
a: Data was fitted using a model for three sequential binding sites. 
b: Data was fitted using a model for single set of binding sites. 
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Table 4.3. Thermodynamic parameters for the binding of neomycin sulfate and paromomycin sulfate to CMD-PEG at pH 7.0 and at 37 °C 
and a Na+ concentration of 50 mM.  
Neomycin Paromomycin 
Binding parameter Cacodylatea Phosphatea HEPESa Tris-HCla Cacodylatea Phosphatea HEPESa Tris-HClb 
N 3 3 3 3 3 3 3 0.73 ± 0.01
K  (X103)(M-1) 2.96± 1.3 0.93 ± 0.34 3.06± 0.98 1.87±0.41 1.67±0.08  2.05±0.07 3.63±0.6 1.72±0.14 
∆Hobs (kcal/mol) -2.96 ±0.16 -2.27± 0.26 -1.02± 0.06 0.50 ±0.02 -2.69±0.02 -1.72±0.01 -0.77±0.01 0.39 ±0.01 
T∆Sobs (kcal/mol) 1.95 1.94 3.90 5.14 1.87 2.96 4.27 4.99 
∆G (kcal/mol) -4.91 -4.21 -4.92 -4.64 -4.56 -4.68 -5.04 -4.60 
 
a: Data was fitted using a model for three sequential binding sites. 
b: Data was fitted using a model for single set of binding sites. 
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According to the proton linkage theory, the observed enthalpy change (∆Hobs) is 
related to buffer ionization by the following relationship[30]: 
∆Hobs = ∆Hint + ∆n ∆Hion                     (2) 
Where  ∆Hint is the intrinsic binding enthalpy (the enthalpy that is determined in a buffer 
with negligible ionization enthalpy), ∆n is the number of protons released or uptaken 
during the binding and ∆Hion  is the buffer heat of ionization. Thus, by plotting ∆Hobs against 
∆Hion of different buffers, the slope of the straight line gives the number of protons linked 
to binding and the intercept gives the intrinsic binding enthalpy (∆Hint). The binding is 
accompanied by proton release to the buffer if the slope is negative and by proton uptake 
from the buffer if the slope is positive. The relationship between ∆Hobs and ∆Hion was linear 
with positive slopes in all cases signifying that the binding of neomycin and paromomycin 
to CMD-PEG was accompanied by proton uptake from the buffers (Figure SI 4.4). The 
numbers of protons uptaken during the binding, as well as the intrinsic thermodynamic 
parameters are listed in Table 4.4. The pKa values of neomycin sulfate amino groups range 
from 6.92 to 9.51 while those of paromomycin sulfate range from 7.07 to 9.46.[31]  The pKa 
values of the free base forms are 5.74-8.8 for neomycin [32] and 6.5-9.13 for 
paromomycin.[33] At pH 7.0, the fraction (fion) of a given drug amino group of known pKa 
that exists in the protonated (-+NH3) state is given by the Henderson-Hasselbalch equation 
(Equation 3): 
 
 
Based on this equation, at pH 7.0 neomycin sulfate has 5.33 out of its 6 amino 
groups in ionized state while neomycin free base has 4.5 amino groups in ionized state. At 
the same pH, paromomycin sulfate has 4.41 out of its 5 amino groups in ionized state while 
paromomycin free base has 3.98 protonated amino groups. Thus, in order to be fully 
protonated at pH 7.0 and 25 ºC, neomycin sulfate should uptake 0.67 protons from the 
buffer (0.11 proton/amino group) while neomycin free base needs 1.5 protons (0.25 
protons/amino group). Paromomycin sulfate needs 0.59 protons (0.11 protons/amino group) 
while paromomycin free base needs 1.02 protons (0.20 protons/amino group) to attain full 
1 
(3) fion = 
1+107-pKa
170 
 
 
 
ionization state. The protons needed to achieve full ionization state are uptaken from the 
buffers. Data in Table 4.4 shows that ∆n uptaken by neomycin and paromomycin at pH 7.0 
and 25 ºC to attain full ionization is closer to the number of protons needed by the free base 
form and not the sulfate salt form for both drugs. This indicates that the complex formation 
takes place between CMD-PEG and the free base form of the drug, even though the sulfate 
forms were used in the experiments. Barbieri and Pilch[33] reported similar findings for the 
binding of paromomycin sulfate to the 16S rRNA A-site. They attributed their findings to 
the dilute state of paromomycin sulfate in the experiments (drug concentration: 0 to 45 µM) 
or to the presence of 150 mM NaCl, which, according to the authors, breaks electrostatic 
bond between the drug amino groups and the sulfate anions. 
Table 4.4. Intrinsic thermodynamic parameters and number of uptaken protons for the 
binding of paromomycin sulfate and neomycin sulfate to CMD-PEG at pH 7.0 (25 °C and 
37 °C) and at pH 8.0 (25 °C) and a Na+ concentration of 50 mM.  
 pH 
T  
(°C) 
∆na  
 
∆Hint b 
(kcal/mol) 
T∆Sintc 
(kcal/mol) 
∆Gd 
 (kcal/mol) 
Neomycin 
7.0 25 0.23 ± 0.10 -1.99 ± 0.15  3.1 ± 0.9 -5.09 ± 1.05 
7.0 37 0.29 ± 0.01 -2.68 ± 0.20 1.99 ± 0.13 -4.67 ± 0.33 
8.0 25 0.29 ± 0.02 -3.03 ± 0.29 1.67 ± 0.06 -4.70 ± 0.35 
Paromomycin 
7.0 25 0.17 ± 0.00 -1.45 ± 0.01 3.16 ± 0.49 -4.61 ± 0.50 
7.0 37 0.24 ± 0.00 -2.24 ± 0.01 2.48 ± 0.20 -4.72± 0.21 
8.0 25 0.34 ± 0.01 -3.54 ± 0.19 0.56 ± 0.05 -4.10 ± 0.14 
 a: Number of protons uptaken per amino group. 
b: Obtained from equation 2. 
c: Calculated using the standard relationship T∆Sint = ∆Hint - ∆G  
d: Calculated using the standard relationship   ∆G = -RT ln K 
 
Similar behaviour observed in our experiments under relatively higher drug 
concentration (6.6 mM for neomycin and 7.92 mM for paromomycin) and lower salt 
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concentration (50 mM NaCl), warrants investigation into the reason behind this 
observation. Proton uptake has also been observed during the interaction between different 
cationic compounds and DNA and was attributed to shift of pKa of the cationic species to 
higher values upon binding. [34-36] The number of protons uptaken during the binding (∆n) 
of neomycin and paromomycin to CMD-PEG increased by increasing pH of the solution. 
Thus, pH increase form 7.0 to 8.0 resulted in increasing ∆n from 0.23 to 0.29 protons/NH2 
for neomycin and from 0.17 to 0.34 protons/NH2 for paromomycin (Table 4.4). The 
increased ∆n resulted in more exothermic ∆Hobs since the proton uptake is an exothermic 
process (Figure 4.3).[34]  Similar observations were reported for the binding of neomycin 
and paromomycin to the A site of 16S rRNA.[37] Similar increase in ∆n was observed by 
increasing temperature from 25 to 37 °C at pH 7.0 (Table 4.4), which may be attributed to 
the temperature-induced decrease in pKa. pKa values of paromomycin amino groups were 
reported to decrease by an average of 0.026 pH units per 1 ºC increase in temperature.[33]  
4.5.1.2. Intrinsic thermodynamic parameters for binding of neomycin and 
paromomycin to CMD-PEG 
Thermodynamic parameters listed in Table 4.4 are intrinsic to the binding of 
neomycin and paromomycin to CMD-PEG and are independent of the buffers used. At pH 
7.0 and 25 °C, the entropic contribution (T∆Sint) to the binding was 3.10 and 3.16 kcal/mol 
for neomycin and paromomycin, respectively. Thus, at pH 7.0 and 25 ºC, the entropy 
change (T∆Sint) accounts for 61 and 68% of the driving force for the binding of neomycin 
and paromomycin to CMD-PEG, respectively. This observation is in good agreement with 
a report on the binding of the same drugs to the A site of 16S rRNA for which it was 
reported that 72% of the driving force for the binding of paromomycin to RNA was derived 
from entropic contributions.[31] Electrostatic interactions between aminoglycosides and 
either RNA or CMD-PEG are associated with counter ions release, which results in entropy 
gain of the system. [38, 39] A temperature increase from 25 to 37 °C at pH 7.0 reduced T∆Sint 
for both neomycin and paromomycin (Table 4.4). A pH increase from 7.0 to 8.0 at 25 °C 
resulted in a more pronounced decrease of T∆Sint. The decrease in T∆Sint as the temperature 
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or pH increases is attributed to the increase in the number of protons uptaken (∆n) during 
the binding of neomycin and paromomycin to CMD-PEG (Table 4.4). Being an 
enthalpically favoured process, proton uptake increases the enthaplic contribution and 
decreases the entropic contribution to the binding free energy. Entropy loss as a result of 
temperature or pH increase was nearly compensated for by the gain in enthalpy (∆Hint) 
resulting in an average decrease of ∆G of around 0.4 kcal/mol with the increase in 
temperature or pH (Table 4.4). The data in Table 4.4 shows also that neomycin has more 
binding affinity to CMD-PEG than paromomycin at 25 ºC and pH 7.0. The higher binding 
of neomycin is enthalpic in origin due to the difference in ∆n, which was higher for 
neomycin (0.23 protons/NH2) compared to that of paromomycin (0.17 protons/NH2).  
4.5.1.3. Heat capacity change (∆Cp) determination 
The heat capacity change (∆Cp) upon binding of neomycin and paromomycin to 
CMD-PEG was determined by carrying out ITC experiments for solutions at different 
temperatures under identical pH and buffer conditions. The heat capacity change at 
constant pressure is the temperature derivative of the enthalpy change (equation 4).  
 
 
 
Plotting ∆Hobs versus temperature yields ∆Cp as the slope of the straight line. We 
determined ∆Cp for the binding of neomycin and paromomycin to CMD-PEG in sodium 
cacodylate buffer at pH 7.0 by carrying out ITC experiments at 20, 25, 37 and 45 °C. ∆Cp 
values were -243.3 and -324.95 cal.mol-1.K-1 for neomycin and paromomycin, respectively. 
These values are not attributed to electrostatic interactions only but should also contain 
contribution from hydrophobic and other interactions. Similar negative ∆Cp values were 
reported for the interaction between dextran sulfate and a series of positively charged 
drugs.[40] Heat capacity changes reflect change in solvent accessible surfaces upon binding. 
Burial of non polar surfaces results in negative ∆Cp while burial of polar surfaces gives 
p 
(4) 
∂ ∆Hobs 
∂ T 
∆Cp = 
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positive ∆Cp.[41, 42] Electrostatic interactions are also known to increase the magnitude of the 
negative values of ∆Cp.[40, 43, 44]  
4.5.2. 1H NMR studies 
We used 1H NMR to probe the structure of the PIC micelles formed by electrostatic 
interactions between CMD-PEG and either neomycin sulfate or paromomycin sulfate. 
Previous studies showed that the formation in water of nanoparticles with core-corona 
structures can be detected by 1H NMR spectroscopy.[45, 46] This takes advantage of the fact 
that protons of the polymer segments forming the core have restricted movement and thus, 
their signals appear broad or did not appear at all. In contrast, protons of the polymer 
segments forming the corona maintain their mobility and their signals appear well resolved.  
1H NMR spectrum of neomycin sulfate (Figure 4.4A) shows three signals for the three 
anomeric protons on the three amino sugars at 5.2, 5.34 and 5.87 ppm. The axial and 
equatorial methylene protons on the substituted cyclohexane ring resonate at 1.66 and 2.2 
ppm, respectively. The other neomycin protons show a series of signals between 3.16 to 
4.45 ppm.[47] Figure 4.4B shows the 1H NMR spectrum of CMD-PEG, which presents 
signals at δ 4.08-4.15, 4.89, and 5.07 ppm, ascribed to protons of the CMD block, and a 
broad strong singlet centered at δ 3.61 ppm due to the PEG methylene protons (-CH2-CH2-
O-).[20] The spectrum of neomycin/CMD-PEG micelles ([amine]/[carboxylate] = 2.5, pH 
7.4, [NaCl] = 0 mM) (Figure 4.4C) features only a strong signal at δ 3.61 ppm, ascribed to 
PEG protons. The signals due to the protons of neomycin and CMD segment of the 
polymer disappeared almost completely confirming the formation of PIC micelles with 
neomycin/CMD core and PEG corona (Figure 4.4C). Spectra of micelles prepared at 1.5 ≤ 
[amine]/[carboxylate] ≤ 2.5 were similar to that presented in Figure 4.4C. Micelles having 
[amine]/[carboxylate] < 1.5 or > 2.5 showed signals characteristic of free drug. This 
confirms that maximum drug loading was achieved for mixture having 
[amine]/[carboxylate] = 2.5. Micelles of this composition have 50 wt% drug, which was 
taken as the actual drug loading since their NMR spectrum shows no signals of free drug 
(Figure 4.4C). The stability of these micelles was challenged by recording their 1H NMR 
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spectrum under physiological conditions (pH 7.4, [NaCl] = 150 mM) (Figure 4.4D). Under 
these conditions, the micelles showed signs of disintegration as evidenced by the 
appearance of signals characteristic of neomycin protons (indicated by arrows in Figure 
4.4D). The micelles disintegration is not complete, however since the intensity of neomycin 
peaks is much smaller than that of neomycin alone recorded under similar conditions 
(Figure 4.4A). Identical 1H NMR experiments performed on the paromomycin/CMD-PEG 
micelles showed results similar to those of neomycin /CMD-PEG.  
Salt-induced disintegration has been observed for several PIC micelles and was 
attributed to the weakening of electrostatic interactions in the micelles core.[48] PIC micelles 
ability to resist salt-induced disintegration depends on many factors including strength of 
the electrostatic interactions, pKas of the interacting groups, presence of additional driving 
forces (e.g. hydrophobic interactions, hydrogen bonding) and polymer architecture. 
Hydrophobic modifications of polymers and cross linking of micelles core have been 
suggested for PIC micelles stabilization.[49, 50] Yuan et al., reported that PIC micelles of 
lysozyme/poly(ethylene glycol)-b-poly(aspartic acid) with hydrophobic groups (phenyl, 
naphthyl and pyrenyl) attached to the ω-end of the polymer had smaller critical association 
concentration and better tolerability to salt-induced disintegration.[49] Herein we 
hypothesize that hydrophobically modified CMD-PEG could lead to more stable micelles. 
To test this hypothesis, we prepared two hydrophobically modified CMD-PEG polymers 
that differ in the grafting density of dodecyl chains: dodecyl18-CMD-PEG and dodecyl38-
CMD-PEG. 1H NMR spectrum of dodecyl38-CMD-PEG in D2O (Figure 4.4E) shows 
signals characteristic of CMD block (at δ 4.08-4.36, 4.89, and 5.07 ppm) and PEG (at δ 
3.61 ppm), in addition to signals of dodecyl chains (at δ 1.18 ppm for –(CH2)10-CH3 and at 
δ 0.78 ppm for –(CH2)10-CH3).  
To test the ability of dodecyl38-CMD-PEG to stabilize the micelles, 1H NMR spectra 
of its micelles with neomycin were recorded in absence (Figure 4.4F) and presence (Figure 
4.4G) of 150 mM NaCl at pH 7.4. As expected the spectrum of the micelles prepared in the 
absence of salt shows only signals attributed to PEG corona of the micelles (Figure 4.4F). 
Interestingly, neomycin/dodecyl38-CMD-PEG micelles prepared under physiological 
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conditions (pH 7.4, [NaCl] = 150 mM) (Figure 4.4G) did not show any signs of micelles 
disintegration. This confirms the ability of this copolymer to stabilize the micelles against 
salt-induced disintegration. These results were confirmed by other techniques, such as 
dynamic light scattering studies (see below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. 1H NMR spectra of neomycin sulfate (A), CMD-PEG (B),  neomycin/CMD-
PEG micelles (pH 7.4, 0 mM NaCl) (C), neomycin/CMD-PEG micelles (pH 7.4, 150 mM 
NaCl) (D), dodecyl38-CMD-PEG (E), neomycin/dodecyl38-CMD-PEG micelles (pH 7.4, 0 
mM NaCl) (F) and neomycin/dodecyl38-CMD-PEG micelles (pH 7.4, 150 mM NaCl) (G). 
All micelles were prepared in D2O at polymer concentration of 2.0 g/L, neomycin 
concentration of 2.1 g/L and [amine]/[carboxylate] = 2.5.   
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Table 4.5. Characteristics of aminoglycosides/CMD-PEG micelles ([amine]/[carboxylate] 
= 2.5) in a phosphate buffer (10 mM, pH 7.0) 
Micelle RHa PDI % Drugb
Neomycin/CMD-PEG 74.9±1.8 0.03±0.03 50 
Paromomycin/CMD-PEG 130.1±0.5 0.08±0.03 49.8 
Neomycin/dodecyl18-CMD-PEG 63.3±0.6 0.08±0.05 50 
Paromomycin/dodecyl18-CMD-PEG 48.5±0.4 0.02±0.03 49.8 
Neomycin/ dodecyl38-CMD-PEG 40.5±0.4 0.06±0.03 50 
Paromomycin/dodecyl38-CMD-PEG 54.5±1.2 0.03±0.02 49.8 
6'''-guanidino-paromomycin/CMD-PEG  110±2.2 0.08±0.02 50 
5''-deoxy-5''-guanidino-paromomycin/CMD-PEG 83.8±2.6 0.04±0.05 50 
a: Mean of six measurements ± S.D. 
b: % drug loading = weight of drug/(weight of micelles)×100. 
 
4.5.3. Size of aminoglycosides/CMD-PEG micelles 
Neomycin and paromomycin micelles with different polymers were prepared in 
phosphate buffer (10 mM, pH 7.0) at different [amine]/[carboxylate] ratios. The RH of 
micelles plotted as a function of [amine]/[carboxylate] are presented in Figure 4.5. All 
drug/polymer mixtures prepared at [amine]/[carboxylate] < 1.0 did not scatter enough light 
indicating the absence of nanoparticles. Paromomycin/CMD-PEG micelles at 
[amine]/[carboxylate] = 1.0 showed RH ~100 nm and polydispersity index (PDI) ~ 0.3. 
Increasing [amine]/[carboxylate] to 1.5 resulted in a drop of RH to ~ 70 nm and PDI to 0.2 
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(Figure 4.5A). RH of the micelles gradually increased by further increase in 
[amine]/[carboxylate] probably as a consequence of incorporating more drug in the 
micelles core. RH levelled off at [amine]/[carboxylate] = 2.5, after which it remained 
constant confirming the NMR results that  maximum drug loading was achieved at this 
point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Effect of the [amine]/[carboxylate] molar ratio on the hydrodynamic radius of 
paromomycin sulfate (panel A) and neomycin sulfate (panel B) micelles with different 
polymers: CMD-PEG (▲), dodecyl18-CMD-PEG (●), dodecyl38-CMD-PEG (■). Micelles 
were prepared in phosphate buffer (10 mM, pH 7.0) at polymer concentration = 0.2 g/L.   
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RH of neomycin/CMD-PEG micelles slightly decreased by increasing the 
[amine]/[carboxylate] ratio and levelled off at [amine]/[carboxylate] = 2.5, again reaching 
the maximum drug loading (Figure 4.5B). PDI was < 0.1 for both neomycin and 
paromomycin micelles prepared at [amine]/[carboxylate] > 1.5 indicating the narrow 
particle size distribution of the micelles.[17] Neomycin micelles had smaller size than those 
of paromomycin (Table 4.5) presumably as a result of tighter electrostatic interactions in 
the core of neomycin micelles due to the presence of an additional amino group in 
neomycin (Figure 4.1). This amino group has pKa of 9.24, which makes it fully ionized at 
pH 7.0.[31]  
Figure 4.5 shows also the RH of neomycin and paromomycin micelles prepared with 
dodecyl18-CMD-PEG and dodecyl38-CMD-PEG plotted as a function of 
[amine]/[carboxylate] ratio. Hydrophobic modification of CMD-PEG significantly affected 
the size of its micelles with paromomycin. Thus, paromomycin/CMD-PEG micelles were 
almost twice as big as those of paromomycin/dodecyl-CMD-PEG micelles at identical 
[amine]/[carboxylate] ratios and polymer concentration. Similar effect was observed for 
neomycin micelles (Figure 4.5B). No significant difference in size was detected between 
paromomycin micelles with either dodecyl18-CMD-PEG or dodecyl38-CMD-PEG 
copolymers (Figure 4.5A). Yet, neomycin/dodecyl38-CMD-PEG micelles were smaller than 
those of neomycin/dodecyl18-CMD-PEG (Table 4.5). PIC micelles have well-solvated core 
and corona.[48] The core of aminoglycosides/CMD-PEG micelles is expected to be hydrated 
and swollen since it is formed by hydrophilic compounds (neomycin and paromomycin-
electrostatically linked to CMD segment of the polymer). On the other hand, 
aminoglycosides/dodecyl-CMD-PEG micelles may have less hydrated core due to the 
presence of hydrophobic dodecyl chains. Less hydrated core together with hydrophobic 
interactions between dodecyl chains probably resulted in PIC micelles with tighter core and 
hence, a smaller size. Gao et al., reported similar results where lysozyme /poly(1-
tetradecene-alt-maleic acid) complexes were smaller than those of 
lysozyme/poly(isobutylene-alt-maleic acid), which was attributed to hydrophobic 
interactions in the case of poly(1-tetradecene-alt-maleic acid).[18]    
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4.5.4. Effect of salt on micelles formation and stability  
 Figure 4.6 shows the effect of salt on the neomycin and paromomycin micelles 
integrity in terms of intensity of scattered light and micelles size. Micelles were prepared in 
phosphate buffer (10 mM, pH 7.0) with CMD-PEG and dodecyl-CMD-PEG polymers. 
Turning our attention first to aminoglycosides micelles with unmodified CMD-PEG, 
paromomycin/CMD-PEG micelles rapidly disintegrated upon increasing salt concentration 
(Figure 4.6A). They lost ~ 80% of their scattered light intensity at [NaCl] of 50 mM and 
disintegrated almost completely at [NaCl] of 100 mM. Neomycin/CMD-PEG micelles were 
more resistant to salt-induced disintegration. For instance, they maintained the same 
scattered light intensity for [NaCl] ≤ 50 mM, after which the intensity rapidly decreased 
reaching ~ 30% of the initial value at [NaCl] = 100 mM (Figure 4.6C). The different salt 
tolerance for neomycin and paromomycin micelles may be attributed to stronger 
electrostatic interactions in the core of neomycin micelles due to the presence of an 
additional amino group. Salt had similar effect on the size of both neomycin/CMD-PEG 
and paromomycin/CMD-PEG micelles (Figure 4.6B and D). Size of both micelles 
increased upon increasing [NaCl] up to 50 and 150 mM for paromomycin and neomycin 
micelles, respectively. Further increase in [NaCl] led to decrease in micelles size, probably 
as a sign of micelle disintegration. Salt causes dehydration of the micelles PEG corona, 
which facilitates the formation of bigger micelles.[20] These results of instability of 
aminoglycosides/CMD-PEG micelles under physiological salt concentration (150 mM 
NaCl) are in agreement with those shown by NMR studies (see above). 
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Figure 4.6. Effect of salt on the intensity of scattered light and hydrodynamic radius of 
paromomycin (panels A and B) and neomycin (panels C and D) micelles with different 
CMD-PEG copolymers: dodecyl38-CMD-PEG (■), dodecyl18-CMD-PEG (●), CMD-PEG 
(▲). Micelles were prepared in phosphate buffer (10 mM, pH 7.0) at final polymer 
concentration = 0.5 g/L and [amine]/[carboxylate] = 2.5. Relative scattering intensity = 
intensity at certain salt concentration/ intensity at salt concentration = 0.  
 
Figure 4.6 shows also the effect of salt on the stability of aminoglycosides/dodecyl-
CMD-PEG micelles. Hydrophobic modification of CMD-PEG copolymers greatly 
enhanced the stability of their micelles with aminoglycosides against increase in salinity. 
Thus, the neomycin/dodecyl18-CMD-PEG micelles maintained their initial size and ~ 40 % 
of their scattering intensity at [NaCl] = 150 mM (Figure 4.6C and D). Better ability to resist 
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salt-induced disintegration was achieved by increasing the level of dodecyl modification of 
CMD-PEG. For instance, neomycin/dodecyl38-CMD-PEG micelles maintained the same 
size and ~ 80% of their initial scattered light intensity for salt concentrations up to 200 mM, 
well above the physiological salt concentration. Hydrophobic modification of CMD-PEG 
had a less pronounced effect on paromomycin micelles stability against increase in salinity. 
Yet, the micelles of paromomycin/dodecyl38-CMD-PEG maintained their initial size and ~ 
80% of their initial scattered light intensity at [NaCl] = 100 mM, compared to negligible 
scattered light intensity for paromomycin/CMD-PEG micelles at the same [NaCl]. 
Interestingly, neomycin/dodecyl38-CMD-PEG micelles prepared under physiological 
conditions ([NaCl] = 150 mM and pH 7.4) showed no signs of micelles disintegration even 
after three month of micelles storage at room temperature. From these results it can be 
concluded that the level of CMD-PEG hydrophobic modification, as well as the basicity of 
the aminoglycoside amino groups are major factors determining micelles stability against 
increase in salinity. Enhanced stability of neomycin/dodecyl38-CMD-PEG against salt-
induced disintegration is probably due to the participation of electrostatic and hydrophobic 
interactions in the formation of tighter micelles core. Similar results were reported 
previously for other PIC micelles.[18, 49] 
In addition to hydrophobic modification of CMD-PEG, we prepared guanidylated 
paromomycin as another approach to increase stability of PIC micelles against salt-induced 
disintegration. Guanidine groups are more basic than amino groups, planar and exhibit 
directionality in their hydrogen bonding interactions.[51] Therefore, we hypothesize that 
guanidylated paromomycin could have stronger electrostatic interactions with CMD-PEG 
than paromomycin leading to more stable micelles. To test this hypothesis, we prepared  
6'''-guanidino-paromomycin and 5''-deoxy-5''-guanidino-paromomycin (Figure SI.4.1, 
supporting information) and tested the stability of their micelles with CMD-PEG at 
different salt concentrations. Guanidylated paromomycin showed better ability to withstand 
salt-induced disintegration. Thus, 6'''-guanidino-paromomycin/CMD-PEG micelles retained 
~ 40 % of their initial scattering intensity at 50 mM NaCl compared to ~ 20 % for 
paromomycin at the same salt concentration (Figure SI.4.3A, supporting information). 
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Replacement of paromomycin 5'' hydroxyl group by a guanidine group (5''-deoxy-5''-
guanidino-paromomycin) resulted in a much better stabilizing effect against salt. As 
illustrated in Figure SI.4.3A, 5''-deoxy-5''-guanidino-paromomycin/CMD-PEG micelles 
maintained the same scattered light intensity for [NaCl] ≤ 50 mM and ~ 30% of their initial 
scattered light intensity at [NaCl] = 100 mM. This enhanced stability of guanidylated 
paromomycin micelles might result from stronger interactions between guanidine groups of 
the drug and carboxylate groups of CMD-PEG.  
4.5.5. pH studies 
4.5.5.1. Effect of pH on the self assembly of CMD-PEG and dodecyl-CMD-PEG in 
aqueous solution 
 Figure 4.7 shows the effect of pH on the intensity of light scattered by different 
CMD-PEG polymeric solutions. Intensity of light scattered by unmodified CMD-PEG 
solutions was very small and almost constant over the 2-9 pH range. This indicates that 
CMD-PEG, under these conditions does not self-assemble into nanoparticles. In contrast, 
dodecyl-CMD-PEG showed pH-dependent self assembly. Thus, intensity of light scattered 
by dodecyl-CMD-PEG solutions was small and constant over the pH range 7-9. At pH < 
6.0, intensity of scattered light increased for both dodecyl18-CMD-PEG and dodecyl38-
CMD-PEG and continued to increase with further decrease in pH. Below pH 5.0, intensity 
of light scattered by dodecyl18-CMD-PEG was less than that of dodecyl38-CMD-PEG. At 
pH > 6.0, carboxylate groups of CMD-PEG are ionized leading to electrostatic repulsion 
that prevents self assembly. Dodecyl-CMD-PEG did not show self assembly at pH > 6.0 
probably because electrostatic repulsions between ionized carboxylate groups offset 
hydrophobic attractions by dodecyl chains. Electrostatic repulsions were absent in acidic 
solutions due to neutralization of carboxylate groups, though CMD-PEG did not form 
nanoparticles due to lack of amphiphilicity. In contrast, dodecyl-CMD-PEG formed 
nanoparticles in acidic solutions due to absence of electrostatic repulsions and presence of 
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hydrophobic interactions between dodecyl chains. At pH 3.0, RH of dodecyl38-CMD-PEG 
and dodecyl18-CMD-PEG were 99.72 ± 8.9 nm and 87.81 ± 7.7 nm, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Effect of pH on the intensity of light scattered by polymeric solutions of 
dodecyl38-CMD-PEG (■), dodecyl18-CMD-PEG (▲), and CMD-PEG (●). Solutions were 
prepared in 10 mM phosphate buffer at polymer concentration of 0.2 mg/mL.   
 
4.5.5.2. Aminoglycosides/CMD-PEG micelles 
The solution pH affects the formation and stability of aminoglycosides/CMD-PEG 
PIC micelles since it affects the degree of ionization of both the drugs and the polymer.  We 
examined by DLS the effect of pH on the integrity of different aminoglycosides/CMD-PEG 
micelles in terms of intensity of scattered light and hydrodynamic radius (Figure 4.8). One 
notices that both the intensity of scattered light and RH were almost constant for 4.0 ≤ pH ≤ 
7.0 for all the drugs studied. This pH range corresponds to full ionization of both the drugs 
and polymer. Therefore, electrostatic interactions between the drugs amino groups and 
CMD-PEG carboxylate groups are most favourable. Scattered light intensity decreased by 
decreasing pH below 4.0 signalling the formation of loose drug/polymer associates due to 
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neutralization of CMD-PEG. Similar decrease in scattered light intensity was observed at 
pH values > 7.0 due to neutralization of the drugs.  
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 4.8. Effect of pH on the intensity of scattered light (A and B) and hydrodynamic 
radius (C and D) of CMD-PEG micelles with different aminoglycosides: neomycin (▲), 
paromomycin (Δ), 6'''-guanidino-paromomycin (○) and 5''-deoxy-5''-guanidino-
paromomycin (●). Micelles were prepared in phosphate buffer (10 mM, pH 7.0) at final 
[CMD-PEG] = 0.5 g/L. Relative scattering intensity = intensity at certain pH/ intensity at 
pH 7.0.  
Scattered light intensity for neomycin and 5''-deoxy-5''-guanidino-paromomycin 
micelles at pH 7.4 was higher than that of paromomycin micelles (Figure 4.8). Moreover, 
the size of neomycin and 5''-deoxy-5''-guanidino-paromomycin was smaller than that of 
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paromomycin micelles. These observations may be attributed due to the presence of an 
additional amino group and a guanidine group in neomycin and 5''-deoxy-5''-guanidino-
paromomycin, respectively. These groups are highly basic and are almost completely 
ionized at pH 7.4 resulting in stronger interactions with CMD-PEG carboxylate groups. 
Identical experiments carried out on the micelles of aminoglycosides/dodecyl-CMD-PEG 
showed similar effect of pH on the micelles formation and stability. 
4.5.6. Effect of freeze drying on micelles integrity 
Both neomycin/CMD-PEG and paromomycin/CMD-PEG micelles were readily 
dispersed in distilled water after freeze drying without the need of lyoprotectants. However, 
the freeze drying process increased the size of the micelles from 85.1 ± 1.5 to 118.48 ± 2.8 
nm and from 149.0 ± 4.8 to 168.9 ± 5.4 nm for neomycin and paromomycin micelles, 
respectively. Size of neomycin/ dodecyl18-CMD-PEG micelles also increased after freeze 
drying and reconstitution from 63.3 ± 0.7 nm to 78.8 ± 0.9 nm. In contrast, neomycin/ 
dodecyl38-CMD-PEG micelles showed RH ~ 40 nm both before and after freeze drying, in 
the absence of cryoprotectants showing the ability of these micelles to withstand the 
stresses of the freeze drying process.  
4.5.7. Effect of dilution on micelles stability 
 Micelles used for in vivo applications are subjected to extensive dilution upon 
intravenous administration. Therefore, they should be stable against dilution for a period of 
time long enough to allow delivery of the encapsulated drug to its target.[52] Figure 4.9 
shows the hydrodynamic radius and scattered light intensity plotted as a function of 
polymer concentration for neomycin/CMD-PEG and paromomycin/CMD-PEG micelles. 
Both micelles were prepared in phosphate buffer (10 mM, pH 7.0) at [CMD-PEG] = 0.5 
g/L and serially diluted to different polymer concentrations using the same buffers. 
Micelles dilution decreased the scattered light intensity due to a decrease in micelles 
concentration. Micelles critical association concentration (CAC) (the minimal polymer 
concentration for which micelles can be detected) was determined from the plot as the 
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concentration corresponding to the onset of the increase in the scattered light intensity 
(Figure 4.9).[53]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Effect of dilution on the hydrodynamic radius (A) and relative intensity of 
scattered light (B) for neomycin/CMD-PEG micelles (■) and paromomycin/CMD-PEG 
micelles (●). Relative scattering intensity = intensity at certain CMD-PEG 
concentration/intensity at CMD-PEG concentration of 0.5 g/L.   
The CAC values were 0.0625 and 0.125 g/L for neomycin and paromomycin 
micelles, respectively. Neomycin micelles were more resistant to dilution than those of 
paromomycin as indicated by their lower CAC. This may be attributed to tighter 
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interactions in the core of neomycin micelles due to the presence of an additional amino 
group. The size of both micellar systems was not affected by the dilution and remained 
constant for polymer concentrations as low as 0.05 g/L. 
4.5.8. Drug release studies 
The release of neomycin from its PIC micelles with CMD-PEG and dodecyl38-
CMD-PEG was evaluated by the dialysis bag method (Figure 4.10). Neomycin release 
experiments were carried out in phosphate buffer at different pH values and different salt 
concentrations since these factors are known to affect drug release rate from PIC 
micelles.[20, 28] Neomycin rapidly diffused out through the dialysis membrane in the absence 
of polymers and almost complete release was achieved after 4 h (Figure 4.10). In contrast, 
micelles-encapsulated neomycin showed slower release rate under all the conditions 
studied. Neomycin release rate from the micelles was strongly affected by ionic strength of 
the release medium. For instance, the slowest release rate was detected in phosphate buffer 
at pH 7.0-7.4 and 0 mM NaCl. Under these conditions neomycin was slowly released from 
the micelles where ~ 30% was released after 24 h. Neomycin release rate was significantly 
increased by increasing [NaCl] from 0 to 150 mM. Thus, after 24 h percent drug released 
increased from ~ 30 % at pH 7.4, [NaCl] = 0 mM to ~ 70% at pH 7.4, [NaCl] = 150 mM. 
Higher drug release rate in the presence of 150 mM NaCl confirms that drug is released by 
an ion exchange mechanism.[54] Similar observations were reported for other PIC 
micelles.[28] Despite higher neomycin release rate under physiological conditions (pH 7.4, 
[NaCl] = 150 mM), the micelles were still able to sustain drug release for more than 24 h 
(Figure 4.10). Neomycin release rate from the micelles was not affected by increasing pH 
from 7.0 to 7.4 neither in presence nor in absence of 150 mM NaCl. Neomycin/dodecyl38-
CMD-PEG micelles showed drug release rate that was not significantly different from that 
of neomycin/CMD-PEG micelles.  It is noteworthy that no burst drug release was detected 
even in the presence of high salt concentration confirming that the drug is located in the 
micelles core. Drug located near nanoparticles surface rapidly diffuses out in the release 
medium giving a burst release effect.[28]   
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Figure 4.10. Release profiles at 37 °C in 10 mM phosphate buffer of neomycin from: 
neomycin alone (■); neomycin/CMD-PEG micelles, pH 7.0, [NaCl] = 0 mM (●);  
neomycin/CMD-PEG micelles, pH 7.4, [NaCl] = 0 mM (▼); neomycin/CMD-PEG 
micelles, pH 7.0, [NaCl] = 150 mM (♦); neomycin/CMD-PEG micelles, pH 7.4, [NaCl] = 
150 mM (▲); neomycin/dodecyl38-CMD-PEG micelles, pH 7.4, [NaCl] = 150 mM (○). 
([neomycin] = 2.0 g/L, [amine]/[carboxylate] = 2.5).  
 
4.5.9. Antibacterial activity of micelles-encapsulated aminoglycosides 
ITC studies showed that neomycin sulfate and paromomycin sulfate bind to CMD-
PEG in a pattern similar to their binding to the A site of 16S rRNA.[31, 37] The reason behind 
this similarity may be that binding in both cases is triggered by electrostatic interactions 
between aminoglycosides amino groups and phosphate groups in rRNA or carboxylate 
groups in CMD-PEG. It should be recalled here that the antibacterial activity of 
aminoglycosides derives from their binding to 16S rRNA. Therefore, it was important to 
confirm that interactions between aminoglycosides and CMD-PEG did not affect their 
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ability to bind to 16S rRNA.  Antibacterial activity of many aminoglycosides encapsulated 
in CMD-PEG micelles was evaluated by exposing a test organism (E. coli X-1 blue strain) 
to different drug concentrations and determining the lowest concentration that prevents 
detectable bacterial growth (minimal inhibitory concentration, MIC). Antibacterial activity 
of several aminoglycosides (neomycin, paromomycin, tobramycin and amikacin) was not 
altered by their encapsulation in CMD-PEG micelles. Thus, whether drugs were free or 
encapsulated in PIC micelles, MICs were 2-8, 4-8, 2.5-5 and 2-8 μg/mL for amikacin, 
neomycin, paromomycin and tobramycin, respectively. These results confirm that 
encapsulation of aminoglycosides in CMD-PEG micelles did not reduce their antibacterial 
activity. Similar results were reported for ciprofloxacin encapsulated in 
polyethylbutylcyanoacrylate nanoparticles and amphotericin B encapsulated in poly(lactic-
co-glycolic acid) nanoparticles.[55, 56] 
4.6. Conclusion 
PIC micelles were formed by electrostatic interactions between two 
aminoglycosides: neomycin sulfate and paromomycin sulfate and different CMD-PEG 
copolymers. ITC studies showed that interactions between either neomycin or 
paromomycin and CMD-PEG were accompanied by uptake of protons from the buffer, the 
number of which was pH and temperature dependent. PIC micelles of 
aminoglycosides/CMD-PEG had a core consisting of drug/CMD complex and a PEG 
corona. Aminoglycosides/CMD-PEG micelles were unstable under physiological 
conditions (pH 7.4, [NaCl] = 150 mM). Interestingly, micelles stability under these 
conditions was significantly improved by hydrophobic modification of CMD-PEG. 
Optimal micelle formation (neomycin/dodecyl38-CMD-PEG) resisted salt-induced 
disintegration for up to 200 mM and sustained drug release under physiological conditions 
for more than 24 h. They maintained their integrity after freeze drying and upon storage at 
room temperature for up to 3 months. Favourable micelles properties (e.g. small size, 
ability to withstand increases in salinity and change in pH) were observed for drugs having 
more cationic groups (neomycin and 5''-deoxy-5''-guanidino-paromomycin rather than 
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paromomycin) and polymer having both carboxylate and dodecyl groups (dodecyl-CMD-
PEG rather than CMD-PEG). Other aminoglycosides (e.g. gentamicin, amikacin and 
tobramycin) were also successfully encapsulated in CMD-PEG micelles. Further in vivo 
evaluation of micelles-encapsulated aminoglycosides is under way since preliminary 
experiments indicated that drugs encapsulated in the micelles retained their antimicrobial 
activity.    
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Appendix C. Supporting information (SI.4) 
 
SI.4.1. Synthesis and characterization of guanidylated paromomycin  
SI.4.1.1. Synthesis of compound 3 (6'''-guanidino-paromomycin) (Figure SI.4.1) 
NaOH (0.80 g, 20 mmol) was dissolved in H2O (5 mL) and this solution was added 
to a solution of compound 1 (0.50 g, 0.26 mmol) in 1,4-dioxane (15 mL). After 16 h, a TLC 
indicated a complete consumption of the starting material and showed the formation of a 
new baseline product (mobile phase: CHCl3:AcOH:MeOH, 20:5:3). A MS analysis 
confirmed the formation of the 6'''-NH2 product. m/z calcd for C65H77N5O22 g+: 1280.5, MS 
found: 1280.6. Dioxane was evaporated under reduced pressure, and the free amino 
compound was decanted in the remaining water as a white gum (0.33 g). A minimum of 
MeOH (3 mL) was added to this white gum and this solution was transferred in water (50 
mL) to obtain a white precipitated that was recovered by filtration. Lyophilization afforded 
a dry product to which CHCl3 (20 mL), Et3N (0.11 mL, 0.78 mmol) and reagent 2 (0.21 g, 
0.47 mmol) were added and the solution was refluxed for 18 h. After evaporation of the 
solvent under reduced pressure, the residue was dissolved in a minimum CH2Cl2 and 
loaded onto a silica gel column. The elution was done with 0 to 5% MeOH in CH2Cl2 to 
obtain the desired N-Cbz protected guanidylated paromomycin (0.41 g, 72%). m/z calcd for 
C72H84N7O26 [M+H]+: 1462.5, MS found: 1462.7. This N-Cbz protected guanidylated 
paromomycin (0.41 g, 0.28 mmol) was dissolved in MeOH (5 mL) and H2O was added 
until the solution became cloudy. 20% Pd(OH)2/C (80 mg) and few drops of AcOH were 
added and the suspension was stirred under hydrogen atmosphere (hydrogen balloon) until 
the conversion of the starting material into the product was completed as indicated by MS 
analysis (6 h). The mixture was filtered through a layer of Celite on cotton, concentrated 
under vacuum, washed with CH2Cl2 twice, dissolved in water and lyophilized to afford 
compound 3 (240 mg, 90%) as a per acetate salt. m/z calcd for C24H48N7O14 [M+H]+: 658.3, 
MS found: 658.4.  
Compound 1 was treated with aqueous NaOH to selectively unprotect the 6'''-NH2 
group via a 6 member cyclic carbamate. The resulting free amino group was guanidylated 
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with reagent 2 and N-Cbz hydrogenolysis afforded the desired 6'''-guanidino-paromomycin 
(3). 
 
SI.4.1.2. Synthesis of compound 5 (5''-deoxy-5''-guanidino-paromomycin) 
Compound 4 (1.2 g, 0.86 mmol) was dissolved in THF (30 mL), few drops of H2O 
(0.1 mL) and PPh3 (0.27 g, 1.0 mmol) were added. 18 h later, the solvent was evaporated 
under reduced pressure and the residue was taken in a minimum of CH2Cl2 and loaded on a 
silica gel column. The elution was done with 4 to 8 % MeOH in CH2Cl2 to obtain the pure 
5''-amino compound (0.20 g, 17%). m/z calcd for C70H81N6O23 [M+H]+: 1373.5, MS found: 
1373.8. This 5''-amino compound (0.20 g, 0.15 mmol) was dissolved in CHCl3 (20 mL), 
Et3N (0.041 mL, 0.30 mmol) and reagent 2 (0.80 mg, 0.18 mmol) were added and the 
solution was refluxed for 18 h. After evaporation of the solvent under reduced pressure, the 
residue was dissolved in a minimum CH2Cl2 and loaded onto a silica gel column. The 
elution was done with 2 to 7% MeOH in CH2Cl2 to obtain the desired N-Cbz protected 
guanidylated paromomycin (0.20 g, 83%). m/z calcd for C87H95N8O27 [M+H]+: 1683.6, MS 
found: 1684.0. This N-Cbz protected guanidylated paromomycin (0.20 g, 0.12 mmol) was 
dissolved in 80% aqueous acetic acid (5 mL) and the solution was heated at 60 °C until a 
MS analysis showed total conversion of the starting material into the benzylidene 
deprotected product (5 h). The solution was evaporated under reduced pressure and the 
residue was dissolved in MeOH (3 mL) and H2O was added until the solution became 
cloudy. 20% Pd(OH)2/C (40 mg) and few drop of AcOH were added and the suspension 
was stirred under hydrogen atmosphere (hydrogen balloon) until the conversion of the 
starting material into the product was completed as indicated by MS analysis (6 h) m/z 
calcd for C80H91N8O27 [M+H]+: 1595.6, MS found: 1595.9. The mixture was filtered 
through a layer of Celite on cotton, concentrated under vacuum, washed with CH2Cl2 twice, 
dissolved in water and lyophilized to afford compound 5 (105 mg, 87%) as a per acetate 
salt. m/z calcd for C24H49N8O13 [M+H]+: 657.3, MS found: 657.4.  
In order to obtain a different guanidylated paromomycin, the known compound 4 
was treated with PPh3 under Staudinger conditions and the resulting amine was 
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guanidylated with reagent 2. Benzylidene deprotection with aqueous AcOH followed by N-
Cbz hydrogenolysis afforded the desired 5''-deoxy-5''-guanidino-paromomycin (5). 
 
SI.4.2. Steady-state fluorescence spectroscopy 
Pyrene (1 X10-6 M) was used as a probe to investigate the micropolarity sensed in 
its solubilization site from measurement of the pyrene polarity index (I1/I3), which is the 
ratio of the intensities of the first and third vibronic peaks in the fluorescence spectrum. 
Pyrene was excited at 334 nm and the emission spectra were scanned from 350 to 550 nm. 
The samples studied were dodecyl-CMD-PEG. I1/I3 ratios were plotted versus polymer 
concentration and the critical association concentration (CAC) values were determined 
from the graph as the concentration corresponding to the first drop in I1/I3. 
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Figure SI.4.1. Synthesis of 6'''-guanidino-paromomycin (3) and 5''-deoxy-5''-guanidino-
paromomycin (5). 
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Figure SI.4.2. FTIR spectra of CMD-PEG sodium salt (A), dodecyl38-CMD-PEG free acid 
(B), and dodecyl38-CMD-PEG sodium salt (C) (powder sample) in the region of 1200-1900 
cm-1.   
 
 
 
 
 
 
 
 
 
 
 
Figure SI.4.3. Plot of intensity ratio (I1/I3) of pyrene emission spectra (λex = 335 nm) versus 
concentration of dodecyl18-CMD-PEG (●) and dodecyl38-CMD-PEG (▲) in water.    
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Figure SI.4.4. Observed enthalpy change (∆Hobs) plotted as a function of the buffer heat of 
ionization for the titration of either neomycin sulfate (▲: pH 7.0, 25 °C, R2 = 0.923; □: pH 
7.0, 37 °C, R2 = 0.989; ∆: pH 8.0, 25 °C, R2 = 0.962) or paromomycin sulfate (■: pH 7.0, 
25 °C, R2 = 0.978; O: pH 7.0, 37 °C, R2 = 0.969; ♦: pH 8.0, 25 °C, R2 = 0.984) into CMD-
PEG in different buffers. The solid lines represent the linear regression fit of the 
experimental data. 
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Figure SI.4.5. Effect of salt on the intensity of scattered light (A) and hydrodynamic radius 
(B) of and 6'''-guanidino-paromomycin/CMD-PEG micelles (♦) and 5''-deoxy-5''-
guanidino-paromomycin/CMD-PEG micelles (◊) prepared in phosphate buffer (10 mM, pH 
7.0) at [CMD-PEG] = 0.5 g/L. Relative scattering intensity = intensity at certain salt 
concentration/ intensity at salt concentration = 0. 
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The design and evaluation of new drug delivery systems remain an active area of 
research both in academia and industry.[1] The  aim of these new drug carriers is to 
maximize efficacy of existing and new drugs and to minimize side effects and toxicity 
associated with their administration.[2] To reach this goal, many new delivery systems have 
been devised, amongst which, polymeric nanoparticles are by far the most promising ones. 
Polymers have been a conventional passive component of many drug formulations and it is 
only recently that polymers become active drug carriers. This development was made 
possible by advances in polymer synthesis and polymer physico-chemistry, which resulted 
in custom-made polymers with diverse structures and functionalities.[3] Micelles of 
amphiphilic copolymers, polyion complex (PIC) micelles, dendrimers, polymersomes, 
nanospheres and nanocapsules are examples of polymeric nanoparticles that are being 
currently under extensive investigation. The extraordinary performance of these 
nanoparticles in terms of maximizing drug efficacy, improving patient compliance and 
reducing drug adverse effects have resulted in their appreciation by the pharmaceutical 
industry. A number of successful nanoparticulate drug formulations are already on the 
market while many other are undergoing clinical trials.[4, 5]  
Although polymeric nanoparticles have been widely used for site specific delivery 
of various drugs, their use for the delivery of ionic water soluble drugs is limited due to 
poor encapsulation efficiency. This limitation has been overcome by the advent of a 
relatively new class of polymeric micelles called PIC micelles that opened a new avenue 
for the encapsulation of ionic drugs.[6] PIC micelles enjoy high drug loading efficiency 
since drug encapsulation relies on electrostatic interactions between the ionic drug and an 
oppositely charged copolymer. Other features of PIC micelles that make them attractive 
drug carriers include ease of fabrication, ability to encapsulate a wide range of ionic drugs, 
excellent colloidal and thermodynamic stability, small size and narrow size distribution. 
PIC micelles have been adopted for several applications including gene therapy, cancer 
therapy and many others due to their exciting properties.  
The present project is an attempt to devise PIC micelles formulations that could 
provide effective delivery of two important classes of antibiotics: aminoglycosides and 
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tetracyclines. Aminoglycosides and tetracyclines are broad spectrum antibiotics that need 
new means of their formulation and delivery. For instance, efficacy of aminoglycosides is 
limited by the nephrotoxicity and ototoxicity associated with their use. These side effects 
could be avoided by proper selection of a PIC micelles formulation that selectively 
maximizes drug concentration in diseased tissue and minimizes it in healthy tissues. 
Furthermore, tetracycline antibiotics, such as minocycline have shown new promising 
neuroprotective properties in several animal models.[7] However, minocycline clinical use is 
limited by its instability in aqueous solutions and its poor pharmacokinetics, which could 
be improved by its encapsulation into a suitable PIC micelles formulation. Thus, a novel 
family of carboxymethyldextran-PEG (CMD-PEG) block copolymers suitable for PIC 
micelles formation with cationic drugs, such as aminoglycosides and tetracyclines was 
developed in this project. Dextran was selected partly due to its well known safety and 
biodegradability and partly due to its structural features that allow introduction of different 
functional groups.[8, 9] PEG was selected in view of its hydrophilicity, biocompatibility and 
ability to prolong circulation time of several nanoparticulate drug delivery systems.[10]  
5.1. Synthesis of CMD-PEG block copolymers 
Carboxymethyldextran-block-PEG (CMD-PEG) (Figure 2.1, Chapter 2) is an 
anionic dihydrophilic block copolymer having carboxymethyl (-CH2COONa) groups 
grafted on the dextran chain. The synthesis protocol of DEX-PEG copolymers involved a 
straightforward end-to-end coupling of DEX-lactone and PEG-amine via a lactone 
aminolysis reaction under mild conditions. Conversion of the neutral DEX-PEG 
copolymers into the corresponding polyanionic CMD-PEG copolymers was achieved by 
carboxymethylation of the dextran block. The degree of substitution (DS) of the dextran 
block, defined here as the molar percent of glucopyranose rings bearing –CH2COONa 
groups was readily controlled by varying the reaction conditions. Thus, CMD-PEG 
copolymers with high carboxylate contents were obtained by treating solutions of DEX-
PEG in an isopropanol/water (85/15 v/v) mixture with aqueous NaOH solution (9.0 M) at 
60 ºC followed by addition of monochloroacetic acid.[11] CMD-PEG with moderate 
207 
 
 
 
carboxylate contents were obtained by carrying out the carboxymethylation reaction in 
aqueous solution.[12] CMD-PEG copolymers have a random distribution of carboxymethyl 
groups along the dextran chain. 
5.2. CMD-PEG copolymers candidates 
Electrostatic interactions between polyanionic CMD-PEG copolymers and cationic 
drugs trigger formation of PIC micelles with a drug/CMD ionic complex core and a PEG 
corona. Relative block length of CMD and PEG segments and charge density of the CMD 
block can affect the properties of the resulting PIC micelles.[13-15] To address this issue, four 
CMD-PEG copolymers were prepared: (i) two copolymers identical in terms of the length 
of CMD and PEG blocks, but different in terms of the charge density of the CMD block 
(30-CMD68-PEG64 and 60-CMD68-PEG64); and (ii) two copolymers in which the charged 
block is the same, but the PEG block is of different molecular weight (80-CMD40-PEG64 
and 85-CMD40-PEG140). To select a CMD-PEG copolymer with optimal properties in terms 
of high drug loading, controlled drug release and micelles stability, the micellization of 
these copolymers and a model cationic drug, diminazene diaceturate (DIM) was studied. 
DIM has two amidino groups with pKa of 11 (Figure 2.3, Chapter 2), which makes them 
fully ionized at physiological pH of 7.4.[16] DIM was selected to characterize the micelles of 
different CMD-PEG copolymers since it formed PIC micelles with other polyanionic 
copolymers, such as PEG-b-PAsp and PEG-b-PGlu.[17, 18] Micelles of 85-CMD40-PEG140 
showed the most satisfactory results in terms of drug loading efficiency, controlled drug 
release and micelles stability (Table 5.1). Therefore, this copolymer was selected for 
encapsulation of other cationic drugs, such as aminoglycosides and minocycline.  
5.3. Preparation of CMD-PEG PIC micelles    
PIC micelles are generally prepared by simple mixing of aqueous solutions of the 
oppositely charged polymer and drug. PIC micelles of DIM/CMD-PEG were prepared by 
either drop-wise or “one shot” addition of DIM solution to CMD-PEG solution. Average 
size was almost the same for micelles obtained by both methods. In contrast, micelles 
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prepared by the drop-wise addition method had much smaller polydispersity index (PDI) 
confirming their unimodal size distribution. DIM/PEG-b-PAsp micelles prepared by the 
“one shot” addition method were polydisperse in size (PDI ~ 0.2).[18]  Thus, the drop-wise 
addition method was used for the preparation of CMD-PEG micelles encapsulating 
minocycline and aminoglycosides (AGs) and resulted in monodispersed micelles (PDI < 
0.1).  
5.4. Formation, structure and drug loading of CMD-PEG 
micelles  
CMD-PEG copolymers have carboxylic acid groups with pKa ~ 4.5 while the 
investigated drugs have cationic groups with different pKas:  ~ 11 for DIM amidino groups, 
9.5 for minocycline C4 amino group (Figure 3.1, Chapter 3) and 7.0-9.5 for neomycin and 
paromomycin amino groups (Figure 4.1, Chapter 4). At pH 7.4, these drugs and CMD-PEG 
copolymers have oppositely charged groups that interact together leading to formation of 
PIC micelles. It is noteworthy that electrostatic interactions between DIM and CMD (in the 
absence of PEG) led to phase separation and precipitation. Replacement of CMD with 
CMD-PEG endowed the system with the amphiphilicity required for PIC micelle formation 
(Figure 5.1). 1H NMR studies confirmed that CMD-PEG copolymers formed PIC micelles 
with PEG corona and CMD/drug core with all the studied drugs (i.e., DIM, MH and AGs) 
(Figure 5.1). The entrapment of a drug in the core of nanoparticles is of prime importance 
since this protects the drug against degradation in harsh physiological environments, 
controls the drug release and modifies its pharmacokinetics.[19] For example, MH 
encapsulated in the core of CMD-PEG micelles was significantly more stable against 
degradation in aqueous solutions than the free drug (Figure 3.4, Chapter 3).  
1H NMR was also used to determine the onset of micellization (the [+]/[-] ratio at 
which the micelles form) and [+]/[-] ratio for maximum drug loading. These two properties 
were dependent on the drug and the CMD-PEG copolymer used to formulate the micelles. 
In the case of DIM micelles, the onset of micellization was affected by the molecular 
weight of neither CMD nor PEG. In contrast, it was dependent on the degree of substitution 
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(DS) of the CMD block. Thus, core-corona micelles were observed at [+]/[-] ≥ 0.8 for 
copolymer having DS  ≥  60% and at [+]/[-] ≥ 1.6 for copolymer with DS ≤ 30%. It should 
be recalled here that CMD-PEG copolymers do not form PIC micelles by themselves and 
that a certain number of DIM molecules should be ionically-linked to the polymer chains to 
create the hydrophobic domains necessary for micelles formation. Consequently, the 
polymers having lower DS (i.e., fewer carboxylate groups) needs higher [+]/[-] ratio to 
achieve the same drug concentration obtained at certain [+]/[-] for polymer with high DS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Formation and structure of drug-loaded CMD-PEG PIC micelles. 
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The drugs used in this project have different physicochemical properties, which 
affected the properties of the resulting micelles. Thus, for the same polymer (i.e., 85-
CMD40-PEG140), micelles form at [+]/[-] ~ 1.0 for DIM and MH and at [+]/[-] ~ 2.0 for 
neomycin and paromomycin. This difference is presumably attributed to the presence of 
aromatic rings in DIM (Figure 2.3, Chapter 2) and MH (Figure 3.1, Chapter 3), which assist 
in creating the hydrophobic domains needed for micelles formation. Neomycin and 
paromomycin are very hydrophilic molecules (Figure 4.1, Chapter 4), therefore more drug 
molecules need to be neutralized to achieve the required amphiphilicity. Maximum drug 
loading was also dependent on the drug and the copolymer (Table 5.1). For all the studied 
copolymers and drugs, maximum drug loading was achieved at charge ratios corresponding 
to CMD-PEG neutralization, after which free drug was detectable in solution. This 
confirms that drug encapsulation takes place primarily by electrostatic interactions. 
Interestingly, 85-CMD40-PEG140 copolymer had drug loading capacity  ≥ 50 wt% for all the 
studied drugs showing its potential as a drug delivery system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
 
 
Table 5.1. Characteristics of different CMD-PEG micelles.  
Drug Polymer % Druga RHb CAC (g/L) 
DIM 85-CMD40-PEG140c 64.3 48.7 ± 0.6 0.048 
DIM 80-CMD40-PEG64 62.0 43.5 ± 0.7 0.032 
DIM 60-CMD68-PEG64 60.1 36.9 ± 0.5 0.014 
DIM 30-CMD68-PEG64 41.4 49.7 ± 0.6 0.095 
MH 85-CMD40-PEG140 50 99.0 ± 2.7 ND 
Neomycin 85-CMD40-PEG140 50 74.9±1.8 0.060 
Neomycin dodecyl18-CMD-PEG 50 63.3±0.6 ND 
Neomycin dodecyl38-CMD-PEG 50 40.5±0.4 ND 
Paromomycin 85-CMD40-PEG140 49.8 130.1±0.5 0.120 
Paromomycin dodecyl18-CMD-PEG 49.8 48.5±0.4 ND 
Paromomycin dodecyl38-CMD-PEG 49.8 54.5±1.2 ND 
a: % maximum drug loading = weight of drug/(weight of micelles)×100. 
b: Mean of six measurements ± S.D. RH measured for micelles prepared at [+]/[-] = 2.0 for 
DIM, 1.0 for MH and 2.5 for neomycin and paromomycin. 
c: In this nomenclature, the prefix denotes the degree of carboxymethylation of the dextran 
block; the subscripts designate the average number of glucopyranosyl and –CH2–CH2–O– 
repeat units of the CMD and PEG segments, respectively.  
ND: not determined. 
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5.5. Size and polydispersity of CMD-PEG micelles 
The size and polydispersity of nanoparticles affect their in vivo fate, effectiveness 
and safety. For instance, oral absorption of nanoparticles ~ 100 nm in diameter was 
reported to be 15 to 250-fold higher than that of micro-sized particles.[20] The diameter of 
all CMD-PEG micelles was ≤ 200 nm, except those of paromomycin/85-CMD40-PEG140 
(Table 5.1). This sub-200 nm size and biocompatibility of CMD-PEG copolymers are 
expected to increase the circulation time of the micelles in the blood.[21, 22] The size of 
CMD-PEG micelles was dependent on the drug and copolymer used in micelle formation 
(Table 5.1). For the same copolymer (i.e., 85-CMD40-PEG140), micelles size increased in 
this order: DIM micelles < neomycin micelles < MH micelles < paromomycin micelles. 
The exact mechanism behind this size difference is not clear. However, since the 
copolymer and experimental conditions (polymer concentration, pH and ionic strength) are 
identical, the difference in micelles size could be attributed to different physicochemical 
properties of the encapsulated drugs (e.g. pKa, hydrophilicity/lipophilicity balance and 
molecular weight). Thus, DIM micelles had the smallest size probably due to high basicity 
of the drug amidino groups (pKa = 11), and the presence of hydrophobic aromatic groups 
(Figure 2.3, Chapter 2). Neomycin micelles were smaller than those of paromomycin 
probably because neomycin has an additional amino group (Figure 4.1, Chapter 4). Higher 
basicity of the drugs cationic groups might lead to tighter electrostatic interactions in the 
micelles core, which resulted in smaller micelles.  
The presence of hydrophobic groups along CMD-PEG copolymer chains affected 
the size of their PIC micelles with neomycin and paromomycin (Table 5.1). Thus, dodecyl-
CMD-PEG micelles encapsulating neomycin or paromomycin were significantly smaller 
than those of the corresponding CMD-PEG. Polymeric micelles of amphiphilic copolymers 
have a so-called “solid core” in aqueous solutions due to the generally high glass transition 
temperature, Tg, of the core forming segments and the almost complete absence of solvent 
in the micellar core. In contrast, PIC micelles have a hydrated core since they are formed by 
electrostatic interactions, a relatively weak driving force compared to hydrophobic 
interactions.[15] PIC micelles of dodecyl-CMD-PEG may have hydrophobic interactions 
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between dodecyl chains in the micelles core leading to less hydrated core and thus, smaller 
micelles. Less hydrated core might also be the reason behind smaller size of DIM/60-
CMD68-PEG64 micelles compared to those of DIM/30-CMD68-PEG64 (Table 5.1).  
5.6. Micelles critical association concentration (CAC)       
  Compared to surfactant micelles, polymeric micelles have lower CAC, which 
guarantees their thermodynamic stability against extensive dilution in vivo.[23] CAC of DIM 
micelles with different CMD-PEG copolymers was dependent on the degree of substitution 
(DS) and the length of the dextran block (Table 5.1). The lowest CAC was recorded for 
micelles formed by the copolymer of longest CMD block and highest DS (60-CMD68-
PEG64), presumably as a consequence of their high drug content. The length of the PEG 
block has only a minor influence on the CAC of the micelles, as seen by comparing the 
values determined for 85-CMD40-PEG140 and 80-CMD40-PEG64 (Table 5.1). The CAC was 
also affected by the drug used to formulate the micelles. Thus, CAC of neomycin micelles 
was half that of paromomycin micelles, probably due to stronger electrostatic interactions 
between neomycin and CMD-PEG. 
5.7. Effect of salt on CMD-PEG micelles stability 
Small molecular weight salts weaken electrostatic interactions in PIC micelles core 
leading to micellar dissociation after certain salt concentration.[24] For DIM micelles with 
different CMD-PEG copolymers, micelles ability to withstand salinity was dependent on 
the DS of the dextran block. Thus, micelles of DIM and copolymers of DS ≥ 60% remained 
stable at NaCl concentrations as high as 300 mM, a value significantly higher than the 
physiological salt concentration (150 mM). This was in contrast with micelles of DIM and 
copolymers of DS ≤ 30%, which disintegrated at NaCl concentrations ≥ 100 mM. 
Aminoglycosides micelles were generally less resistant to increase in salinity than DIM 
micelles with the same CMD-PEG copolymer. Moreover, neomycin micelles were more 
resistant to salt-induced disintegration than those of paromomycin probably due to stronger 
interactions in the core of neomycin micelles. Nevertheless, stability of neomycin micelles 
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at physiological salt concentration was not enough to permit in vivo application. To 
increase stability of aminoglycosides micelles, two approaches were devised: hydrophobic 
modification of CMD-PEG by grafting dodecyl chains to the CMD backbone and 
guanidylation of paromomycin. Interestingly, neomycin and paromomycin micelles with 
dodecyl-CMD-PEG were more tolerable to increase in salinity than those with CMD-PEG, 
probably due to participation of hydrophobic interactions between dodecyl chains in 
micelle stabilization. Stability of dodecyl-CMD-PEG micelles was dependent on the drug 
and grafting density of dodecyl chains: more stable micelles were observed for neomycin 
and copolymers having higher dodecyl content. Neomycin/dodecyl38-CMD-PEG micelles 
resisted salt-induced disintegration for NaCl concentration up to 200 mM. Furthermore, 
guanidylated paromomycin/CMD-PEG micelles were more resistant against salt-induced 
disintegration than those of paromomycin, probably because guanidine groups are more 
basic than amino groups.[25] Therefore, stability of CMD-PEG PIC micelles against 
increase in salinity was dependent on the forces that trigger micelle formation (i.e., whether 
electrostatic interactions only or combination electrostatic and hydrophobic interactions) 
and on the ionic charge density of the cationic drug used to form the micelles.  
5.8. Effect of pH on micelle formation and stability 
Solution pH affects the degree of ionization of CMD-PEG carboxylate groups and 
the drugs cationic groups. Thus, there was a pH range for which the drug and CMD-PEG 
had adequate charge density to form stable PIC micelles. For the same polymer (i.e., 85-
CMD40-PEG140), this pH range was dependent on the drug, probably because the studied 
drugs have different pKas. DIM showed the widest pH range of micelles stability: micelles 
were stable in the pH range 4.0-11.0. In contrast, neomycin and paromomycin micelles 
were stable over a narrower pH range (4.0-7.4 and 4.0-7.0 for neomycin and paromomycin, 
respectively). This may attributed to the presence of two amidino groups in DIM (pKa ~ 
11), which remain positively charged at higher pH values compared to the amino groups of 
neomycin (highest pKa ~ 9.5) and paromomycin (highest pKa ~ 9.4).[16, 26] 
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5.9. Stability of CMD-PEG micelles 
  Nanoparticulate drug delivery system should be colloidally stable for periods of 
time long enough to permit accurate dosing, in vitro and to allow safe delivery of the drug 
to its target, in vivo. Furthermore, nanoparticles should maintain their integrity during 
freeze drying and recover their size after reconstitution in a suitable solvent. CMD-PEG 
micelles encapsulating different drugs were colloidally stable in solutions kept at room 
temperature without phase separation or aggregation for periods longer than two months. 
Moreover, all the micelles maintained their size and stability after freeze drying and 
reconstitution in the absence of cryoprotectants, except DIM micelles which needed the 
presence of 5% (w/v) trehalose.  
5.10. Drug release from CMD-PEG micelles 
Following characterization of different drug delivery aspects of CMD-PEG 
micelles, it was necessary to confirm that the micelles can sustain the release of different 
drugs. For DIM micelles, CMD-PEG copolymers of higher DS showed better control over 
the drug release rate. Thus, micelles of copolymers having high DS (e.g., 85-CMD40-
PEG140) released ∼ 50% DIM after 8 h, compared to ∼ 72% after the same time for 
micelles of copolymers having low DS (e.g., 30-CMD68-PEG64). Different drugs 
encapsulated in CMD-PEG micelles were released in a sustained fashion when compared to 
free drugs. For instance, in vitro testing demonstrated that neomycin was slowly released 
from the micelles where ~ 25% drug was released after 8 h, compared to ~ 100% in the 
case of drug alone. CMD-PEG micelles of different drugs showed higher drug release rate 
in the presence of physiological salt concentration, probably as a consequence of 
weakening of electrostatic interactions in the micelles core. Nevertheless, CMD-PEG 
micelles sustained the release of minocycline and neomycin for up to 24 h under 
physiological conditions (i.e., pH 7.4, 150 mM NaCl). This confirms the potential of these 
micelles to reduce the frequency of drug administration.  
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5.11. Cytotoxicity of CMD-PEG copolymers 
Since CMD-PEG copolymers were designed for drug delivery applications, it was 
imperative to evaluate their cytotoxicity in different cell line. Thus, CMD-PEG cytotoxicity 
was evaluated in two cell lines: human hepatocytes and murine microglia. The liver 
represents the main organ in which biotransformation of drugs and foreign substance takes 
place while the inflamed microglia are the main target for minocycline micelles in the 
central nervous system.[27] CMD-PEG did not reduce the viability of both cell lines when 
treated for 24 h at polymer concentrations as high as 15 mg/mL. This confirms the 
biocompatibility of CMD-PEG copolymers. Indeed, these polymers will be diluted in the 
blood stream following IV injection and local concentrations in the liver tissues are not 
expected to reach such high levels. Moreover, the PEG corona of the micelles is expected 
to prolong the micelles circulation in blood and reduce their uptake in the liver, as 
demonstrated previously with other PEGylated nanoparticles.[28]  
5.12. Pharmacological activity of micelles-encapsulated drugs 
The biocompatibility and other favorable properties of CMD-PEG micelles 
warranted biological evaluation of micelles-encapsulated drugs. Thus, anti-inflammatory 
activity of micelles-encapsulated MH was evaluated in murine microglia (N9) cells 
activated by lipopolysaccharides (LPS). Micelles-encapsulated MH reduced inflammation 
in microglia cells to levels similar to those observed for the free drug. Preliminary 
experiments showed that CMD-PEG copolymer (in the absence of MH) reduced LPS-
induced inflammation in N9 microglia, which could enhance the anti-inflammatory activity 
of MH in either additive or even synergistic manner. Furthermore, the minimal inhibitory 
concentration (MIC) in E. coli of different aminoglycosides encapsulated in CMD-PEG 
micelles was comparable to that of free aminoglycosides. These results confirmed that 
different drugs were released from CMD-PEG micelles in a pharmacologically active form. 
Furthermore, the presence of CMD-PEG copolymers did not reduce the pharmacological 
activity of encapsulated drugs.  
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6.1. Conclusions 
Different carboxymethyldextran-PEG block copolymers (CMD-PEG) of tunable 
charge density were developed for the enhanced delivery for cationic drugs. CMD-PEG 
PIC micelles encapsulating different cationic drugs demonstrated several favorable 
properties: high drug loading capacity, small size and colloidal stability in solution and 
after freeze drying. CMD-PEG micelles had a PEG corona and a drug/CMD core. Drug 
encapsulation in the micelles core sustained its release and protected it against degradation 
in aqueous solutions. Different drugs were released from CMD-PEG micelles in a 
pharmacologically active form. Micelles properties were greatly affected by ionic charge 
density of CMD-PEG copolymers and the type of encapsulated drug. To obtain stable PIC 
micelles, ionic charge density and chemical composition of PIC micelles components need 
to be carefully considered. Physiological conditions (pH 7.4 and 0.15 M NaCl) 
compromised stability of some aminoglycosides micelle formulations, which was greatly 
enhanced by hydrophobic modification of CMD-PEG copolymers. A similar strategy may 
be appropriate to stabilize PIC micelles of other ionic copolymers. By virtue of their 
biocompatibility, small size and ability to reduce adsorption of plasma proteins, CMD-PEG 
micelles are expected to be viable delivery systems for cationic drugs. Collectively, the 
results presented in this thesis will assist in understanding the relationship between 
structural features of ionic drugs and polymers and properties of the resulting PIC micelles. 
This will help in the preparation of PIC micelles with optimized properties that can improve 
therapeutic efficacy and reduce side effects of many ionic drugs.       
6.2. Future work 
The encouraging results obtained in this thesis justify in vivo evaluation of a number 
of CMD-PEG formulations. Thus, minocycline and neomycin micelles will be evaluated, in 
vivo to determine their pharmacokinetics and biodistribution. Furthermore, neuroprotective 
effects of minocycline micelles will be evaluated in mice having unilateral cortical cerebral 
ischemia. Micelles of hydrophobically modified CMD-PEG need to be evaluated more in 
depth for better understanding of the mechanism of micelle stabilization. Other ionic 
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copolymers that form unstable PIC micelles will be modified and their stability against 
increase in salinity will be investigated. This will determine whether the observed 
stabilization effect is specific to CMD-PEG or general phenomena. 
When it comes to the usefulness of DEX-PEG copolymers as delivery systems for 
drugs other than the cationic ones, a number of experiments may be suggested. Firstly, 
CMD-PEG copolymers will be exploited as delivery vehicles for hydrophobic drugs (e.g., 
anticancer drugs) by increasing the grafting density of dodecyl chains or using more 
hydrophobic moieties (e.g., PCL). Secondly, DEX-PEG copolymer will be converted into a 
polycation by attachment of positively charged moieties (e.g., arginine) to the dextran 
block. The resulting positively charged polymers will be used as non-viral gene vectors for 
the encapsulation and delivery of DNA, siRNA or oligonucleotides.  
 Appendix D. Supporting information (SI.5): Properties of the 
drugs used in this thesis 
 
1. Diminazene diaceturate (DIM) 
1.1.  Indications 
DIM (Figure SI.5.1) is a cationic molecule belongs to the group of aromatic 
diamidines. DIM is used in tropical countries for the effective treatment of trypanosomiasis 
in cattle, sheep and goats.[1] It is given as an intramuscular injection of 3-5 mg/kg.   
1.2.  Physicochemical properties 
DIM contains two benzamidine moieties linked via a triazene at the 4 position of 
each ring. The triazene link is susceptible to cleavage resulting in the formation of 4-
aminobenzamidine and a 4-amidinophenyldiazonium salt.[2] DIM is unstable under acidic 
conditions where its half-life at pH 3, is 35 min, decreasing to 1.5 min at pH 1.75. The pH-
rate profile of DIM showed a region (pH 1–4) where specific acid catalysis was dominant, 
followed by a transitional region (pH 5–7), and finally a region (pH > 7) where uncatalysed 
degradation was most important.[2] In this thesis DIM was used as a model cationic drug to 
study the effect of relative block length of CMD-PEG copolymer segments and charge 
density of the CMD block on the properties of the resulting PIC micelles. DIM is water 
soluble, readily available and inexpensive. DIM was shown previously to form PIC 
micelles with other anionic block copolymers such as poly(ethylene glycol)-block- 
poly(aspartic acid)[3] and poly(ethylene glycol)-block-poly(L-glutamate).[4]   
 
 
 
Figure SI.5.1. Chemical structure of diminazene diaceturate 
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2. Minocycline hydrochloride (MH) 
2.1.  Indications 
Minocycline hydrochloride (MH) (Figure SI.5.2) is a semisynthetic tetracycline 
antibiotic with a broad spectrum activity against a wide range of microbes including both 
Gram negative and Gram positive bacteria and both aerobes and anaerobes.[5] MH acts by 
binding to the 30S ribosomal subunit of bacterial ribosomes and interferes with protein 
translation, thereby inhibiting bacterial protein synthesis.[6] Minocycline is routinely 
administered orally for the treatment of infectious and inflammatory diseases, such as acne, 
rheumatoid arthritis, and some sexually transmitted diseases, in doses on the order of 3 mg 
kg-1 day-1.[8]  In addition to its antimicrobial activity, recent studies have shown that 
minocycline is effective as a neuroprotective agent in animal models of many diseases such 
as Huntington’s disease[7], Parkinson disease[8], stroke[9], amyotrophic lateral sclerosis[10], 
traumatic brain injury[11], spinal cord injury[12], focal cerebral ischemia[13] and global 
cerebral ischemia.[14] The mechanisms underlying this neuroprotective effect have been 
shown to involve the inhibition of enzymes linked with cytokine production, such as nitric 
oxide synthase and interleukin-1β converting enzyme. More importantly, minocycline was 
shown to have strong, acute anti-inflammatory effects in the brain, as it can penetrate the 
blood brain barrier and inhibit activation of immune cells and microglia, limiting the 
release of cytokines, and reducing the overall neuroinflammation.[15] 
 
 
 
 
Figure SI.5.2. Chemical structure of minocycline hydrochloride 
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2.2.  Physicochemical properties 
Tetracyclines have in common a fused 4-ring structure, and differ in the chemical 
groups at the 5, 6, and 7 positions. MH was first isolated in 1967, and it contains a 
dimethylamino group at the 7 position (Figure SI.5.2).[16] MH, like other tetracycline 
antibiotics, is stable in the dry powder state for at least 3-4 years.[17] In aqueous solutions, 
however, it is unstable and undergoes a number of degradative changes including 
epimerization and oxidation.[18] MH is more susceptible to oxidation than other 
tetracyclines since its D ring (Figure SI.5.2) is a substituted p-amino phenol. The absence 
of hydroxyl groups at both C5 and C6 prevents the formation of anhydro, or iso compounds, 
which are the common degradation products of other tetracyclines. The stability of 
tetracyclines in solution is dependent on the solution pH, being more stable in acidic 
solutions.[18]  The most common transformation reaction of MH is epimerization, a steric 
rearrangement in the configuration of the dimethylamino group at C4 leading to the 
formation of epi-MH.[19] The pharmacological activity of MH epimer is less than 5 % of the 
parent compound. After 24 h storage at room temperature, MH solutions (10 mg/mL) in 5 
% sucrose and phosphate buffered-saline (PBS) pH 7.4 were discoloured and 
precipitated.[15] MH solutions kept at pH 4.2 and 6.2 maintained 90 and 76 % of their initial 
potency after storage for one week at room temperature, respectively.[18]  
2.3.  Biopharmaceutical properties 
MH has a broader antimicrobial activity compared to other tetracyclines.[5] The 
recommended dosage of minocycline is 100 to 200 mg/day.[16] Oral administration of 200 
mg MH results in almost complete absorption, producing a peak serum concentration of 3 
to 5 μg/mL with a half-life of 11 to 13 h.[6] Tetracyclines are ion chelators and compounds 
containing iron, aluminum hydroxide, sodium bicarbonate, calcium or magnesium salts can 
reduce their absorption. For instance, administration of MH with milk reduces its oral 
absorption by 27%.[20] Intravenous administration of 200 mg MH produces peak serum 
concentrations of about 6 μg/mL.[21] Intravenous doses of minocycline in rats producing 
serum concentrations of both 3.6 μg/mL and 13 μg/mL have been shown to reduce infarct 
size in a model of stroke.[22] Therefore, standard MH doses in human are expected to have 
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neuroprotective effects. MH has an isoelectric point of 6.4, which is about one pH unit 
higher than that of other tetracyclines. This allows MH to diffuse more easily into lipoid 
tissues at physiological pH, including brain, thyroid and fat tissues.[17] Therapy with MH is 
well tolerated when it is used for short durations in doses up to 200 mg/day.[9]  Long-term 
treatment, although recognized as generally safe, has resulted in serious side effects in 
some cases. These include gastrointestinal adverse effects and dizziness[23], staining of 
teeth[24], autoimmune hepatitis[25, 26], lupus[27], hypersensitivity syndrome and serum 
sickness[28]. MH is not recommended for use in young children, pregnant women, patients 
who are hypersensitive to tetracyclines, or patients with renal insufficiency. 
3. Aminoglycosides  
3.1.  Indications 
Aminoglycosides (Figure SI.5.3) are a group of structurally diverse polyamines 
either derived from Streptomyces spp. (streptomycin, neomycin and tobramycin) or 
Micromonospora spp. (gentamicin) or synthesised in vitro (netilmicin, amikacin, arbekacin 
and isepamicin).[29] Aminoglycosides are active against a wide spectrum of micro-
organisms, including Gram-positive and Gram-negative bacteria, mycobacteria and 
protozoa. They have been frequently used in the treatment of serious infections caused by 
aerobic Gram negative bacilli such as pneumonia, urinary tract infections and peritonitis.[30, 
31] Today most frequently used aminoglycosides are gentamicin, tobramycin and amikacin, 
whilst streptomycin remains an important drug in the treatment of tuberculosis, brucellosis, 
tularaemia and plague. Paromomycin and spectinomycin have been used to treat intestinal 
protozoal pathogens and Neisseria gonorrhoeae infections, respectively.[29] The 
antibacterial activity of aminoglycosides results from their interaction with the aminoacyl 
site of 16S ribosomal RNA (rRNA) within the 30S ribosomal subunit.[32]  
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Figure SI.5.3. Chemical structure of neomycin and paromomycin. 
 
3.2.  Physicochemical properties 
Aminoglycosides are polycationic molecules highly soluble in water. Chemically 
there are two major classes of aminoglycosides that contain a central aminocyclitol moiety 
(2-deoxystrptamine (2-DOS)), with one class consisting of 4,5-disubstituted 2-DOS 
compounds and the other consisting of 4,6-disubstituted 2-DOS compounds. Examples of 
the 4,6-disubstituted 2-DOS class include tobramycin, kanamycins A and B, and amikacin, 
while examples of the 4,5-disubstituted 2-DOS class include neomycin B, paromomycin I, 
and lividomycin A. 
3.3.  Biopharmaceutical properties 
Aminoglycosides are administered parenterally or locally, rather than orally due to 
their poor absorption in the gastro-intestinal tract as a consequence of their polar cationic 
nature.[31, 33] The poor cellular penetration of aminoglycosides limit their activity against 
intracellular pathogens.[34] Aminoglycoside antimicrobial activity is mostly concentration-
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dependent, which means that higher concentration of the antibiotic (relative to the minimal 
inhibitory concentration (MIC) against a given organism) induces more efficient killing of 
the organism. High peak concentrations enhance efficacy whilst lower trough 
concentrations reduce the incidence of nephrotoxicity. Therefore, aminoglycosides should 
be given as once-daily administration to achieve these optimal concentrations and results in 
improved efficacy and toxicity outcomes.[35] Nephrotoxicity and ototoxicity are the most 
common side effects of aminoglycosides and they are usually dose-limiting factors in the 
successful therapy using aminoglycosides. The nephrotoxicity of aminoglycosides results 
from the accumulation of a relatively high percentage (~ 10 %) of the intravenously 
administered dose in the kidney.[36]   
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